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Abstract 
 
Tuberculosis (TB) remains one of the most devastating diseases in humans. 
Nowadays, tuberculosis therapy is not sufficient to control the TB epidemic and only 
lasts for 6 months to cure patients and prevent relapse; therefore, the treatment of 
Mycobacterium tuberculosis (Mtb) is particularly challenging (1). New antibiotics, 
mainly those that are derived from new chemical classes, are more likely to be more 
effective against resistant strains. Moreover, expanding the knowledge of the mode 
of action of drugs has important implications in tackling TB. Only empirical 
approaches can be adopted in the journey of discovering new anti-tubercular drugs 
until a clear picture of latency and persister cells’ physiology is achieved. Mtb has 
the extraordinary ability to survive under hypoxia, suggesting a high degree of 
metabolic plasticity. The flexibility conferred by a modular respiratory system is 
critical to the survival of Mtb, thereby also making it a promising area of research for 
new drug targets. This thesis aimed towards the characterisation of cytochrome bd-I 
quinol oxidase (bd-I), a respiratory component that is believed to operate during both 
the replicative and “dormant” Mtb phenotypes. The essential nature of Mtb bd-I, 
which has no human homologue, has been confirmed in a recent deep sequencing 
study of genes required for Mtb growth by Griffin et al. (2), further confirming its 
potential as a novel target. Recombinant Mtb bd-I was successfully expressed under 
the control of the pUC19 lac promoter in the Escherichia coli ML16 bo3/bd-I and 
MB44 bo3/bd-I/bd-II knockout strains, allowing “noise-free” measurement of the 
enzyme. Initial steady-state kinetics of the enzyme was presented using a range of 
quinol substrates, revealing a substrate preference for dQH2 over Q1H2 and Q2H2. A 
number of bd-I inhibitors were identified and their pharmacodynamic profiles 
against Mtb H37Rv were determined. In addition, a pharmaco-metabolomics 
platform was initiated to explore the cellular response of Mtb to current first-line TB 
drugs as well as in house bd-I and type II NADH inhibitors.  The initial findings are 
discussed in the context of the known mode of action of the drugs and future 
research needs in drug discovery of this devastating disease. 
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Chapter I 
General introduction 
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1.1.  Overview 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium 
tuberculosis (Mtb), that most often affect the lungs. Despite the availability of highly 
efficacious treatment for decades, TB remains a major global health problem. TB is 
second only to HIV as the leading infectious killer worldwide (3). 
 
Although active, drug-sensitive TB disease is curable and preventable, although the 
prolonged and demanding current TB drugs regimen leads to the emergence of drug 
resistant strains, which are difficult, complicated, and expensive to treat. Further, 
sub-populations of slow-growing and persistent Mtb are not targeted by the present 
TB drugs regimen. Moreover, the deadly synergy of TB and HIV diseases demands 
first-line treatments that can be fully harmonized as the current TB drugs regimen is 
not compatible with certain common antiretroviral (ARV) therapies used to treat the 
human immunodeficiency virus (HIV)/AIDS.  
 
Nearly 50 years passed with no new TB drugs have been developed, despite the 
flaws with and growing resistance to current TB treatments. Therefore, a shorter, 
faster, simpler and affordable cure for TB could improve treatment compliance, stop 
the spread of the disease, save millions of lives and have tremendous global benefits. 
The new anti-TB treatments should also tackle drug-resistant strains of Mtb, 
including the organisms in the latent state and it should be compatible with the 
current drugs.  
 
Targeting respiration and the electron transport chain of Mtb is framed in the context 
of exciting new developments in tuberculosis drug discovery due to its importance to 
the survival of Mtb. Currently, The drugs diarylquinolines and phenothiazines have 
in common the fact that both target oxidative phosphorylation in mycobacteria (4), 
and that the diarylquinoline TMC207 is involved in a clinical phase II trial and in a 
novel multi-drug regimen in late-stage clinical trials (1). 
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1.2. The global burden of tuberculosis in the world 
TB is a global pandemic, killing someone approximately every 25 seconds. TB 
remains a major cause of morbidity and mortality worldwide. According to the 
WHO, an estimate 8.8 million incident cases of TB globally occurred in 2010, of 
which 1.1 million deaths were among HIV-negative cases of TB and an additional 
0.35 million deaths among people who were HIV-positive (3). 
 
Challenges and burden of TB are arising due to the occurrence of the twin 
pandemics, TB and HIV/AIDS, as well as the emergence of drug resistant strains of 
Mtb. Those challenges in conjunction with poor control programs are leading to the 
resurgence of the disease. An estimated 15% of the population infected with TB (1.4 
million people) are co-infected with HIV (3). Further, there were an estimated 0.5 
million cases of multidrug-resistant TB (MDR-TB) in 2008 (5), where patient with 
MDR-TB shows resistance to the two most effective first-line anti-TB drugs, 
rifampicin and isoniazid (6). Unfortunately, MDR-TB is present in almost all 
countries surveyed (3). 
 
Latent TB, a state when Mtb remain dormant without developing or transmitting the 
disease, poses a massive challenge in controlling TB with estimates of about one-
third of the world's population has latent TB, of which between 5% and 15% will 
develop active disease during the course of their lifetime (3). Additional factors that 
are related to the high TB burden include homelessness, poverty, increasing number 
of refugees and the lack of governmental support in prevention and treatment 
programs in developing countries. The lack of better preventive measures that block 
Mtb transmission or prevent establishment of Mtb infection contributed in increasing 
the burden of TB. The only available vaccine against TB is one-century-old Bacillus 
Calmette-Guérin (BCG) vaccine with incomplete protective efficacy against 
pulmonary TB in adults (3, 7). However, light of hope exists with 11 vaccine 
candidates (in clinical trials) that could offer an excellent protective efficacy (8). 
 
The majority of the estimated TB cases in 2010 happened in Asia (59%) and Africa 
(26%) while smaller proportions of cases were found in the Eastern Mediterranean 
Region (7%), the European Region (5%) and the Region of the Americas (3%) (3). 
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The worldwide distribution of new TB cases per 100,000 individuals is depicted in 
the following Figure (1.1).  
 
Figure 1.1: Worldwide distribution of new TB cases per 100,000 people in 2011 (3) 
 
All this illustrates the tremendous burden that a single disease has globally. 
Therefore, advances in TB research are urgently needed to explore the mysteries of 
Mtb pathogenesis and potential drug targets that could help in eliminating the 
disease.  
 
1.3. Mycobacterium tuberculosis (Mtb): 
1.3.1. The pathogen of tuberculosis: biology and virulence factors 
Tuberculosis is caused by Mtb, a slow growing aerobic-to-facultative anaerobe 
intracellular pathogen that parasitizes macrophages. Mtb belongs to the 
Mycobacterium genus, Mycobacteriaceae family, Corynebacterineae suborder, 
Actinomycetales order, Actinobacteria phylum in the Bacteria kingdom. Mtb are 
gram positive non-motile and rod-shaped bacteria. The cell wall is a major virulence 
factor of Mtb that relates to Mtb intrinsic drug resistance. The Mtb cell wall is built 
of a fascinating diversity of lipids layers, which includes a hydrophilic 
arabinogalactan layer linked to hydrophobic mycolic acids. This arabinogalactan/ 
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mycolic acid layer, which lies on the top of the peptidoglycan layer, is further 
covered with a layer of polypeptides and mycolic acids consisting of free lipid, 
glycolipids, and peptidoglycolipids (Figure 1.2). The cell wall of mycobacterium is 
unique by the dominance of mycolic acids. Other important glycolipids including 
mannose capped lipoarabinomannans (ManLAM), lipomannan (LM), and 
phosphatidylinositol mannoside (PIM) (9). These layers constitute a barrier for both 
hydrophobic and hydrophilic compounds rendering the outer surface of Mtb 
extremely hydrophobic (10, 11).  
 
Importantly, the capacity of Mtb to escape the host immune system and remain alive 
and in a dormant state is considered one of the main Mtb virulence factors. This 
phenomenon is called latency where Mtb remain alive in the human host, in an 
asymptomatic non-transmissible state and with the ability to reactivate and cause 
active disease, having their virulence mechanisms intact.  
 
 
  
Figure 1.2: Schematic representation of the cell wall of Mycobacterium tuberculosis  
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1.3.2. Pathogenesis of tuberculosis 
1.3.2.1. Life cycle of Mtb 
To develop new efficient drugs, it is important to understand the disease process. 
The disease is spread through an aerosol route when people who are sick with active 
pulmonary TB expel bacteria, for instance by coughing or sneezing. Tuberculosis 
commonly affects the lungs (pulmonary TB) and causes symptoms that can include 
coughing up blood, chest pains, fever, and fatigue. However, Mtb can disseminate to 
other parts of the body (extrapulmonary TB) including the central nervous system, 
lymphatic system, bones and joints. Pulmonary TB is by far the most common form 
of tuberculosis, accounting for 86% of all new and relapsed cases worldwide (3). 
 
Mtb usually enters the body by airborne droplet nuclei, which are inhaled and lodge 
in the alveoli in the distal airways. Mtb is then taken up by alveolar macrophages, 
initiating a cascade of events where either successful containment of the infection in 
granulomas or progression to active disease takes place. The notorious success of 
Mtb adaptation inside its human host refers to its ability to impair the normal 
maturation of the phagosome (reprogramming of macrophages after phagocytosis to 
prevent its own degradation). Ideally, Mtb bacteria are internalised inside 
macrophages in a membrane-bound organelle called the phagosome. The phagosome 
undergoes a maturation process along the endocytic pathway leading to fusion with 
late endosomes and finally lysosomes, forming the phagolysosome where some of 
the ingested bacilli are degraded (12). However, bacilli phagocytosed by alveolar 
macrophages can subsequently invade the subtending epithelial layer leading to 
induction of a localized inflammatory response and consequently recruitment of 
mononuclear cells from neighboring blood vessels. This recruitment provides fresh 
host cells for the bacterial population.  
 
In immunocompetent individuals the propensity of Mtb to survive in a pathogen-
friendly phagosome (granuloma) and to establish asymptomatic latent infection is a 
continued threat of TB infection. This is because the immune system is capable of 
effectively containing Mtb regardless of the fact that the infectious microorganism 
may not always be fully eliminated (13). The risk of active disease, disease 
reactivation or death exists in an immune-compromised host (e.g. HIV
 
positive 
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individuals) or patients with chronic diseases such as diabetes/obesity (14).  During 
active TB or disease reactivation, damage in lung tissue occurs and an active 
granuloma displays extensive pathology that eventually ruptures and releases 
thousands of viable, infectious bacilli into the airways. This point of the highly 
infectious form of the disease allows the cycle to resume. Interestingly, it is 
impossible to predict who will fully eradicate Mtb and who will contain latent TB 
infection and remain healthy due to the variance of immune system response from 
person to person  (Figure 1.3) (15, 16).  
 
 
 
Figure 1.3: The life-cycle of Mycobacterium tuberculosis: from infection to host defence 
Primary infection can progress toward active disease or can be contained as latent infection. 
Active TB can: be cured (eradication of Mtb by host’s immune system); be contained as 
latent infection and remain healthy; or lead to death. Latent infection can: develop to active 
disease (reactivation); or be cured. 
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1.3.2.2. Granuloma 
The granuloma is the characteristic feature of human latent pulmonary TB as well as 
an important key factor responsible for immune evasion and reactivation. 
Pathologists have described the lung granuloma as the hallmark of pulmonary TB. 
Granuloma formation is a sign of protective immunity and known to occur in the 
early stages of an infection episode to ensure pathogen containment. However, the 
features of the granuloma are still largely unknown, regardless of the efforts on in 
vitro granuloma models and on in vivo dissections to mimic the human granuloma 
environment (17, 18).  
 
The granuloma is defined as a central core of necrotic tissue surrounded by dense 
layers of immune system cells, like macrophages and lymphocytes, large 
multinucleated cells (Langhans giant cells), dendritic cells and specialised leukocytes 
as well as epithelioid cells and fibroblasts. Development of the tuberculous 
granuloma restrains pathogen dissemination throughout the host and focuses the 
immune response to the site of mycobacterial persistence. This development is 
controlled by cytokines and chemokines produced by leukocytes and local tissue 
cells (17-19). Within granulomas, mycobacteria in activated macrophages adapt to a 
metabolic life-style that makes preferential use of fatty acids, functions under severe 
oxidative and nitrosative stress, increases cell-wall thickness and halts active 
replication (13, 20). Moreover, the highly pathogenic mycobacteria stimulate the 
formation of granuloma-specific foamy macrophages which have a high lipid content 
that constitute a nutrient-rich reservoir for long-term persistence (21).  
 
Various animal models (e.g. guinea pigs, rabbits and nonhuman primates caseous) 
have been used to study granulomas using pimonidazole, an imaging agent that 
indicates hypoxic conditions, and metronidazole, a drug only effective against 
anaerobic bacteria (22). Puissegur et al (2004) replicated an in vitro model of 
granulomas using mononuclear cells, isolated from a BCG-vaccinated non-infected 
individual human blood sample and exposed to mycobacterial antigen-coated beads, 
or live-mycobacteria. This process lead to the production of a cellular aggregation 
response, similar to the granuloma (23).     
 
9 
1.3.2.3. Latency of Mtb 
Latency, persistence, and dormancy are terms that are sometimes used 
interchangeably in describing Mtb and TB pathogenesis. Latency is defined as the 
presence of any tuberculous lesion which fails to produce symptoms of active TB. 
Persistence stand for actual or potential bacterial survival in the face of any stress 
from the host immune system (24). Dormancy has been used to describe both TB 
disease as well as the metabolic state of the tubercle bacillus where dormancy 
involves a reversible metabolic shutdown. Latent infection may be attributable to 
dormant bacteria as well as to bacilli with similar phenotypes as persister cells, 
which will be described shortly (24-26).  
 
This dormant or latent infection presents a vast reservoir of potential reactivation and 
transmission of the disease, making eradication of TB a major challenge. Impairment 
of the immune system either by age, chronic illness or HIV/AIDS cause reactivation 
of these dormant bacilli that can occur at any time, even decades after the primary 
infection took place (27).  
 
The existence of latent TB in an infected individual could be detected by a visible 
calcified granulomatous tissue under X-ray. Further, the infected individual will have 
a strong immune response against Mtb antigens which is detected through tuberculin 
skin testing (TST) (13). Unfortunately TST gives a high rate of false positives that 
makes it inadequate to distinguish if the immunological reaction is due to BCG 
vaccination or previous exposure to pathogenic Mtb. Similarly, it is difficult to 
distinguish if an active TB infection occurred as result of latent TB reactivation or as 
a new incident of infection (11, 28). 
 
1.3.2.3.1. Replication state of dormant Mtb 
The issue of defining the replication state of dormant Mtb is still controversial. 
However, there are two acceptable hypotheses. The first one defends a non-
replication or very slow replication state, a near-static state of Mtb that permits an 
escape from the host immune system and a resistance against antibiotics (13). The 
second hypothesis proposes a dynamic state of constant replication of Mtb, enclosed 
by the immune system. In both states, Mtb developed an elaborate survival 
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mechanism in humans where the immune system in immunocompetent individuals 
engages a lifelong battle against latent TB infection, either eradicating the 
pathogenic Mtb or limiting its replication, creating a long-standing reservoir of 
future disease and contagion (13, 25, 28). 
 
Yang et al (2011) conducted a genomics and molecular epidemiology study that 
support the first hypothesis, a non-replication state of Mtb during latency. However, 
this hypothesis is not conclusive as the study was limited by the small number of 
case studies and by the fact that the mutation rates of the mononucleotide simple 
sequence repeats (SSRs or microsatellites) in Mtb genome are unknown (29).   
 
Other studies in the defence of the second hypothesis were that Mtb bacilli in 
continuous replication during latency are counted by the presence of metabolic 
activity within the Mtb bacilli (28, 30). Moreover, one of the strongest arguments for 
Mtb replication during latency comes from the fact that isoniazid, active against only 
replicating mycobacteria, is able to completely sterilize the host from bacteria, which 
suggests that at least part of the Mtb latent population is replicating (13). Gill et al’s 
(2009) study favoured the second hypothesis as well, where transformed Mtb with 
the unstable plasmid pBP10 were used during mice infection. This study showed loss 
of plasmid during chronic infection which implied a replication state of Mtb during 
this period (31). 
 
1.3.2.3.2. Latency models   
The acknowledegment of the consequence of the latency phenomenon in TB 
pathogenicity drives the research toward latency abrogation. This requires a better 
understanding of the physiological events that lead to latency, thus efforts to 
replicate this state in vitro were made. The Wayne model of hypoxia and the Cornell 
mouse model, the most utilised models, are two examples of modulating some 
conditions that are known to reduce Mtb metabolism and create a state that would 
mimic one or more features of the latency condition.  
 
The Wayne model of hypoxia is one of the best characterized models, where the Mtb 
bacilli are submitted to a slow shift from aerobic to anaerobic conditions by growing 
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bacteria in a constantly stirred liquid medium with no disturbance on the surface of 
the liquid and with a defined proportion between air and liquid in sealed tubes. This 
specific set up leads to a gradual depletion of oxygen from the bottom to the top of 
the tube in a constant manner, which in turn results in a successful adaptation of the 
bacilli to hypoxic conditions. As the latency state is established, the Mtb bacilli enter 
a 2-phase state called non-replicating persistence (NRP), NRP phase 1 (NRP-1) and 
NRP phase 2 (NRP-2) (20, 32, 33). During NRP-1, the oxygen saturation is about 
1% and the number of viable bacteria reaches stationary, although cell enlargement 
leads to a minute increase in the turbidity of the culture (34). Eventually, during the 
next phase NRP-2, the culture transfers to complete anaerobic conditions where the 
oxygen saturation is 0.06% and a significant reduction of metabolism with no 
morphological changes of bacteria take place (33, 34).  
 
With regards to drug susceptibility, although dormant bacilli display increased 
tolerance, they are still susceptible to rifampicin and isoniazid once bacilli resume 
growth. Further, the bacilli are sensitive to metronidazole since metronidazole is 
only active against anaerobic or microaerophilic bacteria. This susceptibility is 
considered as an evidence for hypoxia in the phenomenon of latency (33, 35). 
 
The Cornell mouse model, a drug induced model, is an alternative dormancy model 
where Mtb infected mice are treated with isoniazid and pyrazinamide for only 12 
weeks, resulting in disappearance of active TB disease and rendering uncultivatable 
Mtb bacilli from mouse spleens (36). Consequently, one third of the mice show a 
reappearance of active and drug-sensitive Mtb. Therefore, the latent period of the 
disease is considered to be the 12 weeks between disappearance and then 
reappearance of the infection (37, 38).  
 
A variety of other models have been established to mimic the latency state of Mtb as 
present in the macrophage, phagosome or granuloma environment. For example, the 
nutrition starvation model is based on evidence that indicated the presence of severe 
nutrient limitations in TB lesions (39, 40). The phosphate depletion model is another 
model that represents the macrophage restricted environment (41). Moreover, the 
prolonged stationary-phase model has been developed since similarities between 
persistence and the bacteria that exist in stationary phase, the non-replicating 
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phenomenon, has been proposed (42, 43). Recently, a novel multiple-stress model 
for inducing dormancy in Mtb has been suggested where the bacteria are submitted 
to a combination of stresses which are low oxygen, high CO2, low nutrients and an 
acidic environment. The multiple-stress model can be used in high-throughput 
screening for drugs targeting the persistent bacteria, since it most likely resembles 
the latency environment in the human host (44).    
 
1.3.2.4. Persister cells  
Tubercle bacilli produce heterogeneous bacterial populations, including persisters, 
dormant and growing bacteria. This is due the fact that Mtb are able to reside in 
various microenvironmental statuses that are oxygen-rich (in cavities) or oxygen-
limited (in host macrophages or in granulomatous lesions) conditions, or in other 
stressful conditions (e.g. nutrient starvation, oxidative stress, and acidic pH) (45). 
Persisters can inhabit intracellular and extracellular locations as well as different cell 
types, e.g. adipose tissue and sputum (24, 46, 47). 
 
There is overlap with the bacterial dormancy (persistence) phenomenon and 
persisters where dormant Mtb are applicable to some but not all described 
persistence phenomena (26, 48). The term “persister” donates a well-defined sub-
population of bacteria that survive antibiotic exposure, while “persistence” as 
mentioned earlier points to the bacterial survival in the face of any stress from the 
host immune system (24).  
 
Although mycobacterial persisters are genetically identical to drug susceptible 
bacteria and have non-inheritable phenotypic resistance or tolerance to antibiotics, 
they are still capable of surviving the cidal action of antibiotics (24, 49). Persisters 
necessitate lengthy TB therapy, posing a major challenge for controlling TB. 
Persisters appear to be non-replicating or slowly replicating bacilli where their 
propagation depends on the age of the culture, the antibiotic exposure duration, and 
the type and concentration of antibiotics used in the culture (45, 50, 51).  
 
The mechanisms of persister cell development are complex and may be related to 
those required for persistence (dormancy) in chronic infection. Single-gene mutation 
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studies identify several genes or pathways that might engage in Mtb persister 
formation or maintenance, such as energy-related pathways genes. In INH-treated 
mice, disruption of cydDC genes accelerated Mtb elimination, which entailed 
reduction of antibiotic resistant cells (persisters) (24, 52). CydDC, encoding an ABC 
transporter, is implicated in cytochrome bd-I assembly, an essential enzyme during 
hypoxia and for Mtb viability (2, 53).  
 
1.3.2.5. Yin-Yang model 
There is sparse information defining the subpopulations of Mtb. A yin-yang model, 
applicable to both patients and experimental systems, has been proposed to 
emphasize the heterogeneity, dynamic nature, and interconversion of the diverse Mtb 
subpopulations present. The hypothesis of yin-yang models is that the bacterial 
population consists of growing, slow-growing, and non-growing subpopulations that 
have different metabolic statuses which can interconvert at the level of the bacteria 
(24). This model also provides a possible justification of latent infection (yin) and 
active disease (yang) abilities to interconvert at the level of the host and behave as a 
continuum. Further, the rationale behind the current two-phase TB regime and the 
reasons of using isoniazid as chemoprophylaxis or for treatment of latent TB 
infection (LTBI) could be explained through the yin-yang model as well (24).  
 
There are two yin-yang models. The first one is the yin and yang of persisters and 
replicating bacteria and their interconversions (Figure 1.4). This model suggests that 
the subpopulation of growing bacteria (yang) has a small proportion of non-growing 
or slowly growing persisters (yin). This proportion increases upon entry of the 
bacteria into the stationary phase. Furthermore, this model shows that after a 2-
month intensive-phase treatment with isoniazid (INH), rifampin (RIF), pyrazinamide 
(PZA), and ethambutol (EMB), the remaining persister tubercle bacilli can revert to 
growing form that can be eliminated by INH/RIF combination in the succeeding 4-
month continuance phase of treatment. This model also demonstrates the possibility 
of Mtb to revert from a non-growing form during LTBI to a growing form, that is 
INH susceptible. This in turn explains using INH as prophylactic treatment of LTBI. 
Moreover, this model shows the possibility of phenotypic resistance persister 
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tubercle bacilli to convert into genetic resistance growing bacteria and vice versa 
(24). 
         
Figure 1.4: Yin and yang of persisters and replicating bacteria and their 
interconversions (24, 45). 
 
The second yin-yang model is the yin and yang of latent infection and overt or active 
disease and their interconversions (Figure 1.5). During overt disease (yang), the 
growing bacterial population is the majority while non-growing bacteria or persisters 
are the minority and vice versa with respect to LTBI (yin). These proportions of 
growing and non-growing bacteria vary according to the host immune system and 
antibiotic treatment effectiveness (24).     
 
             
Figure 1.5: Yin and yang of latent infection and overt disease and their 
interconversions (24, 45). 
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1.4. Tuberculosis drugs: 
The current TB chemotherapy evolved from numerous experimental and clinical 
studies where the introduction of the current front-line anti-tuberculosis drugs started 
in 1952 with the discovery of isoniazid (54, 55), which was then followed by 
pyrazinamide (1952) (56-58), ethambutol (1961) (58) and rifampicin (1967) (59-62). 
Recently, a variety of other second-line drugs were introduced such as kanamycin, 
amikacin, capreomycin, cycloserine, ethionamide and thiacetazone. 
 
The current first-line recommended standard TB chemotherapy, called DOTS 
(directly observed treatment, short-course), involves a direct monitoring of the 
patient by trained health professionals of the patient being treated. DOTS is a six 
month therapy consisting of an initial two-month phase of treatment with four drugs, 
INH, RIF, PZA, and EMB, followed by a continuation phase of treatment with INH 
and RIF for another four months. The DOTS regimen is recommended by the WHO 
and has a cure rate of up to 85% with drug-susceptible forms of TB (63-65). 
 
The rationale behind using the combination of drugs regimen is due to the 
synergistic reaction of these drugs as well as the presence of physiologically 
heterogeneous population of the tubercle bacilli. Moreover, this combination serves 
as an attempt to avoid the risk of emergence of drug-resistant strains under 
monotherapy and reduces anti-TB therapy from 18 months to 6 months (33, 66, 67). 
However, long treatment duration could be attributed to the possibility of existence 
of phenotypically tolerant tubercle bacilli after a 2-month intensive-phase treatment 
that can be killed by INH and RIF in the subsequent 4-month continuation phase of 
treatment (24, 68).  
 
With regards to DOTS regimen strengths; within 2 months of treatment initiation, 
99% of tubercular bacilli could be killed by the INH and RIF combination, the two 
most potent anti-TB drugs. Thereafter, RIF and INH are crucial for successful 6-
month treatment regimens as RIF kills low or non-replicating bacilli that are not 
affected by any other anti-TB agents (67).  
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Regarding DOTS limitations, DOTS is an extremely prolonged, demanding and 
complex regimen results in patient non-compliance that leads to the development of 
deadlier heritable drug-resistant strains (69). Further, another massive challenge is to 
control the twin epidemics, TB and HIV/AIDS, which arises from the 
incompatibility of current TB therapy with certain common ARV drugs that are used 
to treat HIV/AIDS (70). Moreover, DOTS is ineffective in controlling MDR-TB in 
high MDR-TB incidence areas (71). Therefore, first-line treatments that can be fully 
harmonized and overcome the current TB drugs flaws are urgently needed. A 
detailed description of the drugs of the DOTS regimen is given below. 
 
With respect to LTBI, the current recommended treatment of LTBI to prevent 
endogenous reactivation consists of 6–12 months of isoniazid. However, this regime 
is limited by the long duration of therapy and potential for hepatic toxicity. 
Therefore, shorter and more intermittent rifamycin-containing regimens have been 
investigated where rifampicin for 4 months is an alternative in the USA and Canada 
whereas in the UK, a 3-month regimen of rifampicin plus isoniazid is used with 
success (72-75). Remarkably, Lin et al (2012) showed that MTZ given for 2 months 
is almost as effective as using an INH/RIF combination in order to prevent 
reactivation of LTBI (76). 
 
1.4.1. First-line tuberculosis drugs: 
1.4.1.1. Isoniazid 
Isoniazid (Figure 1.6), a pyridine derivative of nictoinamide, is the most widely 
prescribed first-line drug for the treatment of TB. Isoniazid (INH, isonicotinic acid 
hydrozide) is a highly bactericidal drug against actively growing bacilli and 
bacteriostatic for non-dividing Mtb. INH is a small hydrophilic compound that is 
thought to enter Mtb through porins in the mycobacterial cell wall (77). The 
accumulation of isoniazid has been also attributed to the role of an active efflux (78-
80).  
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                          Figure 1.6: Structure of isoniazid, C6H7N3O 
   
INH is a pro-drug activated by the mycobacterial enzyme catalase-peroxidase 
(KatG), a hemoprotein possessing catalase-peroxidase, Mn
2+
-dependent peroxidase, 
cytochrome P450-like oxygenase, and peroxynitritase activities (81, 82). A number 
of stable KatG mediated isoniazid metabolites have been identified which include 
isonicotinic acid, isonicotinamide and pyridine-4-carboxyaldehyde (83). However, 
none of these stable metabolite themselves are bactericidal and it is likely that 
bactericidal activity is attributed to reactive intermediate species, isonicotinic acyl 
radicals and anions (84).  
 
Our knowledge of the mechanism of action of INH is limited despite numerous 
studies that have been done. Isoniazid is particularly effective at inhibiting the 
synthesis of mycolic acid needed for the Mtb cell wall (85). The synthesis of mycolic 
acid in Mtb is attributed to a number of proteins including an enoyl-acyl carrier 
protein reductase (InhA), an acyl carrier protein (AcpM) and a β-ketoacyl-ACP 
synthase (KasA). These proteins (InhA, AcpM and KasA) are hypothesised as 
targets for the isoniazid active metabolites as mutation in these proteins show a low 
level of INH resistance (86). 
 
One of the proposed mechanisms by which INH is able to inhibit InhA and therefore 
mycolic acid synthesis is that Mtb KatG oxidizes isoniazid, a prodrug, to an 
isonicotinic acyl radical, which then couples to reduced nicotinamide adenine 
dinucleotide (NADH) (84, 87). In this theory, isonicotinic acyl radicals covalently 
bind to NAD
•
 radicals to form isonicotinic acyl NADH that is thought to be a potent 
inhibitor of InhA. Inhibition of InhA by the INH-NADH adduct probably results in a 
weakened mycobacterial cell wall and, eventually, death of the pathogen (84). 
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Likewise, it has been suggested that the INH activity also arises from the coupling of 
INH
•
 to reduced nicotinamide adenine dinucleotide phosphate (NADPH), forming an 
INH-NADPH adduct, which is an inhibitor of MabA. MabA is one of several 
proteins involved in the type II fatty acid synthases (FAS-II) mycolic acid synthesis 
pathway (88). An alternative theory on INH activity is the isonicotinic acid 
hypothesis (89). Here it is proposed that isoniazid is metabolised to a stable 
metabolite, isonicotinic acid, which remain in its ionic form at physiological pH 
leading to ion trapping and accumulation of isonicotinic acid in Mtb. Thereby, 
isonicotinic acid competes with, and displaces, nicotinic acid (NA) during the 
bacterial synthesis of NADH, leading to the formation of the meta-isomer of NADH 
wich inhibits InhA mediated fatty acid synthesis (90).        
 
The origins of INH drug-resistance in Mtb can be traced to mutations in KatG, 
coding for the only identified catalase–peroxidase in Mtb (81), or to mutations in the 
promoter regions of InhA (91). KatG mutations are found to confer high levels of 
INH resistance (92). Resistance to INH in Mtb is also linked to reduced NDH-2 
activity in NDH mutants, as this leads to an increase in intracellular NADH levels 
(93, 94). Moreover, other factors such as neutralization of isoniazid by the 
overproduction of arylamine N-acetyltransferase (95), limitation of NAD
+
-binding 
proteins (96, 97), and the overexpression of antioxidant enzymes that compensate for 
the loss of function of the KatG protein (98) bestow resistance to INH.  
 
INH has been used clinically since 1952 as a first-line antimicrobial for tuberculosis 
(99) and is highly regarded as an anti-TB drug, due to the fact that it is highly potent, 
well tolerated by the patient and relatively cheap. It is also prescribed to infants as 
prophylactic therapy (100, 101). Among the first-line drugs, INH is the only 
bactericidal agent that easily crosses the blood-brain barrier (102, 103). However, the 
main drawbacks of INH are INH-related severe toxicity, which is peripheral 
neuropathy and hepatotoxicity (104) and the fact that INH acts exclusively on 
actively growing bacilli. 
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1.4.1.2. Rifampicin 
Rifampicin (RIF) (Figure 1.7) is a large lipophilic semi-synthetic derivative of the 
natural product rifamycin, obtained from culture filtrates of Streptomyces 
mediterranei. RIF uptake is mediated by diffusion through the cell wall, in a process 
that is influenced by the cell wall arabinogalactan content (77).  
                                
                       Figure 1.7: Structure of rifampicin, C43H58N4O12 
 
RIF is a broad-spectrum antibiotic with potent bactericidal activity against both 
active and dormant tubercle bacilli. It inhibits RNA synthesis by binding to the 
central region of the β-subunit (81 bp) of RNA polymerase (encoded by the rpoB 
gene), which effectively blocks transcription (105-107). Therefore, RIF continues to 
exhibit some bactericidal action, even after O2 depletion occurs (33).   
 
Resistance to RIF is the main reason of treatment failure and fatality as it is one of 
the essential drugs in modern chemotherapy (108). Mutations in the 81 bp region of 
rpoB are the most common mutations associated with rifampicin resistance 
(approximately 96%) (105).   
 
Importantly, simultaneous use of rifampicin and antiretroviral drugs is 
complicated by drug–drug interactions (DDI).  This DDI is caused by the 
potent induction by rifampicin of a number of drug-metabolising enzymes 
involved in antiretroviral drugs metabolism and transport (109). Moreover, 
rifampicin is not highly toxic on its own, however some studies showed that the 
incidence of hepatotoxic effects associated with rifampicin monotherapy is around 
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2%, but rarely associated with fulminant hepatitis (110, 111). Otherwise, rifampicin 
toxicity is mostly idiosyncratic, and only a small percentage is attributable to an 
allergic, hypersensitivity type reaction which leads to symptoms including fever, 
rash, flu-like syndrome, acute renal failure, haemolytic anaemia, thrombocytopenia, 
and anaphylactic events (112).  
 
1.4.1.3. Ethambutol 
Ethambutol (EMB) is a bacteriostatic agent that has activity against growing bacilli 
but has no effect against non-replicating bacilli (Figure 1.8). EMB is a small, 
hydrophilic agent that is thought to cross the mycobacterial wall via the porin 
channels, although some evidence of active uptake exists (77).  
                                        
                               Figure 1.8: Structure of ethambutol, C10H24N2O2 
 
The specific mode of action of EMB is still uncertain. EMB exerts its activity by 
interfering with the synthesis and assembly of arabinogalactan (113), with secondary 
effects upon lipoarabinogalactan (114) and mycolic acids (115), essential lipids in 
the Mtb cell wall. EMB is assumed to act via inhibition of three arabinosyl 
transferases: EmbA, EmbB, and EmbC. These arabinosyl transferases are essential in 
Mtb, where EmbA and EmbB are required for the synthesis of arabinogalactan, and 
EmbC is involved in the synthesis of LAM (116-119). EmbB has been proposed as 
the target of EMB in Mtb (120) although Goude et al (2009) found that EmbB is not 
the only target and that EmbC is one of the cellular targets of EMB action (119).  
 
The genetic basis of resistance to EMB in mycobacteria has been referred to 
mutations in EmbCAB operon, especially EmbB. High levels of resistance were 
attributed to a combination of mutations in EmbB codon 306 and EmbC codon 270 
(119, 121). The most frequent adverse effects associated with EMB are ocular 
toxicity, manifested by optic or retrobulbar neuritis, and hepatotoxicity (122, 123).  
21 
 
1.4.1.4. Pyrazinamide 
Pyrazinamide (PZA) (Figure 1.9), a structural analogue of nicotinamide, is a 
paradoxical drug, showing good activity against tubercle bacilli at acid pH (124) and 
being more effective against old cultures than young cultures (125), and also more 
active at low oxygen or anaerobic conditions (126). PZA is a prodrug of active agent 
pyrazinoic acid (POA). PZA introduction allowed TB therapy to be shortened from 1 
year to 6 months.  
                                                      
                               Figure 1.9: Structure of pyrazinamide, C5H5N3O 
 
However, it shows no activity against Mtb grown in standard culture conditions in 
vitro (127), unless acidic conditions are introduced (128) which probably facilitate 
the accumulation of POA inside the bacilli (129, 130). The acidic environment in 
vivo is thought to be generated by either a small decrease in phagosome pH which 
occurs due to binding of the early endosomes, or by early inflammation following 
Mtb infection (131).  
 
Zhang and colleagues (129, 130) have reported that, PZA enters Mtb through porins 
and is converted to POA by the PZase/nicotinamidase enzyme. POA in turn leaves 
Mtb via a weak efflux pump or by passive diffusion. The presence of Mtb in acidic 
environment allows the POA, which is uncharged and protonated, to enter Mtb and 
accumulate as the rate of POA influx is greater than the efflux. Accumulation of 
pyrazinoic acid is thought to be vital in mediating PZA antimicrobial activity (124).   
 
There are a number of postulated mechanisms of action of POA. The first postulated 
hypothesis is that the accumulation of protonated POA brings protons into the 
bacilli, leading to acidification of the cytosol which eventually causes disruption of 
the Mtb membrane energetic by collapsing the membrane potential and affecting 
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membrane transport. The PZA effectiveness against dormant Mtb is attributed to the 
reduction of its ability to maintain membrane potential (132). The second proposed 
hypothesis is that PZA and POA inhibit fatty acid synthesis in Mtb through type I 
fatty acid synthases (FAS-I) inhibition at pH 6 (acidic condition) but not at pH 6.8 
(133).               
 
The mycobacterial enzyme PZase, encoded by the pncA gene of Mtb, is essential for 
converting PZA to POA. A mutation in the gene pncA, which encodes PZase, is the 
major mechanisms of PZA resistance (134). The non-uptake of the pro-drug is an 
additional mechanism of resistance to the PZA that is known to exist but has not 
been fully investigated. It has been demonstrated that the accumulation of both PZA 
and nicotinamide, but not isoniazid, in mycobacteria is partially dependent on an 
uptake process, which could be an active transport or facilitated transport with 
subsequent ATP dependent metabolism (134).     
      
In terms of tuberculosis treatment PZA is relatively non-toxic. The toxicity of PZA 
is dose-related (110, 135) and has the frequently described adverse events (AE) of 
arthralgia and hepatotoxicity (110, 136). 
 
1.4.2. Second-line tuberculosis drugs 
The emergence of strains resistant to DOTS drugs causes a major concern for TB 
treatment. Therefore, alternative TB drugs, known as the second-line TB drugs, are 
available to be used (Table 1.1). These second-line drugs include fluoroquinolones, 
such as ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin as well as 
aminoglycosides, injectable agents, such as streptomycin, amikacin, kanamycin and 
capreomycin. Further, they include bacteriostatic second-line drugs, cycloserine, 
ethionamide and para-aminosalicylic acid (73). Quinolone drugs were shown to have 
high activity against Mtb and have been used as second-line drugs for the treatment 
of drug-resistant TB since the late 1980s (124).  
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1.4.2.1. Streptomycin 
Streptomycin (STR), an aminoglycoside antibiotic, was the first effective drug 
against Mtb, representing the beginning of modern Mtb chemotherapy (Figure 1.10).  
                                 
                     Figure 1.10: Structure of streptomycin, C21H39N7O12 
 
Primarily, the STR mode of action is associated with interfering with protein 
synthesis by inhibiting initiation of mRNA translation, that in turn results in 
misreading of the genetic code and damaging of the cell membrane. Specifically, 
STR binds tightly to the conserved A site of 16S rRNA in the 30S ribosomal subunit. 
STR has an effect only on replicating tubercle bacilli. However, the intracellular 
location of the bacilli could render STR inactive (67, 123, 124).  
 
Streptomycin remains an important drug for treating diseases caused by Mtb, but it is 
no longer first-line. This could be referred to number of factors, including rapid 
development of resistance to this drug, and since the combination of INH and STR 
had little overall effect and must be given by injections. STR resistance is linked to 
mutations in rpsL (S12 ribosomal protein) and rrs (16S rRNA) genes that encode 
small ribosomal subunit (67, 123, 124, 137). 
 
1.4.3. Metronidazole, a drug against anaerobic bacteria 
Metronidazole (MTZ) (Figure 1.11) is classified as a nitroimidazole and as 
antitubercular which kills only dormant and persister Mtb under hypoxic/anaerobic 
conditions. Metronidazole acts on damaging the pathogen deoxyribonucleic acid 
(DNA) but has poor activity against replicating tubercle bacilli. Recently, Zhang 
(2012) and Lin et al (2012) found that MTZ alone can prevent reactivation of LTBI 
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to active disease (35, 76). Metronidazole serves as a control in the anaerobic TB 
studies (138, 139). A Phase II clinical trial in South Korea sponsored by the National 
Institute for Allergy and Infectious Diseases (NIAID) (www.niaid.nih.gov), is 
currently studying the effect of adding MTZ to the treatment against MDR-TB (138).  
 
                                               
                               Figure 1.11: Structure of metronidazole, C6H9N3O3 
 
1.4.4. Resistant tuberculosis phenotypes 
The sporadic appearance of drug resistant Mycobacterium tuberculosis strains is an 
inevitable consequence of using anti-TB antibiotics. There are factors that accelerate 
the emergence of these resistance strains, including the aforementioned DOTS 
limitations, inadequate chemotherapy prescriptions, poor management of drug 
supplies, the use of drugs of unproved bioavailability and poor direct observation of 
TB patients throughout the treatment course. There are two types of resistance, TB 
primary resistance occurs when the person is infected with an already Mtb drug-
resistant strain and TB secondary resistance (acquired resistance) occurs when TB 
patients who are infected with Mtb drug susceptible strains develop resistance (6, 
138).   
 
MDR-TB and extensively drug-resistant TB (XDR-TB), resistant phenotypes, are 
acquired by a sequence of cumulative mutations in the genes involved in individual 
drug resistance (140). MDR-TB is defined as TB caused by strains of 
Mycobacterium tuberculosis that are resistant to at least isoniazid and rifampicin, the 
backbone of any successful TB treatment programme. In the other hand, XDR-TB is 
a form of TB caused by bacteria that are resistant to isoniazid and rifampicin (i.e. 
MDR-TB) as well as to any of the second-line drugs, namely aminoglycosides, and 
fluoroquinolones (73).  Recently, a high level of challenge in TB management has 
been appeared by the emergence of totally-drug-resistant tuberculosis (TDR-TB) or 
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very extensively-drug-resistant tuberculosis (XXDR-TB). This type of TB resistant 
strain, reported in Italy and Iran, is resistant to all first- and second-line drugs (141, 
142).  
 
The highest proportions of MDR-TB ever documented in a subnational area where 
MDR-TB has reached 0.5 million cases per year and in some countries accounts for 
up to 28% of new TB cases (Figure 1.12). XDR-TB was found in 5.4% of MDR-TB 
cases and eight countries reported XDR-TB in more than 10% of MDR-TB cases (5). 
A map showing the worldwide distribution of XDR-TB cases is displayed in Figure 
(1.13) where large parts of Africa do not have reported XDR-TB cases as result of 
laboratory limitations in diagnosis (WHO 2010). 
 
 
 
Figure 1.12: Distribution of Notified MDR-TB (population rate per 100,000) – 2010 
(143) 
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Figure 1.13: Worldwide distribution of countries reporting at least one case of XDR-
TB (in red), according to WHO report, 2010 (144). 
 
Patients with MDR TB can be cured with appropriate management based on second-
line TB drugs although they are inherently more toxic and less effective than first-
line drugs. Therefore, a reliable assessment of drug resistance (drug susceptibility 
testing, DST) is an essential prerequisite to support clinical decision making and 
helps to prevent the emergence of further drug resistance in patients with MDR TB. 
This strategy is called the DOTS-Plus strategy (145, 146) or individualized regimen. 
A regimen of at least four drugs should be implemented: injectable anti-tuberculosis 
drugs, kanamycin, amikacin or capreomycin, a fluoroquinolone, an oral 
bacteriostatic second-line drug and pyrazinamide. The duration of the MDR-TB 
treatment can last from 8 to 20 months, which could be modified according to the 
patient’s response to therapy, with increased risks of adverse reactions after 12 
months. However, this individualized regimen is difficult to apply in low income 
areas and thus a standardized approach has the advantages of making it easier to 
estimate drug needs and to train personnel in the treatment of MDR-TB patients.  
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The standardized approach should include at least pyrazinamide, a fluoroquinolone, 
a parenteral agent, ethionamide (or prothionamide), and either cycloserine or p-
aminosalicylic acid (PAS) if cycloserine cannot be used. Unfortunately the current 
recommendations do not necessarily apply to XDR-TB patients as there is lack of 
evidence for the best drug regimens for treating these patients.  XDR-TB patients can 
be cured although the probability of success with the current drugs available is much 
lower than in patients with ordinary TB or even MDR-TB. Effective treatment of 
XDR-TB depends on the speed and the accuracy of the diagnosis as well as on a 
good selection of the second-line drugs that are available to clinicians (147). A 
summary of the mechanisms of resistance involved with each of the first- and 
second-line drugs is displayed in Table (1.1). 
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Table 1.1: Summary of drugs currently used against TB and their mechanisms of resistance (67, 138, 140). 
 
 
Drug Effect on Mechanism of action Target 
Mutations associated with resistance 
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Isoniazid Replicating bacilli 
Inhibits mycolic acid 
synthesis 
InhA, KasA and AcpM 
katG  (Catalase-peroxidase) 
inhA  (Enoyl ACP reductase) 
Rifampicin 
Replicating and 
dormant bacilli 
Inhibits RNA synthesis RNA polymerase β-subunit rpoB  (β-subunit of RNA polymerase) 
Ethambutol Replicating bacilli 
Inhibits arabinogalactan 
synthesis 
EmbB and EmbC 
EmbB and EmbC (Arabinosyl 
transferase) 
Pyrazinamide Dormant bacilli 
Depletes membrane 
energy 
Unknown (possibly inhibits FAS-I 
or alters membrane energetics) 
pncA (Nicotinamidase/pyrazinamidase) 
Streptomycin Replicating bacilli Inhibits protein synthesis 
A site of 16S rRNA in the 30S 
ribosomal subunit 
rpsL  (S12 ribosomal protein) 
rrs  (16S rRNA) 
B
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l 
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o
n
d
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e 
d
r
u
g
s Amikacin/Kanamycin Replicating bacilli Inhibits protein synthesis Ribosomes rrs  (16S rRNA) 
Capreomycin No conclusive data Inhibits protein synthesis 
Methylated nucleotides in 
ribosomal subunits 
tlyA  (2'-O-methyltransferase) 
rrs  (16S rRNA) 
Fluoroquinolones No conclusive data Inhibit DNA gyrase DNA gyrase gyrA-gyrB  (DNA gyrase subunit A/B) 
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s 
Ethionamide Replicating bacilli 
Inhibits mycolic acid 
synthesis 
InhA 
ethA   (Flavin monooxygenase) 
inhA   ( Enoyl ACP reductase) 
Para-aminosalicylic acid No conclusive data Inhibits folate metabolism Possibly Dihydropteroate synthase 
inhA (Enoyl ACP reductase) 
thyA  (Thymidylate synthase) 
Cycloserine No conclusive data 
Inhibits peptidoglycan 
synthesis 
Alanine racemase 
D-alanine-D-alanine ligase 
alr  (Alanine racemase) 
ddl  (D-alanyl-alanine synthetase A) 
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1.5. Mycobacterium tuberculosis and a vision for the future 
1.5.1. The Genomic era in the study of Mtb 
The publication of the complete annotated genome of the Mtb laboratory strain 
H37Rv in 1998 was the beginning of the genomic era of Mtb (148). Since then, the 
Mtb clinical strain CDC1551 and six related mycobacteria, M. leprae, M. ulcerans, 
M. avium, M. avium paratuberculosis, M. smegmatis, and M. bovis have been fully 
sequenced (149). The annotation of Mtb genomes is an on-going process where more 
information is being added constantly to the annotation platform.  
 
Sequencing the Mtb genome is considered an important milestone in modern history 
of TB study. Currently, the complete genome of Mtb H37Rv is available in NCBI. 
This culminates in a composite sequence of 4,411,532 base pairs (bp), with a G + C 
content of 65.6% (http://www.ncbi.nlm.nih.gov/genome/166). This G + C rich 
genome is a characteristic of Gram positive Actinobacteria and confers high stability 
of the DNA. The Mtb genome represents the second-largest bacterial genome 
sequence currently available after that of Escherichia coli (E. coli) (150) with 90% 
of a total 4047 genes identified as functional of which 3988 are protein coding genes 
(148, 151, 152). Another striking feature of the Mtb genome is the abundance of 
genes coding for enzymes involved in fatty acid metabolism (more than 250 genes) 
compared with only 50 genes in E. coli (148). Mtb also has the amazing potential to 
produce over 100 enzymes implicated in the β-oxidation of fatty acids and it contains 
both the FAS I and FAS II fatty acid synthase systems (153).  
 
Regarding the post-genomic era, relating the annotated genome sequence to the 
physiological functions of a cell is considered the main goal of this era. Therefore, 
comparative and functional genomics has advanced since the publication of the 
complete genome sequence, notably through the study of the transcriptome, the 
proteome and the biogenesis of Mtb. The full transcriptome of Mtb has been studied 
using different TB experimental models, activated and naive mice macrophages 
(154-156). Moreover, Cappelli et al (2006) were the first to describe Mtb gene 
expression in human macrophages (157) while Rachman et al (2006) conducted the 
study on human lung tissue (surgical specimens) directly (158). Application of 
comparative proteomic analysis explored the critical proteins involved in Mtb 
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pathogenicity (159). Metabolomic-based methods offer integrated readouts of the 
genome and the proteome on a physiologically global scale. Specifically, 
metabolomics is the study of metabolite profiles, the end products of biological cell 
or organism processes. This approach provides the benefit of identifying and 
analysing metabolites in response to various physiological conditions (160, 161), for 
instance, studying a drug’s effect upon the metabolitc level, a topic that will be 
discussed later (Chapter V).  
 
Studying gene essentiality in bacteria employs familiar genome-scale methods, 
which are a microarray hybridization or conventional sequencing. These methods 
allowed mapping the sites of transposon insertions in large libraries of random 
mutants and identifying the regions of the genome that were unable to sustain 
mutation, which probably indicate the essentiality of these genes for the survival of 
the organism (116, 162-165). However, these methods suffer from significant 
drawbacks, resulting in uncertainty of an essential region location. Griffin et al 
(2011) used highly parallel Illumina sequencing to characterize transposon libraries 
achieving a precise identification of essential open reading frames (2).  Recently, 
Zhang et al (2012) coupled high-density mutagenesis with deep sequencing and 
found a high level of agreement with Mtb essential genes data that were reported by 
Griffin et al (2011) (2, 166).  
 
1.5.2. Mycobacterium tuberculosis metabolism  
The metabolic machinery of any bacteria is made up of two tightly linked 
biochemical networks: the carbon metabolic pathways (carbohydrates, fatty acids 
and amino acids metabolism), the tricarboxylic acid (TCA) cycle and the membrane-
embedded electron transport chain (ETC). The carbon metabolism provides the 
respiratory chain with electrons (mostly as NADH and reduced flavin adenine 
dinucleotide (FADH2)). The ETC components allow the cell flexibility in the H
+
/e
-
 
ratio (the number of protons delivered to the periplasmic side of the membrane per 
electron) and rapid responsiveness in the rate of ATP synthesis in response to O2 and 
carbon availability (167, 168). 
Adaptation of Mtb to the host environment is a defining feature of its pathogenicity. 
The key of this adaptation is the metabolic reprogramming of Mtb during acute and 
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chronic (latent) phases of TB disease. However, biochemical knowledge of Mtb 
metabolic networks remains scarce.   
 
1.5.2.1. Carbohydrate, TCA cycle 
During aerobic in vitro growth of Mtb, various carbon sources feed into central 
carbon metabolic (CCM) pathways such as D-glucose (dextrose), glycerol and 
acetate, where each carbon source is widely catabolized into intermediates of 
glycolysis/gluconeogenesis, the pentose phosphate pathway (PPP) and the TCA 
cycle (160, 168). de Carvalho et al (2010) concluded that Mtb did not exhibit diauxic 
growth (consuming individual carbon substrates in a preferred sequence) but Mtb 
can catabolize multiple carbon sources simultaneously, leading to enhanced 
monophasic growth. For instance, while co-catabolizing glucose and glycerol, Mtb 
preferentially metabolized glucose into intermediates of glycolysis and PPP, and 
glycerol for TCA cycle intermediates. However, concurrently, Mtb also incorporated 
low levels of glycerol into glycolytic/gluconeogenic and pentose phosphate 
intermediates (160). In the absence of exogenous sugars, glycolytic intermediates are 
precursors for biosynthetic pathways as well which are generated by 
gluconeogenesis (154).  
 
The TCA cycle is the major energy-generating pathway in aerobic organisms as it 
plays essential roles in cell metabolism, providing reduced equivalents for energy 
generation and biosynthetic reactions as well as yielding precursors for lipids, amino 
acids and heme synthesis. Mtb is considered an aerobic-to-facultative anaerobe 
bacillus and has functional genes coding for all enzymes of the standard TCA cycle 
regardless of its ability to survive for long periods in a hypoxic environment (33, 
148). In fact, it is intriguing that the TCA cycle in Mtb is unusual in that α-
ketoglutarate dehydrogenase (KDH) is replaced by α-ketoglutarate decarboxylase 
(KGD), which is absent in mammalian cells, and a succinic semialdehyde 
dehydrogenase (169, 170). In the γ-Aminobutyric acid (GABA) shunt, an alternative 
pathway from α-ketoglutarate to succinate via succinic semialdehyde (SSA) was 
proposed which replaces the succinyl-CoA in Mtb TCA cycle (169). Although this 
pathway supports growth on carbohydrates when the glyoxylate shunt is inoperable, 
Mtb still requires production of succinyl-CoA by an alternate enzyme, anaerobic-like 
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α-ketoglutarate:ferredoxin oxidoreductase (KOR) (171). Importantly, the presence of 
a functional glyoxylate shunt and KOR could bypass the requirement for KDH 
activity. These observations show that, unlike most organisms, Mtb employes two 
different pathways from α-ketoglutarate, one that functions simultaneously with β-
oxidation, KOR-dependent, and one that functions in the absence of β-oxidation, 
KGD-dependent (171, 172). 
 
1.5.2.2. Fatty acids metabolism, Glyoxylate shunt 
During infection, Mtb switches its carbon sources of glycerol and glucose to fatty 
acids, where upregulation of Mtb genes involved in fatty acid catabolism has been 
observed in vivo from the lungs of mice and humans (173-175). A transcriptional 
profiling study of Mtb recovered from macrophages in vitro showed induction of 
genes involved in the β-oxidation of fatty acids upon converting the microbe from 
aerobic to anaerobic respiration (154). Mtb possesses more than 250 enzymes 
involved in lipid metabolism, which includes enzymes for lipid biosynthesis as well 
as degradation, where host cell lipids degradation is crucial for the intracellular life 
of the organism (148, 176). 
 
Two pathways are required for fatty acid utilization by bacteria: the β-oxidation 
cycle and the glyoxylate shunt. The β-oxidation cycle is the dominant route for 
oxidative degradation of fatty acids in bacteria and eukaryotes, yielding acetyl-CoA 
and propionyl-CoA. Acetyl-CoA molecules are generated from the β-oxidation of 
both odd- and even-chain-length fatty acids, while propionyl-CoA comes from odd-
chain-length fatty acids degradation, and can also be generated by catabolism of 
cholesterol, methyl-branched fatty acids and branched-chain amino acids (168, 177, 
178). 
 
The importance of the glyoxylate shunt, which has no mammalian counterpart, was 
demonstrated by McKinney et al (2000), who showed that the persistence of Mtb in 
macrophages and mice requires the glyoxylate shunt enzymes, isocitrate lyases (ICL 
1 and 2) (172). Similarly, it has been proposed that glyoxylate cycle enzymes are 
activated during adaptation to the low oxygen environment of the granuloma. Upon 
using fatty acids as the principal carbon source, replenishment of TCA cycle 
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intermediates (anaplerosis) occurs via the glyoxylate cycle that converts acetyl-CoA 
into oxaloacetate. In the glyoxylate shunt, ICL 1 and 2 catalyse the cleavage of 
isocitrate into glyoxylate and succinate while malate synthase (MLS) mediates the 
condensation of glyoxylate and acetyl-CoA into malate (168, 175). Isocitrate lyases 
(ICLs) play two main roles during infection, bypassing carbon loss under limited 
nutrient availability by using the glyoxylate shunt and preventing accumulation of 
toxic propionyl-CoA (16). ICLs are jointly required for fatty acid catabolism, in vivo 
growth in the macrophage and mice, and for virulence in Mtb, as mutant bacteria 
lacking icl1 and icl2 cannot grow in mice and are rapidly eliminated (179). Beste et 
al (2011) demonstrated a role for ICLs and the glyoxylate shunt during slow growth 
rate of Mtb on glycerol suggesting that they operate under more general conditions 
(180).  
 
The methylcitrate cycle in Mtb is operational with ICL 1 and 2 serving dual roles as 
ICLs in the glyoxylate shunt and as a 2-methylisocitrate lyase (MCL) in the 
methylcitrate cycle (175, 181). Propionyl-CoA is assimilated via the methylcitrate 
cycle which oxidizes propionyl-CoA to pyruvate (182). Mtb uses the 
methylmalonyl-CoA pathway to metabolize propionyl-CoA for cell wall synthesis 
(175). Moreover, ICLs control propionate levels when the bacterium uses specific 
carbon sources, such as cholesterol, fulfilling a detoxification function (177, 183). 
Pandey and Sassetti (2008) showed that Mtb utilizes cholesterol, a major component 
of host cell membranes, during Mtb persistance in the lungs of chronically infected 
animals as well as during the growth of Mtb within IFN-γ-activated macrophages 
that predominate at this stage of infection (183). During cholesterol catabolism 
metabolic modification is centered on propionyl-CoA and pyruvate pools that 
necessitate the stimulation of the propionyl-CoA-assimilating methylcitrate cycle 
(MCC) enzymes (184). It is becoming apparent that fatty acid metabolism is pivotal 
during infection and that the glyoxylate shunt could be a good target for drug 
development. However, the possibility of a parallel uptake of additional carbon 
sources such as sugars, fatty acids and amino acids from the human host during 
infection cannot be excluded, as been observed in cholesterol uptake mutants that 
grow normally in resting macrophages of infected mice (183, 184). 
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Although it has been suggested that mycobacteria in vivo-growth is lipolytic rather 
than lipogenic, fatty acid biosynthesis still plays an important role (148). Mycolic 
acids, representing essential components of the mycobacterial cell wall, are very 
long-chain β-hydroxy fatty acids with a long α-alkyl side chain (185). The 
biosynthetic pathway of mycolates involves two types of fatty acid-synthesizing 
systems, FAS-I and FAS-II (148). The multifunctional FAS-I polypeptide contains 
all the functional domains required for de novo fatty acid synthesis (186). 
Mycobacterial FAS-II elongates acyl-CoA primers generated by FAS-I to a mixture 
of homologous fatty acids of longer chain lengths (meromycolic acids) (187).   
 
Redox couples in Mtb are NAD
+
/NADH, NADP
+
/NADPH and FAD/FADH2, all of 
which are vital for both anabolic and catabolic reactions. NAD
+
, an efficient electron 
sink, is used as a cofactor in several oxidising reactions. A constant level of NADH 
is maintained during various phases of growth in vitro, while the concentration of 
NAD
+
, a major contributor to a change in NADH/NAD
+
 ratio, is variable. A higher 
ratio of Mtb NADH/NAD
+
 is generated during the transition from aerobic to 
anaerobic growth phase (188, 189). β-oxidation of fatty acids consumes NAD+ and 
FADH in every cycle of fatty acid oxidation, therefore type II NADH dehydrogenase 
(NDH-2) induction signals the need of NAD
+
 regeneration to maintain the NAD
+
 
pool (154). Concurrently, the β-oxidation of fatty acids yields one NADH and one 
FADH2 molecule for every acetyl-CoA generated. Consequently, NADH and 
FADH2 channel the electrons to the ETC, which consecutively oxidises and reduces 
multiple redox centres before generating ATP (188). 
 
1.5.2.3. Amino acids metabolism 
The existing knowledge about amino acid metabolism in mycobacteria is limited. 
Generally, L-asparagine is the preferred source of nitrogen for the growth of 
mycobacteria but can be replaced by L-alanine, L-glutamine or L-glutamic acid. In 
glycerol-enriched media, glutamate becomes the preferred source of nitrogen (190). 
One of the most important precursors for gluconeogenesis are free amino acids 
which might increase when amino acids are not utilized for protein anabolism but are 
oxidized by impairment of protein synthesis (191). The Mtb genome revealed a 
statistically significant preference for the amino acids alanine, glycine, proline, 
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arginine and tryptophan all of which are encoded by G + C rich codons, and a 
comparative reduction in the use of asparagine, isoleucine, lysine, phenylalanine and 
tyrosine amino acids, encoded by A + T rich codons (148). 
 
During infection, due to the high demand for amino acids as substrates for energy 
production, many amino acids significantly increased in the lung, spleen, liver, and 
serum of Mtb-infected mice. Moreover, Shin et al (2011) found that intermediates of 
pyrimidine metabolism, uracil, uridine, and UDP-glucose, and intermediates of 
purine metabolism ATP, AMP, inosine, allantoin, and xanthine were high in Mtb-
infected mice (191).  
 
Central carbon metabolic pathways of Mtb are depicted in the following Figure 
(1.14), including the major catabolic intermediates and amino acids. Importantly, 
these metabolic pathways are found to be critical for the virulence of Mtb during 
infection. 
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Figure 1.14: Central metabolic pathways of Mycobacterium tuberculosis (192-194) 
Central carbon metabolic pathways depicting a bioinformatic inventory of Mtb’s CCM 
pathways, inculding the anabolic monomers (amino acids; purple boxes) and the major 
catabolic intermediates from which they derive (dashed grey arrows) are shown. Major 
carbon substrates are shown in green boxes. The CCM pathways are colour-coded as present 
in the key panel. KOR, α-ketoglutarate:ferredoxin oxidoreductase and KGD, α-ketoglutarate 
decarboxylase. His, Histidine; Arg, Arginine; Asn, Asparagine; Asp, Aspartic acid; Ala, 
Alanine; Cys, Cysteine; Gln, Glutamine; Glu, Glutamic acid; Gly, Glycine; Ile, Isoleucine; 
Leu, Leucine; Lys, Lysine; Pro, Proline; Ser, Serine; Thr, Threonine; Trp, Tryptophan; Tyr, 
Tyrosine; Val, Valine; Phe, Phenaylalanine; Met, Methionine. 
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1.5.3. Electron transport and respiration in Mycobacterium tuberculosis 
The importance of the flexibility, conferred by a modular respiratory system, in the 
survival of Mtb has led to the targeting of the ETC components in the context of 
developing new anti-TB drugs.  
 
Mtb oxidizes a variety of electron donors including succinate, NADH, lactate, 
malate, proline and glycerol using different aerobic, microaerophilic and anaerobic 
respiratory systems. Consequently, the generated electrons are transported to any 
terminal electron acceptors that include oxygen, nitrate, nitrite and fumarate. ETC 
contains electron carriers in heme molecules, copper atoms or flavin prosthetic 
groups forms. Generally, dehydrogenases transfer electrons from cytoplasmic 
electron donors into the quinone pool, in the centre of the ETC, resulting in reducing 
menaquinone to menaquinol. Subsequently, the menaquinol is oxidized back to 
menaquinone by the cytochrome bc1 complex. Successively, bc1 complex passes 
electrons to a terminal oxidase, cytochrome bd-I oxidase. In anaerobic respiration, 
terminal reductases comprising nitrate reductases and fumarate reductase replace the 
terminal oxidase. Finally, electrons are transferred to the terminal electron acceptor. 
A proton motive force (PMF) forms as a result of simultaneous action between 
electron migration across the chain and proton passage from the cytoplasmic side 
into the periplasmic side of the membrane. Production of ATP is a result of gradient 
dissipation by movement of the protons through a membrane-associated ATP 
synthase back into the cytoplasm (195). The composition of the respiratory system of 
Mtb is shown in Figure (1.16). The biochemical properties and physiological roles of 
the specific respiratory system components of Mtb are described in more detail. 
 
1.5.3.1. Electron donors 
NADH:menaquinone oxidoreductases, also known as NADH dehydrogenases 
(NDH), are one of the main electron donors of the Mtb respiratory system. NDH 
play an essential role in transferring electrons from NADH to the quinone pool and 
in NAD
+
 recycling. Mtb has three different NDH: a type I NDH (NDH-1) and two 
type II NDH (NDH-2 and NDH-2A). The redox activity in NDH-1 is coupled to 
proton translocation while in NDH-2 and NDH-2A is not. NDH-2 and NDH-2A are 
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single-subunit dehydrogenases that catalyse electron transferring from NAD(P)H to 
the quinone pool without proton translocation across the membrane (195). Studies 
have suggested that NDH-1 and NDH-2A are dispensable for Mtb growth in vitro, 
while NDH-2 is required for optimal Mtb growth in vitro (116). Further, NDH-2A 
was shown to have no role in the virulence of Mtb in SCID mice (2, 196). Weinstein 
et al (2005) found that the classic inhibitors of NDH-1 (rotenone, piericidin A, and 
pyridaben) did not inhibit overall oxidoreductase activity (197). Thus, NDH-2 is 
suggested to function as the main NDH of the Mtb respiratory chain (198).  
 
Succinate dehydrogenase (SDH) is known as complex II of the ETC and catalyses 
the oxidation of succinate to fumarate and the reduction of the quinone. SDH is an 
essential part of the TCA cycle and has a role in aerobic respiration (195, 199, 200). 
The Mtb respiratory chain has other dehydrogenases, L-lactate (LDH), Glycerol-3-
phosphate (G3PDH), malate (MDH) and proline dehydrogenase (PDH), for 
oxidizing the other electron donors but without identified function (195). 
 
1.5.3.2. Quinones in Mycobacterium tuberculosis 
Quinones are lipid-soluble molecules that have a critical role in the ETC as a 
reversible redox component, carrying electrons between electron donors and 
acceptors (201). In bacteria, quinones present in different forms, which are 
ubiquinone, menaquinone, and/or demethylmenaquinones, of which menaquinone is 
known as the sole quinone in Gram-positive bacteria (Figure 1.15). Mycobacteria 
have only menaquinone according to the genomic data of Mtb (148). The variant of 
menaquinone in Mtb contains nine isoprene units (MQ-9) (202). MQ-9 synthesized 
by a series of enzymes encoded by menABCDEH (203). Menaquinone has a lower 
redox potential than ubiquinone that confers less tendency to accept electrons and 
being reduced (195). The quinone structure consists of a hydrophobic isoprenoid unit 
rendering quinone soluble in the interior of the membranes (204). 
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                 Figure 1.15: Structures of (a) Ubiquinone and (b) Menaquinone 
 
1.5.3.3. Electron Acceptors  
The cytochrome bc1 reductase-cytochrome c oxidase super-complex comprises 
cytochrome bc1 reductase (bc1 complex) which catalyzes the oxidation of 
menaquinol (MQH2) and the aa3-type cytochrome c oxidase (CcO). Electrons from 
the bc1 complex are passed through an iron-sulphur cluster and cytochrome c to the 
CuA atom in the CcO where the reduction of O2 to water takes place. This catalysis is 
coupled with proton translocation across the membrane, resulting in greater energy 
conversion (195).    
 
Cytochrome bd-I oxidase is a terminal oxidase that oxidizes menaquinol and reduces 
O2 to water (195). Cytochrome bd-I oxidase has the ability to generate a PMF by 
trans-membrane charge separation, unlike heme-copper terminal oxidases, with a 
“proton pump” mechanism (205). Generation of PMF by trans-membrane charge 
separation is conducted by virtue of the fact that protons resulting from the oxidation 
of ubiquinol are released into the positive (periplasmic) side of the membrane, while 
the protons used to convert O2 to H2O are taken from the negative (cytoplasmic) side 
(205, 206).  
 
Amongst the mycobacteria, Mtb is the most competent reducer of nitrate, containing 
two homologues of nitrate reductases (NRs) encoded by narGHJI and narX. NR 
catalyses the reduction of nitrate to nitrite, granting Mtb with the ability to persist 
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under O2 depletion (anaerobic condition) and/or nitrate abundance conditions (195, 
207).    
 
Fumarate reductase (FRD) is more efficient at catalyzing the reduction of fumarate 
to succinate and the oxidation of quinol (QH2), the reverse reaction of SDH. FRD 
accepts electrons from QH2 and acts as terminal electron acceptor under anaerobic 
conditions. FRD is suggested to be involved in the mechanism of Mtb persistence 
(195, 199, 200).  
 
In Mtb there are genes that encode a cytoplasmic NirBD nitrite reductase and 
sulphite/nitrite reductase, NirA. Through the action of anaerobic nitrite reductases, 
the nitrite resulting from degradation of reactive nitrogen intermediates or nitrate 
respiration can be reduced to ammonia (195).  
 
F0F1 ATP synthase, encoded by the atpBEFHAGDC operon, is a multisubunit 
complex consisting of a membrane-embedded proton-pumping F0 part and a 
cytoplasmic, catalytic and non-catalytic nucleotide binding domain, F1. During 
aerobic respiration, the enzyme is responsible for the production of ATP by 
oxidative phosphorylation whereas in anaerobic respiration, it works as ATPase, 
pumping protons through the membrane. The F0F1 ATP synthase can utilize the PMF 
across the bacterial cytoplasmic membrane for the synthesis of ATP (195, 208).  
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Figure 1.16: Components of the electron transport chain in Mycobacterium tuberculosis (209) 
The chain electron donor components are Ndh/NdhA-type II NADH: (mena)quinone oxidoreductase (two isoforms), SDH-succinate dehydrogenase, G3PDH-
glycerol-3-phosphate dehydrogenase, LDH-L-lactate dehydrogenase, MDH-malate dehydrogenase, PDH-proline dehydrogenase and nuo-type I NADH 
(complex I). Electron acceptors are cytochrome bc1-aa3 super complex-the cytochrome bc1 reductase-cytochrome c oxidase super-complex and an alternative 
terminal oxidase pathway which comprises cytochrome bd oxidase (quinol oxidase), FRD-fumarate reductase and NR-nitrate reductase. Chain components 
also include F0F1 ATP synthase (complex V), MK-9-menaquinone-9 and MKH2-menaquinol. P and n correspond to the positive and negative sides of the 
respiratory membrane with respect to proton translocation. Proton movements are indicative only and do not represent H
+
/e
-
 ratios for the respective 
complexes. The orientation and topology of the subunits are indicative only. 
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1.5.4. Cytochrome bd-I oxidase 
1.5.4.1. Definition 
Cytochrome bd-I oxidase is a respiratory quinol: O2 oxidoreductase found in many 
prokaryotes, including strictly anaerobic bacteria such as Desulfovibrio vulgaris 
Hildenborough (DvH) (210). Respiratory oxygen terminal oxidases are a class of 
enzymes at the end of the respiratory chain of organisms that couple the oxidation of 
a respiratory substrate, cytochrome c or QH2, to the reduction of O2 to water. This 
type of reaction leads to the bioenergetic function of cytochrome bd-I oxidase 
through the production of a PMF by a vectorial charge transfer of protons (211).  
 
1.5.4.2. Subclasses 
Oxygen reductases (terminal oxidases) are classified into three distinct families 
which are the heme-copper family, the alternative oxidase (AOX) family and the 
cytochrome bd family. The cytochrome bd family are quinol oxidases with no 
homology to any subunit of the heme-copper family or the AOX family. The 
cytochrome bd family does not have copper or non-heme iron (53, 211-214). 
Moreover, based on structural and spectroscopic observations, the cytochrome bd 
family is sub-classified into the A-subfamily (long Q-loop), B-subfamily (short Q-
loop) and the cyanide insensitive oxygen reductases (CIO) (211). The Q-loop is a 
hydrophilic domain of subunit I of cytochrome bd-I oxidase and has been implicated 
as part of the quinol binding site. The long Q-loop bd-family members have an insert 
in the C-terminal portion of the Q-loop, while the short Q-loop bd-members do not 
have this insert (211, 215). At the gene sequence level, CIO has no differentiating 
characteristic that could distinguish CIO from other members of cytochrome bd 
family. However, CIO has been characterized by low heme d content and resistance 
to cyanide (211, 216).  
 
Interestingly, although many aerobic prokaryotes do not contain any member of the 
bd family, some prokaryotes have more than one bd family member, for instance, 
two: E. coli (217, 218); three: Vibrio cholerae (219); and as many as six bd-type 
oxidoreductase: some Acidithiobacillus strains (211). In Mtb, there is only one bd 
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family member, the cydAB-encoded cytochrome bd-I oxidase (148) that serves as an 
alternative terminal oxidase pathway under oxygen-limited conditions (195, 209).  
 
1.5.4.3. Physiological functions 
The cellular bioenergetic function of cytochrome bd-I is the production of a PMF via 
liberation of protons upon quinol oxidation (218, 220). Cytochrome bd-I grants 
bacteria with a number of vital physiological functions. Cytochrome bd-I permits 
colonization of O2-poor environments (221, 222), by working as an O2 scavenger in 
order to prevent degradation of O2-sensitive enzymes such as nitrogenase (223). This 
enzyme was found to support anaerobic photosynthetic growth as well (224). 
Moreover, it is of interest to note the positive correlation between the level of 
cytochrome bd-I expression and microbial pathogen virulence which was observed 
in tuberculosis, pneumonia, life-threatening sepsis and meningitis (211, 221, 225). 
Further physiological functions of cytochrome bd-I oxidase are in improving 
bacterial tolerance to nitrosative stress (211, 226, 227), contributing in detoxification 
of hydrogen peroxide in E. coli (228), suppressing extracellular superoxide 
production in Enterococcus faecalis (229), and involvement in the degradation of 
aromatic compounds in Geobacter metallireducens (230). Under conditions of nitric 
oxide (NO) stress, cytochrome bd-I was overexpressed, granting nitric oxide 
resistance to E. coli (231). It has been suggested that Mtb cytochrome bd-I oxidase 
may thus serve to maintain an energized membrane during the persistent stages of 
infection, NRP stage 1 and 2 (20), and forms a part of the Mtb defence system 
against immune-mediated oxidative damage (232).  Shi et al (2008) wrote that 
cytochrome bd-I oxidase is a potential enzyme candidate that may defend against 
reactive oxygen and nitrogen species (ROS and RNS) produced by the host adaptive 
immunity during tuberculosis infection (233).  
 
1.5.4.4. Cytochrome bd expression conditions 
There are many stressful conditions that influence the expression of cytochrome bd 
family in E. coli. For instance, low O2 tension (234), alkalinization of the medium 
(235), high temperature (236), the presence of poisons in the environment (for 
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example, cyanide) (237), uncouplers-protonophores (235, 238) and high hydrostatic 
pressure, observed in Shewanella violacea DSS12 (239). In Mtb, a high level of 
cytochrome bd-I expression was recorded during NRP stages 1 and 2 growth 
conditions, categorized by low O2 tension and metabolic slowdown (20). In M. 
smegmatis, although the threshold pO2 for cyd induction is at 1% air saturation, 
cyanide induces cydAB gene expression at 21% air saturation (Kana et al., 2001). 
Further, DNA microarray analyses showed an up-regulation of Mtb H37Rv cydA 
(2.7-fold) during Mg
2+
 starvation (240). CydAB gene expression in Mtb was up-
regulated by inhibitors of CcO and during adaptation to hypoxia (241) which is 
probably a response to the disruption of the bc1-aa3 pathway (242). Similarly in M. 
smegmatis, up-regulation of cytochrome bd-I oxidase occurred in response to 
disruption of the bc1-aa3 respiratory pathway as well (242). However, Mtb cydAB 
gene expression showed no up-regulation during hydrogen peroxide (H2O2) or 
menadione treatment (241).  
 
1.5.4.5. Genetics 
1.5.4.5.1. Genes of Mycobacterium tuberculosis encoding the protein subunits 
and assembly factors of the cytochrome bd-I oxidase 
The genes involved in the expression of the cytochrome bd-I oxidase are the cydA 
and cydB genes, encoding subunits I and II of the cytochrome bd-I oxidase, 
respectively. The cydDC genes, located immediately downstream of the cydA and 
cydB genes, encode an ABC-type transporter which is implicated in the assembly of 
functional bd-type oxidase (195, 232, 243-247) and in maintaining redox 
homeostasis in the periplasm (53, 248, 249).  
 
1.5.4.5.2. Regulation of cydAB operon expression      
Two global transcriptional regulators, Arc and Fnr control the expression of the 
cydAB operon (250). Arc is a two-component regulatory system, ArcA and ArcB, of 
which ArcA responds to the oxidation state of the quinone pool, sensed by ArcB 
(251). Under microaerophilic conditions (O2 tension of 2-15% of air saturation), a 
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high level of phosphorylated ArcA activates the cydAB operon in E. coli (252). The 
Fnr regulator is active only during anaerobic growth and it serves as redox sensor. 
During the transition to anaerobic conditions (O2 tension of less than 2% of air 
saturation), the active Fnr regulator inhibits cytochrome bd-I (250). However, the 
induction of cyd expression differs between organisms. For example, the threshold of 
O2 tension for cyd induction in M. smegmatis (253) and Mtb (221) is suggested to be 
at 1% air saturation while in E. coli it is found to be at 10% air saturation (254). 
     
1.5.4.6. Cofactors and substrates 
The oxidation of quinols by cytochrome bd-I enzyme as an electron acceptor is 
species-specific. For example, in E. coli the cytochrome bd-I enzyme can oxidize 
both ubiquinol (UQH2) and menaquinol (MQH2) whereas in B. stearothermophilus, 
the substrate of cytochrome bd-I is MQH2 and in Azotobacter vinelandii is UQH2 
(255, 256). MQH2 is the substrate in Mtb as mentioned previously (195).  
  
Cytochrome bd-I oxidase has a three-heme enzyme comprising two protoheme IX 
groups (hemes b558 and b595) and a chlorin (heme d). The low-spin hexacoordinate 
heme b558 accepts electrons from a quinol (257) whereas the high-spin heme d is 
recognized as the O2 binding site and it catalyses the reduction of O2 to water. 
Construction of cydA and cydB mutants in E. coli located heme b558 on subunit I and 
hemes b595 and d on subunit II of cytochrome bd oxidase (258, 259). Using mutant 
strains defective in cydB, Green et al (1986) managed to express, purify and retain 
only heme b558 (cydA–encoded) (260). The location of heme b558 heme b595 and heme 
d is predicted to be near the periplasmic surface (215, 261).  The α-band of the 
reduced heme d in the absolute absorption spectrum of E. coli cytochrome bd-I 
showed a peak at 628–632 nm. The α-bands of the reduced heme b558 and heme b595 
at room temperature reveal maxima at 560–562 nm and at 594–595 nm respectively, 
in the difference absorption spectrum (262, 263).  
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1.5.4.7. Proposed catalytic mechanism  
Cytochrome bd-I oxidases in E. coli are known to have a relatively high affinity for 
O2 (Km = 0.3 µM) and the ability to generate PMF by trans-membrane charge 
separation, unlike heme-copper terminal oxidases which operate with a “proton 
pump” mechanism (205, 213, 231). The electron transfer sequence in cytochrome 
bd-I is thought to be QH2 → heme b558 → [heme b595 → heme d] → O2. This process 
will be explained in detail in Chapter (III). 
 
1.5.4.8. Inhibitors of cytochrome bd-I 
Quinol oxidase inhibitors are classified into two main groups: inhibitors that operate 
at the Q-binding site (Q-like compounds) and inhibitors that act at the O2 
binding/reducing site (heme ligands) such as cyanide, azide or nitrite. Importantly, 
inhibitors acting at the oxygen reduction site tend to be moderately weak (53, 211, 
213). Therefore, investigations for specific inhibitors of the bd-I type oxygen 
reductases, which could be used in clinical practice, took place where aurachins C 
and D and their alkyl-substituted derivatives were found to be potent inhibitors 
against quinol oxidases (264). Gramicidin S (GS), a cationic cyclic decapeptide, was 
found to be a potent inhibitor against E. coli bd-I (IC50 5.3 μM) as well. However, 
the membrane lipid bilayer was found to be the main target of GS rather than bd-I 
(265).  
 
1.5.4.9. The importance of bd-I and latency 
Tackling latent TB is a main goal in the new era of TB drug discovery, providing a 
promising approach for shortening the duration of current TB therapy, as seen for 
PZA (126), RIF (266), TMC207, a novel diarylquinoline (267) and MTZ (35). 
Latency is a condition that displays the ability of Mtb bacilli to adapt under any 
stress from the host immune system. The importance of cytochrome bd-I oxidase in 
dormant Mtb bacilli or in persister cells of Mtb during latency was proposed by 
different studies. Initially at the genome level, cydAB-encoded cytochrome bd-I 
oxidase was defined to be essential for Mtb survival (2). The critical role of the 
cytochrome bd-I oxidase was further defined in the context of Mtb bacilli adaptation 
to stress conditions. Transcriptional studies confirmed the significance of this 
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enzyme both in vivo and in vitro where the level of Mtb bd-I expression was higher 
under hypoxic conditions (20, 212, 221). Boshoff et al (2004) found that the 
cydABDC operon was up-regulated in response to the respiratory inhibitors such as 
the phenothiazines (e.g. thioridazine, TRZ), the CcO-specific inhibitors (cyanide and 
azide) and redox cycling agents (menadione and clofazimine). Moreover, the study 
found that isoniazid- and pyrazinamide-treated Mtb showed up-regulation of the 
cydABDC operon (241). Interestingly, the F1-ATPase-defective E. coli and 
Corynebacterium glutamicum mutants were found to have specific up-regulation of 
less efficient PMF generation components, such as NDH-II and cytochrome bd-I, to 
avoid generating excess PMF (268, 269). This observation emphasises the 
importance of cytochrome bd-I during restricted conditions such as latency where 
ATP synthase was found to be down regulated. Importantly, single-gene mutation 
studies suggested that cydDC, encoding an ABC transporter and implicated in 
cytochrome bd-I assembly, might engage in Mtb persister formation or maintenance 
(24, 52).    
 
1.5.5. Transcriptional changes in respiratory chain components of 
Mycobacterium tuberculosis among various growth models  
The fact that there is a high degree of microenviromental diversity encountered by 
the tubercle bacillus during infection in humans originates from different extents of 
cavitary disease (Tuberculosis) within a single patient, and since within a lesion 
several immunological microenvironments exist to exert different effects on bacterial 
subpopulations (15, 20). As the science behind these microenvironments remains 
unknown, in vitro models have been developed to mimic the environments that are 
thought to be encountered by Mtb in vivo. Models in which the tubercle bacilli enter 
into a state of NRP include, but are not restricted to, carbon starvation (Loebel 
model) (270), O2 depletion in vitro (Wayne model) (33) and the chronic stage of 
infection in mice (195).    
 
Oxygen limitation is believed to be a crucial factor affecting the metabolism of Mtb 
during pathogenesis, since the granuloma would have such hypoxic environments 
(20, 25, 271). Numerous studies analysed the transcriptome of Mtb in a hypoxic 
model and suggested that the NRP state was associated with O2 depletion and nitrate 
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reduction (221, 241, 271, 272). Bacon et al (2004) recorded a strong induction of the 
narX and narK2-encoded NR and nitrate/nitrite transporter respectively, during 
growing Mtb in a chemostat at 1% air saturation, signalling a shift to nitrate 
metabolism. In the Wayne model, a gradual O2 depletion resulted in the initial 
establishment of the NRP-1 state (1% air saturation), followed by NRP-2 (0.06% air 
saturation), a state acknowledged by a widespread of metabolic cessation. 
Simultaneously, the following genes: cydA, cydB, cydC, and cydD were induced to 
3.1-, 2.9-, 1.6- and 2.6-fold, respectively, while the expression level of the bc1–aa3 
super complex remained unchanged (33, 34, 43, 221). Concomitant with these 
changes was the down-regulation of the intracellular ATP level of oxygen-starved 
bacilli (Wayne bacilli) by 5-fold compared to that of exponentially growing bacilli 
(273, 274).   
 
The carbon starvation model, accompanied by O2-limiting conditions resulted in 
down-regulation of 47% of aerobic respiration genes, among which were 
cytochrome bd-I oxidase, SDH and ATP synthase, and the up-regulation of genes 
encoding FRD and NR (195, 270).  The hallmark of Mtb growth in resting bone-
marrow-derived macrophages model was the reduction of aerobic respiratory 
components, NDH-1 and CcO, concurrently with the down-regulation of ATP 
synthase coding genes. These observation were indicative of low energy necessities 
during intracellular growth (154). Simultaneously, an induction of nitrate/nitrite 
transport, NR and FRD in activated macrophages were indicative of their availability 
as alternate electron acceptor in the intracellular environment of Mtb (275).   
 
Regarding the transcriptional profiling of Mtb respiratory chain components using in 
vivo models, there are three distinct respiratory states defined during Mtb 
colonization of mouse lungs (murine model). The first respiratory state occurs during 
the acute phase and is characterized by a bioenergetically efficient state, as 
evidenced by up-regulation of genes encoding ATP synthase, NDH-1 and CcO 
subunits (221). The second respiratory state appears as result of NO production, a 
central component of the host immune response. This state is characterized by the 
down-regulation of bioenergetically efficient respiratory components and ATP 
synthase and concurrent up-regulation of microaerophilic respiration genes, 
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cytochrome bd-I oxidase and nitrate reduction and transport (221). Moreover, NO 
marks the appearance of the third respiratory state, characterized by the down-
regulation of cytochrome bd-I oxidase and strong up-regulation of NRs (221). 
However, challenging Mtb with NO drove the organism to nitrate reduction and led 
to up-regulation of cytochrome bd-I oxidase and NDH-2 (195, 271, 276, 277).  
 
The respiratory states of Mtb in human disease are not well characterized. 
Nonetheless, it is worth noting that some studies detected the expression of NR, 
together with FRD genes in the granulomatous region that is found in the pericavity 
and in the distal lung (158, 278). 
 
1.6. Potential future anti-TB drugs 
1.6.1. TB drugs global alliance 
The current TB treatment regime has many challenges, which include complex 
dosing schedules, long treatment times, and growing rates of drug resistance. The 
Stop TB partnership set a goal for adequately controlling TB and to ultimately 
eradicate it by 2050, and for this to be a reality, new drugs, diagnostics and vaccines 
will be required (http://www.stoptb.org/). Generally, the Target Product Profiles of 
new TB drugs state that drugs need to be effective against resistant strains as well as 
able to treat latent infection, compatible with anti-retroviral therapy, suitable for 
paediatric populations and shorting and simplifing the duration of treatment (279).   
 
1.6.2. Important drugs that target Mtb ETC 
A new anti-tubercular drugs, targeting the ETC component of Mtb, is currently in 
clinical development and known as TMC207 (R207910, Bedaquiline). TMC207 is a 
novel diarylquinoline that demonstrates a potent anti-TB activity both in vitro and in 
vivo with the same target specificity on both replicating and dormant bacilli (280). 
TMC207 acts by specifically targeting the subunit c, encoded by the gene atpE of the 
F1F0-ATP synthase, causing a pronounced bactericidal effect (267). TMC207 is 
currently in Phase IIb clinical trials for the treatment of patients with MDR-TB (274, 
281).  
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Phenothiazines are old drugs that re-emerged recently as potential anti-TB agents. 
Phenothiazines target the Mtb ETC through inhibiting type II NADH: menaquinone 
oxidoreductase. Warman et al (2012) showed that phenothiazine activity against Mtb 
NDH-2 is directly correlated to antitubercular activity against Mtb under both 
aerobic and anaerobic growth conditions. However, the potential and known 
toxicities of the phenothiazine class still exist. Therefore, phenothiazines could be 
used as potential templates on which to base future anti-TB drugs that overcome the 
current drawbacks (282). 
 
1.6.3. Other future drugs candidates 
Owing to the fact that each of anti-TB drugs has potential as a starting point for the 
discovery of a new clinical candidate, new chemical entities have progressed in 
clinical development based on chemical tailoring of existing drugs or drug classes. 
Two approved fluoroquinolones (moxifloxacin and gatifloxacin), DNA gyrase 
inhibitors, have shown promising results for treating resistant TB strains and 
shortening the duration of treatment. The parent scaffold of moxifloxacin and 
gatifloxacin is nalidixic acid and they are currently in phase III clinical trials where 
the efficacy of these drugs in replacing either INH or ethambutol in first-line therapy 
is being tested (138, 279, 283, 284). Furthermore, cell wall synthesis inhibitors, PA-
824 and OPC-67683 (nitroimidazole family), with a remarkable antitubercular 
activity are in phase II clinical trials, and they are remodelling of Metronidazole. 
PNU-100480 is a protein synthesis inhibitor, developed from Linezolid 
(oxazolidinone family), and is in phase II clinical trials as well (279). Moreover, 
SQ109 (diamine derivative) is a new cell wall synthesis inhibitor, and targets a 
mycolic acid transporter (MmpL3). SQ109 is in Phase II clinical trials and shows 
synergistic effects with the antitubercular drugs isoniazid and rifampicin (138, 281, 
285, 286).  
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1.7. Objectives 
This thesis sets out to expand the current knowledge of the ETC of Mtb.  
Specifically, the thesis has focused on an important, but hitherto little studied 
component, the cytochrome bd-I quinol oxidase.  A basic characterisation of this bd-
I quinol oxidase has been undertaken as well as an initial study to determine its 
pharmacological potential as a drug target.  As an extension to this work, an initial 
pharmacometabolomics study was undertaken to determine the cellular 
consequences of targeting this component.  The specific objectives include; 
 Cloning and expression of Mtb cytochrome bd-I oxidase (Mtb bd-I), 
using two different heterologous expression systems (ML16 (bo3/bd-I) 
and MB44 (bo3/bd-I/bd-II)). 
 Steady state characterisation of Mtb bd-I in the two expression models. 
 Pharmacological profiling of Mtb bd-I in the two expression models and 
chemical validation of the target. 
  Set up of a pharmacometabolomics platform to assess the cellular 
consequence of perturbation on Mtb metabolism by known drugs and 
selective ETC inhibitors. 
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Chapter II 
Generation and characterisation of a heterologous 
expression system for Mycobacterium tuberculosis 
cytochrome bd-I oxidase in an E. coli respiratory 
knockout (bo3/bd-I) mutant strain. 
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2.1. Introduction 
The aim of this study was to explore the features of the Mtb cytochrome bd-I oxidase 
(Mtb bd-I) through initially cloning the enzyme, followed by characterizing the 
expression, growth conditions and the spectroscopic signature of this enzyme.  
 
Kana et al (2001) previously demonstrated the ability of recombinant Mtb 
cytochrome bd-I oxidase to restore bd-I activity in a M. smegmatis mutant strain 
(253).  However, detailed studies of Mtb cytochrome bd-I in terms of functionality 
and inhibitor profiling have not yet been performed. 
 
The Mtb genome encodes approximately 4,000 genes contained within 4,411,529 
base pairs (148, 287, 288). The Rv1623c, Rv1622c, Rv1621c and Rv1620c genes, 
encoding the cydABDC operon (5,967 bp), are found between 1,819,963 and 
1,825,887 base pairs of the Mtb genome (Figure 2.1). 
   
 
Figure 2.1: The position of the cydAB genes in the context of the Mycobacterium 
tuberculosis genome 
The cytochrome bd-encoding genes (cydA and cydB) are found adjacent to genes (cydD and 
cydC) encoding an ABC-type transporter.  
 (http://genome.tbdb.org/annotation/genome/tbdb/GeneDetails). 
 
An Escherichia coli bo3/bd-I knockout strain was used to develop a heterologous 
expression system for Mtb bd-I. A brief description of Mtb and E. coli quinol 
terminal oxidases will be presented. 
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As stated previously, Mtb has two terminal oxidases, the cytochrome bc1 reductase-
cytochrome c oxidase super-complex and the cytochrome bd-I oxidase (195) (Figure 
2.2, A). Cytochrome bd-I oxidase contains two structural subunits, subunits I and II, 
encoded by cydA and cydB respectively. CydDC of the cydABDC operon, encoding 
an ABC-type transporter, are implicated in the assembly of a functional bd-type 
oxidase and in maintaining redox homeostasis in the periplasm through exporting 
cysteine (53, 232, 247, 248). Cytochrome bd-I oxidase is an enzyme that couples the 
oxidation of a respiratory substrate quinol (two-electron donor) to the four-electron 
reduction of O2 to water. The high-affinity cytochrome bd-I oxidase is able to 
scavenge oxygen under microaerophilic conditions. Upregulation of this enzyme in 
vitro and in vivo has been observed at the transition to chronic infection, providing 
initial evidence for the importance of cytochrome bd-I oxidase in the adaptation of 
Mtb to host immunity (221, 253, 289). 
 
E. coli possesses three terminal quinol oxidases; cytochrome bo3, cytochrome bd-I 
and cytochrome bd-II, encoded by the cyoABCDE, cydAB and appBC operons, 
respectively (218, 290) (Figure 2.2, B). Cytochrome bo3 is from the heme-copper 
family of terminal oxidases while cytochrome bd-I and cytochrome bd-II are 
members of the cytochrome bd-family (211). Dassa et al (1991) demonstrated the 
homology between cytochrome bd-II subunits (encoded by appC and appB) and 
cytochrome bd-I subunits (encoded by cydA and cydB) with 60% and 57% 
homology of amino acid sequences, respectively (291). Thus, the spectral features of 
cytochrome bd-II closely resembles those of cytochrome bd-I, rendering them 
spectrophotometrically undistinguishable (217). The well-studied E. coli cytochrome 
bd-I oxidase has a three-heme form, which includes heme b558, heme b595 and heme 
d, with signature peaks at 560 nm, 596 nm and 629 nm, respectively. Similarly, the 
difference spectrum of E. coli cytochrome bd-II showed the presence of heme d (626 
nm), heme b595 (589 nm), and heme b558 (559 nm) (212, 217).  
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A) 
    
B) 
  
 
Figure 2.2: The electron transport chain of Mycobacterium tuberculosis and of E. coli 
A) Components of the electron transport chain in Mtb of which cytochrome bd-I oxidase 
(quinol oxidase) is an alternative terminal oxidase. Figure adapted from Fisher et al (2009) 
(209). B) Components of the electron transport chain in E.coli. The chain electron donor 
components are Ndh/NdhA-type II NADH: (mena)quinone oxidoreductase (two isoforms), 
SDH-succinate dehydrogenase, G3PDH-glycerol-3-phosphate dehydrogenase, LDH-L-
lactate dehydrogenase, FDH-formate dehydrogenase, H2DH-H2 dehydrogenase,  and nuo-
type I NADH (complex I). Electron acceptors are the cytochrome bo3 oxidase and an 
alternative terminal oxidase pathway which is cytochrome bd-I oxidase, cytochrome bd-II 
oxidase, FRD-fumarate reductase, TMAORD-TMAO reductase and NR-nitrate reductase. 
Chain components also include the F0F1 ATP synthase (complex V), MQ-8-menaquinone-8 
and MQH2-menaquinol. P and n correspond to the positive (periplasmic) and negative 
(cytoplasmic) sides of the respiratory membrane with respect to proton translocation. Proton 
movements are indicative only and do not represent H
+
/e
-
 ratios for the respective 
complexes. The orientation and topology of the subunits are indicative only.  
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Here we describe the use of the ML16, an Escherichia coli bo3/bd-I knockout strain 
to express Mtb cytochrome bd-I terminal oxidase (Chapter II and III); the use of an 
E. coli bo3/bd-I/bd-II triple-knockout strain for the heterologous expression of Mtb 
cytochrome bd-I is described in Chapter IV.  As mentioned previously in Chapter 
1.5.4.4, different cytochrome bd members have distinctive expression features. For 
example, the expression of cytochrome bd-I in E. coli and Mtb is recorded during 
both aerobic and microaerophilic growth conditions (20, 212), while induction of 
cytochrome bd-II in E. coli is associated with a shift to anaerobic growth or 
stationary phase, as well as with phosphate, carbon or glucose starvation (217, 218, 
290, 292). Therefore, cytochrome bd-II in E. coli is likely to function under even 
more O2-limiting conditions than cytochrome bd-I (293).  
 
 
Figure 2.3: Components of the electron transport chain of ML16, an E. coli mutant 
strain  
The ML16 respiratory chain has all the electron donor components of wild-type E. coli but 
only cytochrome bd-II oxidase, FRD-fumarate reductase, TMAORD-TMAO reductase and 
NR-nitrate reductase as electron acceptors. Chain components also include F0F1 ATP 
synthase (complex V) and MQH2-menaquinol. P and n correspond to the positive 
(periplasmic) and negative (cytoplasmic) sides of the respiratory membrane with respect to 
proton translocation. Proton movements are indicative only and do not represent H
+
/e
-
 ratios 
for the respective complexes. The orientation and topology of the subunits are indicative 
only.  
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Growth cycles were monitored for wild-type E. coli, ML16 and transformed strains 
with a view to studying the effect of the recombinant Mtb cytochrome bd-I on the 
transformed cells. The standard systematic growth cycle of any bacteria should 
include four main phases; lag phase, exponential phase, stationary phase and decline 
phase. Following inoculation of cells into a synthetic medium, the time which 
elapses before cell growth accelerates is known as the lag phase. The exponential 
phase is when the culture grows at a constant rate, and the growth rate is proportional 
to the culture density. The stationary phase refers to a culture that shows no further 
increase in the number of cells (i.e. non-replicating cells or the rate of death equal to 
the rate of growth). Entry into the stationary phase is a transition period for the cells 
in which cells exit from the cell cycle, maintain viability during starvation, and 
resume growth when starvation is relieved. During the stationary phase studies show 
the importance of the proteins made and the regulation of their synthesis and their 
essentiality for the survival of the cell, which will be discussed later (294-296). 
Importantly, the stationary-phase model of Mtb latency is based on studying the 
persistence phenomena of Mtb during this phase (42, 43). The last phase of the 
‘standard’ bacterial life cycle is the decline phase, which is characterized by toxic 
waste accumulations, food depletion and bacterial death (294-296). 
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2.2. Material and methods 
2.2.1. Amplification of Mycobacterium tuberculosis cydABDC operon 
2.2.1.1. Primer design 
Each primer described herein was designed from the published genome sequence of 
the Mycobacterium tuberculosis cydABDC operon from the TB data base 
(http://www.tbdb.org/). Primers were custom synthesised by Invitrogen, UK. Pairs of 
oligonucleotide primers (Table 2.1) for PCR reactions were designed to be 
complementary to the cydABDC operon to be replicated, with one primer designed to 
bind the sense strand and another for antisense strand. 
 
Table 2.1: The oligonucleotide primers for amplifying the cydABDC genes from 
Mycobacterium tuberculosis H37Rv 
cydABDC  PCR primers Primer sequence (5' → 3') 
Forward Primer CCG GAG ATG ACA GAT GAA TGT CGT CG 
Reverse Primer GGC GTT ACG TGC TGA TAT CGA TGA CTC AGG 
. 
The forward and reverse primers were designed to incorporate both the initiation and 
termination operon.  
 
An additional 18 internal oligonucleotide primers were designed to provide 
sequencing coverage of the entire 5,967 bp gene sequence. The entire operon was 
checked for frameshift, silent and other mutations which could affect the expression 
of cytochrome bd-I oxidase protein. The primers used for sequencing are 
summarised in the following table (Table 2.2). 
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Table 2.2: The oligonucleotide primers used for sequencing of the cydABDC genes 
cydABDC sequencing primers Primer sequence (5' → 3') 
Forward Primer 15 CGA TCT GCA GCA GGA ATA CC 
Forward Primer 16 
GGT TCG GTG TCA TCG CAG CG 
Forward Primer 17 
GCT CAA CGC CTA CAC CCT GC 
Forward Primer 18 
GGA CGT ATT GGG TTT TCC GG 
Forward Primer 19 
CCA TTG TGG TGA TCA CAC TGC 
Forward Primer 20 
CCA GTT TCA TGC CGC AGC TGA CG 
Forward Primer 21 
GCT GTA CTA GAC GAG TTG CCC 
Forward Primer 22 
CCC TTA TCT ATC ACC GGC TGG 
Forward Primer 23 
GCA ACG TCA TCG CCG ACT CAC AAC G 
Reverse Primer 4 
GGC CGG TAG TCG TTT GGT CC 
Reverse Primer 5 
CGC CCA TAC CGA CAT GAG CG 
Reverse Primer 6 
GGT TTT CAA AGC GAT GAA CAC CGC 
Reverse Primer 7 
GGT GGA GGT ATC CGT TCA GC 
Reverse Primer 8 
CCA TGA AGA TCG GTA TCA GG 
Reverse Primer 9 
CGG TGA GAT CAT ACG GTG CG 
Reverse Primer 10 
CAC GTG TTG TTC GGT GCG GG 
Reverse Primer 11 
GCA TGT TGG CCA GTT CGT CGA CG 
Reverse Primer 12 
GGC AAC AAC ATC AGG ATG GC 
 
The primers were designed against the published cydABDC sequence (http://www.tbdb.org/) 
to bind at intervals along the inserted cydABDC operon. 
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2.2.1.2. Polymerase chain reaction of cydABDC operon 
The cydABDC-encoding genes were amplified from Mtb genomic DNA prepared 
from a culture of Mtb H37Rv supplied by Dr. Amanda Brown (Queen 
Mary, University of London).  
 
Polymerase chain reaction (PCR) reactions were carried out in a 50 µl volume, 
containing 2 µl (about 20 µmol) of each primer (Table 2.1), 1 µl of the DNA to be 
amplified (typically 10 ng), 25 µl 2x Phusion
®
 Master Mix (New England BioLabs, 
UK), 1.5 µl dimethyl sulfoxide (DMSO) and 18.5 µl of sterile dH2O. The PCR 
reaction for amplifing the cydABDC sequence was performed using a Bio-RAD PCR 
thermal cycler (Bio-RAD, UK). The PCR reaction involved an initial denaturation 
step of 98 °C for 2 min, followed by 35 cycles of (a) denaturation at 98 °C for 10 s, 
(b) annealing at 64 °C for 40 s and (c) polymerisation at 72 °C for 4 min, followed 
by a final polymerisation step of 72 °C for 7 min. PCR product was run on an 
ethidium bromide-containg 1% agarose gel alongside a 1 kb DNA ladder 
(Invitrogen, UK) to check the size of the PCR product (297). The resulting DNA 
bands were visualized by exposure to UV light briefly in order to avoid damaging 
the DNA. 
 
It is worth mentioning that Pyrococcus furiosus (Pfu) DNA Polymerase (Fermantas, 
UK) and Crimson
TM
 Taq DNA polymerase (New England BioLab, UK) were used at 
different annealing temperatures (55-65) °C with the purpose of amplifying the 
cydABDC operon, but both enzymes gave unsuccessful results. Therefore, Phusion
®
 
Master Mix (New England BioLabs, UK), a high-fidelity PCR Master Mix, was used 
for amplification of the cydABDC operon, owing to fusion of a novel Pyrococcus-
like enzyme with a processivity-enhancing domain. Phusion
® 
Master Mix is capable 
of amplifying long DNA templates (7.5 Kb-20 Kb) with high accuracy and fidelity 
(50X greater than Taq polymerase) (298, 299). Phusion
® 
Master Mix has a 
processivity that is 10-fold greater than Pfu DNA polymerase and 20-fold greater 
than that of Taq DNA polymerase.  
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2.2.1.3. Purification of PCR products 
Purification of PCR product was conducted following confirmation that the PCR 
product was the expected size (5,967 bp) of the cydABDC operon. This method is 
important in order to remove agarose and other contaminants away from the PCR 
product that may inhibit further cloning steps. The DNA fragment was purified using 
a QIAquick Gel Extraction Kit (Qiagen, Germany). The ~ 6000 bp cydABDC DNA 
band was excised from the agarose gel with a sterile scalpel. The gel slice was 
weighed before 3 volumes of buffer QG were added to 1 volume of the gel slice. The 
mixture was incubated at 50 °C
 
for 10 min before being vortexed intermittently until 
completely dissolved gel fragments was achieved. The sample was transferred into 
QIAquick spin column in a 2 ml collection tube and centrifuged at high speed 
(13,000 g) for 1 min. The flowthrough was discarded and the Qiaquick column was 
returned to the same collection tube. In order to remove all the residual of agarose, 
0.5 ml of buffer QG was added to QIAquick column and centrifuged for 1 min at 
13,000 g.  The flow through was discarded and the QIAquick column was 
centrifuged for a further 1 min at 13,000 g. For the elution step, the QIAquick 
column was transferred into a clean 1.5 ml microcentrifuge tube and 50 µl 
diethylpyrocarbonate (DEPC)-treated water (Ambion, UK) was added before 
centrifugation at maximum speed (13,000 g) for 1 min. A NanoDrop 1000 U 3.7.1 
(Thermo scientific, UK) was used in order to check the purity and the concentration 
of the PCR product, which was then stored at -20 °C until required. 
 
2.2.1.4. Agarose gel electrophoresis 
Agarose gels were used to separate the DNA fragments in the PCR products or from 
the restriction enzyme digestions. In this study 1% agarose gels (Sigma Aldrich, UK) 
were prepared in 1 x Tris-Acetate-EDTA (TAE) consisting of 40 mM Tris, 20 mM 
acetic acid and 1 mM EDTA, pH 8.0 (Sigma Aldrich, UK). The mixture was heated 
for 2 min in a microwave oven and cooled at room temperature. Subsequently, 
ethidium bromide (0.25 μg.ml-1) (Sigma Aldrich, UK) was added before pouring the 
gel solution into a gel cast on flat surface. DNA samples were mixed with 6 x 
loading dye (Invitrogen, UK) and loaded before being electrophoresed for 30 - 40 
min at a constant current of 90 volts. Once completed, the gel was visualised by UV 
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illuminator (Syngene Bioimaging, UK) and analysed using Genetools analysis 
software (Syngene Synoptics Ltd. Cambridge, UK). The DNA fragments were 
compared with DNA molecular weight marker (Invitrogen, UK).  
 
2.2.2. TA cloning 
A-tailing of the PCR product was applied to add cohesive ends to the cloned DNA 
fragment, thus facilitating its insertion into the pCR
®
II, TA cloning vector 
(Invitrogen, UK). This reaction was achieved by incubating 7 µl (~50 ng) of the 
isolated fragment with 1 µl of 1 mM dATP, 1 µl of Taq polymerase and 1 µl x10 
Taq polymerase buffer (New England BioLab, UK) in a total reaction volume of 10 
µl at 70 °C for 20 min. The pCR
®
II, TA cloning vector was selected due its 
following advantages, eliminating any enzymatic modifications of the PCR product; 
allowing transcription from either direction into the insert; and not demanding PCR 
primers that contain restriction sites. Moreover, the pCR
®
II, TA cloning vector 
enhanced screening chances, as it possesses genes that confers ampicillin and 
kanamycin resistance, either one could be used for propagation. It has the lacZ gene 
as well that can be used for blue/white screening as uninterrupted lacZ expresses β-
galactosidase, an enzyme which converts 5-bromo-4-chloro-3-indolyl β-D-
galactopyranoside (X-gal) to a blue derivative in the presence of isopropyl-β-D-
thiogalactoside (IPTG, which is a stable mimic of lactose and induces expression of 
lacZ). Functional β-galactosidase will not be expressed once the insertion at the 
multiple cloning sites (MCS) occurs, and thus no formation of coloured product 
occurs, resulting in white colonies, which should contain plasmid with the desired 
gene cloned. 
 
Subsequently, attempts were made to ligate the A-tailed fragment into the pCR
®
II, 
TA cloning vector (Invitrogen, UK). All ligations were carried out in a 10 µl reaction 
volume with any shortfall of volume being made up with dH2O. The ligation 
reaction contained 3 µl of A-tailed PCR product, 2 µl of pCR
®
II, 1 µl of each 
provided T4 DNA ligase and x10 buffer and 3 µl of dH2O. The reaction was 
submitted for an overnight incubation at 14 °C before the ligation reactions being 
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transformed into TOP10 competent cells. The ligation mixture of pCR
®
II-TOPO and 
cydABDC operon created the pCR
®
II, TA/cydABDC construct, designated as pTM3. 
 
2.2.3. Preparation of media: 
2.2.3.1. LB Broth (Luria-Bertani medium) 
All growth of cells was carried out in sterilised LB medium (Sigma Aldrich, UK). 
Required antibiotics were added to the LB solution when the medium had cooled 
below 50 °C, but prior to use.   
 
2.2.3.2. LB agar plate media  
Sterile agar plates were prepared using LB agar medium (Sigma Aldrich, UK) and 
required antibiotics were added to the LB solution when the medium had cooled 
below 50 °C, but prior to setting. 
 
2.2.4. Transformation of One Shot® TOP10 chemically competent E. coli 
Transformation was performed following the standard methods of Sambrook and 
Russell (2001) (297). The ligation mixture pTM3 was transformed into One Shot
® 
TOP10 chemically competent E. coli (Invitrogen, UK) by the heat shock method. 
This method involved incubating a standard volume (14 µl) of Top 10 competent 
cells with 2 µl of recombinant plasmid DNA (pTM3) on ice for 30 min. Cells were 
then heat shocked at 42 °C for 1 min before being returned to ice for 2 min. About 
180 µl of pre-warmed S.O.C medium (Invitrogen, UK) was added to the cells, which 
were then incubated at 37 °C in a shaking incubator at 200 rpm for 1 h. In order to 
have blue/white screen colonies for successfully ligated plasmid, 20 µl of X-Gal 
substrate was added to the cells. Subsequently, 150 µl of the cells were then plated to 
LB agar containing appropriate antibiotics (100 µg.ml
-1 
ampicillin) and incubated 
overnight at 37 °C. The following day, white colonies were picked from the plates 
and grown in 5 ml LB medium containing 100 µg.ml
-1 
of ampicillin at 37 °C in a 
shaking incubator at 200 rpm. Glycerol stocks of the plasmid-containing cells were 
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made from these cultures. Thereafter ampicillin was used in order to sustain plasmid 
transformant growth and for selectivity. 
 
2.2.5. Glycerol Bacterial Stock 
Glycerol stocks were prepared using 100 μl of 50% (v/v) sterile glycerol and 500 μl 
of bacterial suspension in LB medium. The bacterial suspension was kept at -80 °C
 
for future use. 
 
2.2.6. Mini preps 
Mini preps were carried out using QiaAmp (Qiagen, UK). A white colony (plasmid-
containing cell) from a fresh LB agar plate was used to inoculate 10 ml LB medium 
containing appropriate antibiotic (100 µg.ml
-1 
ampicillin) and incubated overnight at 
37 °C
 
in a shaking incubator at 200 rpm. Subsequently, the culture was centrifuged 
for 5 min at 10,000 g. The supernatant was poured off and the pelleted cells were 
resuspended in 250 µl of cell resuspension solution (P1) before being transferred to a 
microcentrifuge tube. The addition of 250 µl of buffer P2 was followed by inverting 
the tubes 4-6 times until the cell suspension turned blue signifying lysis of the cells. 
The mixture was neutralized by the addition of 350 µl Buffer N3 neutralisation 
solution and immediately mixed thoroughly by inverting the tube before being 
centrifuged at 13,000 g for 10 min at room temperature.  The cleared lysate was 
transferred into a QIAprep spin column and was centrifuged at 13,000 g for 1 min 
and the flowthrough was discarded. The column was washed twice, first with 500 µl 
of buffer PB and then with 750 µl of buffer PE solution and after each wash the 
column was centrifuged for 1 min at 13,000 g at room temperature. The flowthrough 
was discarded and followed by an additional 1 min centrifuge step to remove 
remaining wash buffer.  Finally, the plasmid DNA was eluted in 50 µl of buffer EB 
by centrifugation at 13,000 g for 1 min at room temperature. The DNA concentration 
was measured using a NanoDrop 1000 U 3.7.1 (Thermo scientific, UK) and stored at 
-20 °C
 
until required. 
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2.2.7. Screening of positive clones pTM3 by restriction enzyme analysis 
Screening of the positives clones was conducted in order to validate successful 
cloning and subcloning of the inserted gene into the vectors, and successful 
transformation of the ligated gene into the E. coli host. The reaction mixture for 
pTM3 digestion was in a total reaction volume of 30 µl that contained 2.5 µl of 
pTM3, 2 µl of 10x fast digest buffer, 1 µl of EcoRI restriction endonuclease 
(Fermentas, UK) and 24.5 µl of dH2O. The reaction was incubated at 37 °C for 15 
min then inactivated at 80 °C for 5 min. Following digestion, 10 µl of digested 
plasmid with 2 µl of 6 x loading dye were loaded to a 1% agarose gel, containing 
ethidium promide (0.25 µg.ml
-1
), run alongside 1 kb DNA ladder (Invitrogen, UK). 
Electrophoresis was conducted in 1 x TBE running buffer at 90 volts for 30 min and 
the gel was visualised under UV light. 
 
2.2.8. Analysis by automated sequencing 
pTM3 (200 ng) produced positive results by PCR and restriction enzyme analysis, 
and was sequenced using automated DNA sequencing (Cogenics, UK), and the 18 
internal primers (Table 2.2) which were designed for the sequencing reaction.  
 
2.2.9. Maxi prep 
A maxi prep was used to obtain good yields of recombinant plasmid DNA to be used 
for sub-cloning of pTM3 into the pUC19 expression vector. A single colony of 
TOP10 competent cells containing pTM3 was inoculated into 5 ml LB broth, 
containing 100 µg.ml
-1 
ampicillin before being overnight incubated at 37 °C
 
with 
vigorous shaking at 200 rpm. 500 μl of this culture was added into 100 ml LB/100 
µg.ml
-1 
ampicillin broth and submitted for overnight incubation at 37 °C
 
with 
vigorous shaking at 200 rpm. The culture was harvested by centrifugation at 13,000 
g at 4 °C. The supernatant was discarded, and the bacterial pellet was resuspended 
completely in 1 ml of buffer P1 followed by 1 ml Buffer P2. The tube was mixed by 
inverting several times until the cell suspension turned blue indicating lysis of the 
cells. The mixture was neutralized by the addition of 1.4 ml Buffer N3 neutralisation 
solution and immediately mixed thoroughly by inverting the tube. The bacterial 
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lysate was subjected to centrifugation at 13,000 g for 20 min at room temperature. 
The cleared lysate was transferred into QIAprep spin column and centrifuged at 
13,000 g for 1 min and then the flowthrough was discarded. The column was washed 
twice, firstly with 500 µl of buffer PB and then with 750 µl of buffer PE solution and 
following each wash the column was centrifuged for 1 min at 13,000 g at room 
temperature. The flowthrough was discarded and the column was further centrifuged 
for 1 min at 13,000 g to remove remaining wash buffer. Finally, the plasmid DNA 
was eluted in 50 µl of buffer EB by centrifugation at 13,000 g for 1 min at room 
temperature. The DNA concentration was measured using a NanoDrop 1000 U 3.7.1 
(Thermo scientific, UK) and stored at -20 °C
 
until required.  
 
2.2.10. Sub-cloning of pTM3 into pUC19 expression vector 
The pUC19 vector was selected for protein production as it possesses an ampicillin 
resistance gene that enables screening for plasmid-containing cells and helps to 
prevent contamination of the cell cultures. Moreover, it has a MCS in the lacZ gene 
to give flexibility in selecting the restriction enzyme or the enzymes used for 
cloning. 
 
In order to express Mtb cytochrome bd-I oxidase protein, the cloned gene was 
excised from pTM3 using the restriction site EcoRI present in both pTM3 and 
pUC19 expression vectors. The digests were analysed by visualisation on a 1% 
agarose gel and the gene fragments gel purified (Qiagen, Germany).  
 
The sub-cloning reactions were as follows: The first reaction was for pTM3 
digestion which involved a total reaction volume of 30 µl that contained 2.5 µl 
plasmid DNA (pTM3), 2 µl of 10x fast digest buffer, 1 µl of EcoRI restriction 
endonuclease (Fermentas, UK) and 24.5 µl of dH2O. The reaction was incubated at 
37 °C for 15 min then inactivated at 80 °C for 5 min. Following digestion, the 
reaction product was run alongside 1 kb DNA ladder (Invitrogen) on a 1% Aquapor 
LE gel (Invitrogen, UK) containing ethidium promide (0.25 µg.ml
-1
). The desired 
fragment (the operon of interest) was excised from the gel and purified using 
QIAquick Gel Extraction Kit (Qiagen, Germany) (Chapter 2.2.1.3) in order to 
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remove undesirable products that may hinder later stages of the cloning processes. 
The concentration of DNA yield was measured using a NanoDrop 1000 U 3.7.1 
(Thermo scientific, UK).  
 
The second reaction was for pUC19 digestion which involve a total reaction volume 
of 30 µl that contained 5 µl pUC19 vector, 2 µl of 10x fast digest buffer, 1 µl of 
EcoRI restriction endonuclease (Fermentas, UK) and 22 µl of dH2O. The reaction 
was incubated at 37 °C for 15 min then inactivated at 80 °C for 5 min. Afterwards, 
dephosphorylation was carried out to prevent the re-ligation of the double-digested 
expression vector pUC19 which involved adding 2 µl of Antractic phosphatase 
buffer and 2 µl of Antractic phosphatase enzyme to the reaction. The reaction went 
through consequent incubation at 37 °C for 10 min and 65 °C for 10 min, 
respectively. Following digestion, the reaction product was run alongside 1 kb DNA 
ladder (Invitrogen) on a 1% Aquapor LE gel (Invitrogen, UK) containing ethidium 
promide (0.25 µg.ml
-1
). The desired fragment was excised from the gel and purified 
using QIAquick Gel Extraction Kit (Qiagen, Germany) (Chapter 2.2.1.3) in order to 
remove other undesirable products that may hinder later stages of the cloning 
processes. The concentration of DNA yield was measured using a NanoDrop 1000 U 
3.7.1 (Thermo scientific, UK).  
 
The vector and insert were ligated in 10 µl reaction volumes, containing 1 µl of 
digested pUC19, 7 µl of digested pTM3, 1 µl of 10x T4 ligase buffer and 1 µl of T4 
Ligase. The reaction was incubated overnight at 16 °C to create the 
pUC19/cydABDC construct (designated as pTMA). 
 
2.2.11. Transformation of ligated expression vector into One Shot® TOP10 
chemically competent E. coli 
The ligated expression vectors (pTMA) were transformed into TOP10 E. coli cells 
following the above mentioned protocol (Chapter 2.2.4). The ligation mixture was 
transformed using heat-shock transformation into TOP10 chemically competent E. 
coli cells and plated on LB agar containing 100 µg.ml
-1 
ampicillin.  
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2.2.12. Selection of recombinants 
Viable colonies from the transformation were cultured in ampicillin-enriched LB 
medium and the plasmid extracted by Miniprep (Qiagen, UK) (as described in 
section 2.2.6). In order to confirm the success of the cloning step, restriction enzyme 
digests were performed and visualised on 1% agarose gels, containing ethidium 
promide (0.25 µg.ml
-1
). pTMA was analyzed using PstI (NEB, UK) and EcoRI 
(Fermentas, UK) restriction enzymes.  
 
The first reaction was for digestion of pTMA in a 30 µl reaction volume, containing 
3 µl of plasmid DNA (pTMA), 2 µl of 10x fast digest buffer, 1 µl of EcoRI 
restriction endonuclease (Fermantas, UK) and 24 µl of dH2O. The reaction was 
incubated at 37 °C for 15 min. The second digestion reaction of pTMA was 
conducted using PstI (NEB, UK) in a 30 µl reaction volume, containing 2 µl of 
plasmid DNA (pTMA), 2 µl of BSA buffer, 3 µl of buffer 3, 1 µl of PstI restriction 
endonuclease (NEB, UK) and 22 µl of dH2O. The reaction was incubated at 37 °C 
for 1 h and 50 min. Following digestion, the reactions products were run alongside 1 
kb DNA ladder (Invitrogen, UK) on a 1% Aquapor LE gel (Invitrogen, UK) 
containing ethidium promide (0.25 µg.ml
-1
). 
 
2.2.13. Preparation of competent ML16 E. coli cells 
In order to express Mtb cytochrome bd-I protein, specific competent cells were 
required to incorporate and replicate the plasmid conveying the Mtb cydABDC 
operon. Competent cells were constructed using ML16, an E.coli bo3/bd-I knockout 
strain, donated by Professor Robert B. Gennis, Illinois. The ML16 (ΔrecA, ΔcydAB, 
ΔcyoABCDE::Cmr) strain lacks two types of quinol:oxygen oxidoreductase 
(cytochrome bo3 and cytochrome bd-I terminal oxidases) but has only one type of 
quinol:oxygen oxidoreductase (cytochrome bd-II terminal oxidase). ML16 has a 
chloramphenicol resistance cassette as it was constructed following the protocol of 
Datsenko and Wanner (2000) that based on using phage-based E. coli homologous 
recombination system (300). ML16 is a derivative of E. coli C43 (DE3) (genotype F
-
 
ompT gal hsdSB (rB
-
mB
-
) dcm lon λDE3) (301, 302).   
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Competent ML16 cells were produced by the magnesium chloride/calcium chloride 
method. This involved overnight aerobic and O2-limited cultures. The aerobic culture 
condition was as follow: 200 ml LB medium (in a 500 ml flask) enriched with 2.5 
µg.ml
-1
 chloramphenicol incubated at 37 °C in a shaking incubator at 200 rpm. The 
O2-limited culture involved inoculation of an overnight aerobic ML16 culture into 
375 ml LB medium enriched with 2.5 µg.ml
-1
 chloramphenicol (in a 500 ml flask), 
sealed with a rubber plug with a head-space ratio of 0.5 and incubated at 37 °C in a 
shaking incubator at 200 rpm.  
 
Competent cells preparations were performed according to the standard protocols of 
Sambrook and Russell (2001) (297). 100 ml of the cultures were centrifuged (4000 
g) for 10 min at 4 °C once an OD600= 0.44 was reached. The optical density was 
determined using a Thermo Spectronic instrument (Genesys, UK). Then, the cells 
were resuspended in 30 ml ice-cold 80 mM magnesium chloride/ 20 mM calcium 
chloride per 100 ml of culture volume. The cells were centrifuged as before, 
resuspended in 4 ml of ice-cold 100 mM calcium chloride solution with the addition 
of 200 µl of 50% (v/v) glycerol. The cells were then aliquoted (200 µl) into cold 
Eppendorf tubes and stored at -80 °C until required. The competent cells were 
designated as AnML16 (O2-limited grown ML16) and AML16 (aerobically grown 
ML16). 
 
2.2.14. Transformation of pTMA into ML16 competent cells 
A 200 µl volume of each AnML16 and AML16 competent cells were transformed 
with the pTMA (10 µl) by firstly co-incubating on ice for 30 min followed by heat 
shock at 42 °C for 90 s, before returning samples to ice for 2 min. 300 µl of pre-
warmed S.O.C medium (Invitrogen, UK) was added to the cells, which were then 
incubated at 37 °C in a shaking incubator for 1 h at 200 rpm. 150 µl of the cells were 
then plated to agar plates containing appropriate antibiotic, which was a combination 
of both 100 µg.ml
-1 
ampicillin and 2.5 µg.ml
-1
 chloramphenicol to sustain plasmid 
transformant growth, and incubated at 37 °C aerobically and anaerobically. 
AnaeroGen sachet (Thermo Scientific, UK) was used to generate an anaerobic 
atmosphere. After 2 days of incubation, colonies were picked from the plates and 
grown in 5 ml LB medium containing an appropriate concentrations of antibiotic at 
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37 °C in a shaking incubator at 200 rpm. These cultures were then used for making 
glycerol stocks of the plasmid-containing cells and for larger scale cultures and 
plasmid preparation.  
 
Of note, transformants of pTMA into aerobic ML16 competent cells (AML16) took 
3 days to grow on agar plates and 2-3 days in 5 ml LB broth over both growth 
conditions (aerobic and anaerobic). In contrast, transformants of pTMA into O2-
limited ML16 competent cells (AnML16) was successful for both growth conditions 
(aerobic and anaerobic).  
 
2.2.15. Large-scale culture 
The successful transformant colonies were grown in selective O2-limited conditions, 
375 ml of LB (in a 500 ml flask), containing 100 µg.ml
-1 
ampicillin and 2.5 µg.ml
-1
 
chloramphenicol, sealed with a rubber plug with a head-space ratio of 0.5. An 
negative control (untransformed AnML16 competent cells) was grown in the same 
selective O2-limited condition, but without ampicillin. The inoculum size was 0.2% 
of 375 ml LB broth. For clarification, the two strains that were used throughout 
experiments were untransformed AnML16 competent cells (henceforth ML16) and 
transformed AnML16 competent cells (henceforth TML16).  
 
In addition, the same successful transformant colonies were grown in aerobic 
conditions, 200 ml of LB (in a 500 ml flask) containing 100 µg.ml
-1 
ampicillin and 
2.5 µg.ml
-1
 chloramphenicol. An negative control (untransformed AnML16 
competent cells) was grown in the same aerobic conditions but without ampicillin. 
The inoculum size was 0.2% of 200 ml LB broth. 
 
In similar manner, BL21(DE3) pLysS, (F 
–
ompT hsdSB (rB
–
mB 
–
) gal dcm (DE3) 
pLysS (Cm
R
)), was also cultured as a wild-type E. coli strain in both aerobic and O2-
limited growth conditions, supplemented with 34 µg.ml
-1
 chloramphenicol. BL21 
(DE3) bears pLysS, a compatible chloramphenicol-resistance plasmid, that produces 
T7 lysozyme, a natural inhibitor of T7 RNA polymerase (303).  
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During both aerobic and O2-limited growth condition, IPTG was added at the 
beginning of the culture (i.e. along with inocula) to 1 mM final concentration 
(personal communication with Dr. Ashley Warman and Dr. Nick Fisher). Cultures 
were incubated at 37 °C in a shaking incubator at 200 rpm for 19 h.  
 
It is worth commenting that selecting the above mentioned growth parameters, the 
addition of IPTG at the beginning of the culture and incubating cells for 19 h, was 
reliant on ML16 growth monitoring, which showed reduction of OD600 after 19 h of 
O2-limited incubation (described later, Figure 2.3.7.2).  
 
2.2.16. Preparation of 50 mM KPi, 2 mM EDTA, pH 7.5 buffer  
For kinetic assays 50 mM KPi, 2 mM EDTA, pH 7.5 buffer was used throughout 
experiments, unless otherwise stated. This buffer was prepared as follow: a 50 mM 
K2HPi (dipotassium hydrogen phosphate trihydrate) + 2 mM EDTA 
(ethylenediaminetetraacetic acid), pH 10 solution and a 50 mM KH2Pi (potassium 
dihydrogen orthophphosphate) + 2 mM EDTA, pH 5.8 solution were prepared. 
Subsequently, these two solutions were mixed to produce a 50 mM KPi + 2 mM 
EDTA buffer at pH 7.5.  
 
2.2.17. Membrane preparations 
Membrane preparations were carried out following the protocol of Fisher et al 
(2009) (209). TML16, ML16 and BL21(DE3) pLysS from both aerobic and O2-
limited large-scale cultures (grown in defined conditions as described above (section 
2.2.15) were harvested by centrifugation at 4000 g for 10 min using a Beckman 
centrifuge (Beckman Coulter, UK). Following supernatant removal, the cell pellets 
were resuspended in buffer (50 mM KPi, 2 mM EDTA, pH 7.5) and incubated on ice 
with hen egg lysozyme to a final concentration 200 μg.ml-1 for 10 min. The cells 
were broken by two passes through a standard laboratory cell disruptor (Constant 
Systems, UK) operating at 20,000 psi and then the debris pelleted by centrifugation 
at 12,000 g at 4 °C for 20 min. The supernatant was collected and centrifuged by 
ultracentrifuge at 100,000 g at 4 °C for 1 h, depositing the membranes as a highly 
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viscous pellet. This was collected and resuspended with the aid of a Potter 
homogenizer (Sigma Aldrich, UK) in 2 ml of 50 mM KPi, 2 mM EDTA buffer (pH 
7.5) per litre of original culture volume. Glycerol was added to a final concentration 
of 10% (v/v) and the membrane suspension stored in 50 μl aliquots at -80 °C until 
required. The total protein concentration of the membrane suspension was measured 
by Bradford assay (Chapter 2.2.18). To maintain enzyme activity, aliquots were not 
repeatedly freeze-thawed, and were stable for at least 6 months when stored at -80 
°C. 
 
2.2.18. Determination of protein concentration 
The Bradford assay (304) was carried out in order to determine the protein 
concentration used for spectral analysis and to quantify the specific enzyme activity 
from membrane preparations. The Bio-Rad Reagent (Bio-Rad, UK) was diluted with 
distilled water in 1:4 ratio. A known concentration of bovine serum albumin (BSA) 
(2 mg.ml
-1
) was used in order to obtain a standard curve. A standard curve was 
generated using BSA (Sigma Aldrich, UK) at concentrations ranging from 0.2-0.9 
mg.ml
-1
. The protein samples were prepared in a serial dilution ranging from 1 in 2.5 
to 1 in 35. Subsequently, 2 μl of each samples was plated in triplicate into a 96 well 
plate. The automated dispenser Varioskan (Varioskan
TM
, Thermal Corporation) was 
used to dispense 200 μl of Bradford Reagent into each well. The plate was incubated 
in the dark for 5 min at room temperature before determining the protein 
concentration using Skant® Software (Varioscan™ , Thermo Corporation) reading  
the absorbance at 595 nm. 
 
2.2.19. Initial spectroscopic study of Mtb cytochrome bd-I oxidase 
Initial UV-visible spectroscopic analysis of freshly prepared membranes was carried 
out on a Cary 300 Bio UV/visible spectrophotometer (Varian, UK). Assays of total 
volume 700 μl were performed with 200 μl of the crude recombinant membrane 
suspended in 500 μl of (50 mM KPi, 2 mM EDTA, pH 7.5) buffer. Spectra over a 
wavelength range of 500 – 700 nm were recorded for the oxidised membrane alone 
in the presence of potassium hexacyanoferrate (III), as well as in the presence of 
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reductants sodium dithionite. A difference spectrum was generated by subtracting 
the oxidised spectrum from the reduced spectrum. 
 
2.2.20. Growth curves 
Growth was monitored by measuring the optical density (OD) at 600 nm using a 
Thermo Spectronic instrument (Genesys, UK) over a time course (hours) and under 
the same aerobic and O2-limited growth conditions (section 2.2.15). A redox 
indicator (resazurin), a rapid qualitative test, was used in order to monitor the 
respiratory state of the cells during growth. Resazurin was added to the media to 
final concentration of 0.0002% (w/v) according to the protocol of Karakashev et al 
(2003) (305). Aerobic cultures exceeded the 19 h of incubation to monitor the 
stationary phase of the cells. Pictures were taken to record the colour change of 
resazurin in the medium. 
 
2.2.21. SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate protein samples according to their molecular weight. The percentage of 
resolving gel used was 10%. The monomer solution of the resolving gel consisted of 
acrylamide/bis-acrylamide solution, (30% w/v) (Bio-RAD, UK) distilled H2O, 1.5 M 
Tris-HCl (pH 8.8) (Sigma Aldrich, UK), 10% (w/v) SDS (Sigma Aldrich, UK), 20% 
ammonium persulphate (APS) (Sigma Aldrich, UK) and 10 μl N,N,N\N'-
tetramethylethylenediamine (TEMED) (Fluka, UK) per 10 ml gel mix. The monomer 
solution was mixed gently and poured into glass plates assembled by instructions 
from the Mini-Protean III Electrophoresis Manual (Bio-RAD, UK). The gel was 
covered with water-saturated ethanol to ensure an even surface and to reduce 
polymerisation. After the gel had polymerised, the ethanol was removed by capillary 
action using a paper towel. The stacking gel, a 4% monomer solution, was prepared 
using the following materials: 530 µl 30% (w/v) arylamide/bis (Bio-Rad, UK), 2.39 
ml H2O, 1 ml 0.5 M Tris-HCl (pH 6.8), 40 µl 10% (w/v) SDS, 40 µl of 20% APS 
and 6 µl TEMED. This mixture was poured over the resolving gel with the comb 
fitted and allowed to polymerise for 30 min at room temperature. 
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2.2.22. Sample Preparation for SDS-PAGE 
Different protein sample dilutions (1:10, 1:25 and 1:50) were prepared using assay 
buffer (50 mM KPi, 2 mM EDTA, pH. 7.5). For each sample, 10 µl of the protein 
sample was mixed with an equal volume of DTT (dithiothreitol). Prior to gel 
loading, samples were boiled for 5 min at 90 °C. The proteins were separated on 
SDS-PAGE using 1 X SDS-running buffer (0.196 M glycine, 48 mM Tris-base, 
0.04% (w/v) SDS, pH 8.3) at a constant current of 60 milliamps for 60 min.  
Afterwards, the gel was stained with Expedion instant blue (a Comassie Blue based 
staining solution) (Expedion, UK). Staining was carried out for 30 min with slow 
agitation before being destained in distilled water. The prestained, broad range 
protein marker SpectraTM Multicolor Broad Range Protein Ladder (Fermentas, UK) 
was used to estimate the resulting protein band sizes. 
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2.3.  Results 
2.3.1. Amplification of the Mycobacterium tuberculosis H37Rv cydABDC operon 
Using specific primers (Chapter 2.2.1.1), genomic DNA of Mtb strain H37Rv was 
subjected to amplification by PCR. The primers (Table 2.1) were designed to 
facilitate amplification of the whole cydABDC operon, yielding a single amplicon of 
5,967 bp (Figure 2.4). This figure indicates that the PCR conditions have been 
optimised and primers are specific for the targeted gene. This amplicon is predicted 
to encode proteins of 1934 amino acids using the TB data base 
(http://www.tbdb.org/). 
                                          
Figure 2.4: Amplification of Mycobacterium tuberculosis H37Rv cydABDC operon 
The cydABDC operon predicted to be 5,967 bp was amplified from Mtb H37Rv genomic 
DNA. Lane M contains 1 kb DNA Ladder (Invitrogen), lane 1 shows the PCR products of 
the cydABDC operon that shows a single band of size ~ 6 kb. The PCR products were 
visualised on a 1% agarose gel containing 0.25 µg.ml
-1
 ethidium bromide (Sigma Aldrich, 
UK). 
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2.3.2. Screening of positive clones of pTM3 in TOP 10 E. coli host 
The amplicons of the cydABDC operon were initially cloned to the pCR
®
II-TOPO
®
 
vector using the TOPO-TA cloning kit (Invitrogen, UK). TOPO-TA cloning 
provides fast and efficient cloning strategies for direct cloning of the PCR products 
into a high copy number plasmid vector. The cloning of PCR products into the 
TOPO vector created the 9,578 bp pCR
®
II-TOPO
®
/cydABDC construct (pTM3). 
 
The success of the pTM3 cloning was validated using restriction enzyme analysis 
(described in Chapter 2.2.7). White colonies from each transformation were picked 
and cultured overnight in LB medium containing 100 µg.ml
-1
 ampicillin. The 
following day, plasmid DNA was isolated using a Qiagen Miniprep kit before being 
subjected to restriction digest analysis.  Figure 2.5 shows the results from digesting 
plasmid isolate with EcoRI. The positive clone produced two bands corresponding to 
the predicted digest fragments (3,599 and 5,979 bp).  The recombinant plasmids 
were designated as pTM3 (Figure 2.6). In order to check pTM3 for errors, the 
plasmid was submitted for automated sequencing by Cogenics (UK) using 18 
internal primers (Table 2.2) designed against the published cydABDC sequence 
(http://genome.tbdb.org). These oligonucleotides were designed to provide 
sequencing coverage of the entire 5,967 bp operon. The automated DNA sequencing, 
using the BLAST programme (http://blast.ncbi.nlm.nih.gov), revealed that the pTM3 
is 100% identical with the published sequence and is free from errors, and that the 
gene could now be transferred to plasmids suited for the expression of the encoded 
proteins. 
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Figure 2.5:  Restriction enzyme digestion analysis of a transformed colony of the pTM3 
construct 
The EcoRI restriction digest of the pTM3 plasmid was run alongside 1 Kb DNA ladder (lane 
M) (Invitrogen), resulting in two expected bands of 5,979 bp and 3,955 bp (lane 1) 
confirming that the pTM3 construct has been correctly created. Digestion was visualised by 
exposure to UV light following electrophoresis on 1% agarose gels containing 0.25 µg.ml
-1
 
ethidium bromide. 
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Figure 2.6: Plasmid map of pCR
®
II-TOPO
®
 bearing the Mycobacterium tuberculosis 
cydABDC operon 
pCR
®
II-TOPO
®
 (Invitrogen, UK) was used to construct the recombinant cydABDC directly 
from a PCR reaction. The pCR
®
II-TOPO
®
 Invitrogen vector is a 4.0 kb linearised vector. 
The pCR
®
II-TOPO
®
 vector contains a lac promoter to allow the expression of the lacZ gene 
which encodes the first 146 amino acid of β-galactosidase. Interruption of lacZ by the 
insertion of PCR product may give rise to white colonies. The presence of both the 
kanamycin and ampicillin resistance genes in the vector allows for selection and 
maintenance in E. coli. The vector contains a pUC origin which allows replication, 
maintenance and high copy number in E. coli. The vector has f1 origin which allows rescue 
of the sense strand for mutagenesis and single-strand sequenancing. The plasmid map was 
generated using BVTech Plasmid (BVTech Plasmid.5.1 software). 
 
2.3.3. Sub-cloning of pTM3 into the pUC19 expression vector 
The plasmid pTM3 was sub-cloned into the pUC19 expression vector. This was 
carried out by digestion of the plasmid to excise the cydABDC insert from the TOPO 
vector and subsequent ligation to the pUC19 vector. pTM3 and the pUC19 vector 
were first digested using EcoRI and the appropriate fragments subsequently ligated 
as described in (section 2.2.10) before being transformed to TOP10 E. coli cells 
(section 2.2.11). Colonies were picked, and subjected to overnight liquid culture 
followed by miniprep DNA isolation. An EcoRI digest (Figure 2.7, A), cutting the 
plasmid twice in the insert region to give 5,981 bp and 2,686 bp fragments, verified 
the clone as correct. These data were backed up using a PstI digest (Figure 2.7, B), 
cutting twice in the insert region to give 5,047 bp and 3,620 bp fragments. The 
digests confirmed the successful production of the positive recombinant plasmid, 
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designated as pTMA construct (pUC19/cydABDC construct) (Figure 2.8), which was 
then used in attempts to express the Mtb cytochrome bd-I oxidase protein.  
A) 
                                     
B) 
                                
Figure 2.7: Restriction enzyme digestion analysis of transformed colonies of pTMA 
constructs 
A) EcoRI restriction digests (Fermentas, UK) of three potential clones of the pTMA plasmid 
run alongside 1Kb DNA ladder (lane M) (Invitrogen). Two bands of 5,981 bp and 2,686 bp 
for the clones in lanes 2 and 3 identify the correctly cloned construct. The plasmid in lane 1 
was not correctly digested by EcoRI digest, again confirming unsuccessful creation of the 
pUC19-cydABDC construct. B) The PstI restriction digests (NEB, UK) of three potential 
clones of pTMA run alongside 1Kb DNA ladder (lane M) (Invitrogen, UK). Two expected 
bands of 5,047 bp and 3,620 bp for the clones in lanes 2 and 3 identify the correct construct. 
The plasmid in lane 1 was not correctly digested by PstI, indicating it is not a successful 
pUC19- cydABDC clone. All digests were visualised by exposure to UV light following 
electrophoresis on 1% agarose gels containing 0.25 µg.ml
-1
 ethidium bromide. 
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Figure 2.8: Plasmid map of the pUC19 expression vector bearing the Mycobacterium 
tuberculosis cydABDC operon 
The pUC19 plasmid contains a lacZ gene which has similar features to pCR
®
II-TOPO
®
 
vector. The presence of the lacZ gene allows recombinants to be selected by blue/white 
screening. pUC19 also possesses the ampicillin resistance gene that enables selection. The 
plasmid construction was carried out by excising the cydABDC from pCR
®
II-TOPO
®
 vector 
and ligating into the pUC19 multiple cloning sites (between EcoRI restriction sites). The 
plasmid map was generated using BVTech Plasmid (BVTech Plasmid.5.1 software). 
 
2.3.4. The effect of recombinant Mycobacterium tuberculosis cytochrome bd-I on 
cell pigmentation 
The colour of harvested cells during membrane preparation process was assessed 
with a view to examining the effect of recombinant Mtb cytochrome bd-I oxidase 
(Mtb bd-I) on cell pigmentation. The transformed double-knockout cells 
(TML16) showed a colour change to a red/brown pigmentation following 
harvesting both aerobic and O2-limited cultures. In contrast, the untransformed 
double-knockout cells (ML16) had a light yellow pigmentation following 
harvesting aerobic and O2-limited cultures (Figure 2.9).   
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      A)  B)  
       
  
Figure 2.9: Effect of Mtb bd-I on cell pigmentation 
A) Harvested ML16 and TML16 cells. B) The cell pellets of ML16 and TML16 were 
resuspended in buffer (50 mM KPi, 2 mM EDTA, pH. 7.5). ML16 had a light yellow 
pigmentation whereas TML16 (bearing Mtb bd-I) was accompanied by a change in the 
colour of the cells to a red/brown pigmentation.  
 
2.3.5. Expression studies of cydABDC operon in the ML16 host 
Successfully transformed cells (TML16) and untransformed cells (ML16) were 
subjected to 1 mM IPTG induction at 37 
o
C to express the predicted Mtb bd-I protein 
using the previously mentioned culture conditions (Chapter 2.2.15). Membranes of 
the induced culture were prepared (Chapter 2.2.17) and subjected to SDS-PAGE 
analysis (sections 2.2.21 and 2.2.22). Figure 2.10 shows the expressed proteins. 
There were a group of 4 bands expressed around 180 kDa in TML16, all of which 
might indicate the expression of cydABDC genes. There were also two distinct bands 
above and below 52 kDa which might indicate the overexpression of cydA and cydB, 
which will be confirmed later. However, due to the fact that the molecular weights of 
all cydABDC genes are relatively close to each other, makes it difficult to be certain 
to which genes these two bands relate.   
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Figure 2.10: SDS-PAGE analysis of the recombinant Mtb cytochrome bd-I oxidase 
M, marker of standard proteins whose molecular weights are indicated on the left. Lanes 1, 2 
and 3 correspond to TML16 samples with different dilutions 1:10, 1:25 and 1:50 
respectively, while lanes 4, 5 and 6 correspond to ML16 samples with dilutions 1:50, 1:25 
and 1:10 respectively. The molecular weights of cydA, cydB, cydD and cydC genes 
according to the ProtParam tool (hosted by ExPASy http://web.expasy.org/protparam/) are 
53 kDa, 38 kDa, 55 kDa and 59 kDa respectively. There are a group of 4 bands at around 
180 kDa in TML16 samples (lane 1, 2 and 3). There are also two distinct bands above and 
below 52 kDa. The stock concentration of TML16 and ML16 were approximately 8 mg.ml
-1
 
and 4.3 mg.ml
-1
, respectively.  
 
2.3.6. Initial spectroscopic study of the Mycobacterium tuberculosis cytochrome 
bd-I 
The difference spectra (reduced minus oxidized) of wild-type E. coli BL21 (DE3) 
LysS strain, ML16 and TML16 cells, which were grown during both aerobic and O2-
limited conditions, were recorded at room temperature using sodium dithionite as 
reductant and potassium hexacyanoferrate (III) as oxidant (Figures, 2.11-2.13). The 
significant difference between TML16 and ML16 spectra was the presence of a 
distinctive peak at 631 nm corresponding to that of the heterologous Mtb 
cytochrome bd-I in TML16. 
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2.3.6.1. Wild–type E. coli (BL21(DE3)pLysS) strain 
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Figure 2.11: Reduced minus oxidized spectra of wild-type E. coli BL21 (DE3) LysS 
strain 
The difference spectra (reduced minus oxidized) of wild-type E. coli BL21 (DE3) LysS 
strain were recorded at room temperature using sodium dithionite as reductant and 
potassium hexacyanoferrate (III) as oxidant. There are three distinct features spectra 
recorded in A) O2-limited and B) Aerobic E. coli cultures, which are cytochrome b at 560 
nm, cytochrome a1 at 596 nm and cytochrome d at 629 nm. The cells were grown in O2-
limited condition using closed shaken flasks with a head-space ratio of 0.5 and induced at 
time = 0 h with 1 mM IPTG. The ratios of heme d (629 nm) with respect to heme b560 as a 
reference peak are 0.51 in O2-limited condition and 0.3 in aerobic condition. These peaks 
have been normalized according to the following equation (Value-min/max-min). The final 
protein concentration of O2-limited membranes was approximately 5.7 mg.ml
-1 
and for 
aerobic membranes was approximately 4 mg.ml
-1 
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2.3.6.2. Double-knockout E. coli (ML16) strain 
A) 
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Figure 2.12: Reduced minus oxidized spectra of ML16 
The difference spectra (reduced minus oxidized) of ML16 were recorded at room 
temperature using sodium dithionite as reductant and potassium hexacyanoferrate (III) as 
oxidant. There is a distinct feature in the spectra recorded in both A) O2-limited and B) 
Aerobic ML16 cultures, showing peak at 602 nm. The cells were grown in O2-limited 
condition using closed shaken flasks with a head-space ratio of 0.5 and induced at time = 0 h 
with 1 mM IPTG. The ratios of heme (602 nm) with respect to heme b557 as a reference peak 
are 0.85 in O2-limited conditions and 0.44 in aerobic conditions. These peaks have been 
normalized according to the following equation (Value-min/max-min).  The final protein 
concentration of O2-limited membranes was approximately 1.2 mg.ml
-1 
and for aerobic 
membranes was approximately 2.2 mg.ml
-1 
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2.3.6.3. Transformed double-knockout E. coli (TML16) strain 
A) 
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 Figure 2.13: Reduced minus oxidized spectra of TML16 
The difference spectra (reduced minus oxidized) of TML16 were recorded at room 
temperature using sodium dithionite as reductant and potassium hexacyanoferrate (III) as 
oxidant. Cytochrome d at 631 nm is a distinct feature of recombinant Mtb cytochrome bd-I 
in both A) O2-limited and B) aerobic TML16-10 cultures. The cells were grown in O2-
limited conditions using closed shaken flasks with a head-space ratio of 0.5 and induced at 
time = 0 h with 1 mM IPTG. The ratios of heme d (631nm) with respect to heme b558 as a 
reference peak are 0.3 in O2-limited conditions and 0.13 in aerobic conditions. These peaks 
have been normalized according to the following equation (Value-min/max-min). The final 
protein concentration of O2-limited membranes was approximately 2.8 mg.ml
-1 
and for 
aerobic membranes was approximately 4.3 mg.ml
-1
. 
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2.3.7. Assessment of growth phenotypes  
To qualitatively evaluate the contribution of cytochrome bd-I to respiration, 
monitoring the growth of E. coli BL21 (DE3) LysS strain, AnML16 and TML16 
cells was conducted to identify the differences between wild-type, mutant and 
transformed cells respectively. Resazurin (Raz), a redox indicator, shows a 
qualitative result for the bacterial respiratory state. In appropriate reducing 
conditions, Raz (blue in colour) irreversibly loses an oxygen ion to become resorufin 
(Rru) (Figure 2.14). Rru (orange/pink in colour) can undergo a further reduction to 
colourless dihydroresorufin, which is a reversible reaction by atmospheric oxygen 
and is mainly favoured upon total consumption of Raz (306). Raz is able to 
differentiate strict anaerobes (blue in colour) from microaerophiles (orange/pink in 
colour) and other strict aerobes (colourless) (305). Owing to the fact that Raz has a 
dark blue colour which is the starting colour of any culture medium, the dark blue 
colour in this study, therefore, did not represent a strict anaerobic bacteria respiratory 
state, but represents no metabolic activity or O2 consumption. 
 
 
Figure 2.14: Structures of resazurin in various oxidation states 
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2.3.7.1. Wild–type E. coli BL21(DE3) pLysS strain 
The growth of BL21(DE3) pLysS (wild-type E. coli) was monitored through both 
aerobic and O2-limited growth conditions (Figure 2.15). During the O2-limited 
growth, after 6 h incubation, the colour of Raz was reduced to dark orange/pink 
(Rru) during the exponential phase at OD600 ~ 0.38. Cells achieved highest density 
after 12 h of incubation (OD600 ~ 0.44) and maintained a stationary plateau for about 
10 h. Similarly, during aerobic growth, the colour of Raz after 6 h of incubation was 
reduced to dark orange/pink but with a slow growth rate at the beginning of 
exponential phase. Wild-type E. coli attained maximal density (OD600 ~ 1.5) after 42 
h of aerobic incubation and maintained a stationary plateau for about 15 h before 
starting to decline.   
  
Figure 2.15: Growth of BL21 (DE3) pLysS (wild-type E. coli) supplemented with a 
redox indicator (resazurin) 
Growth was monitored by recording optical density (OD600) values of aerobic, shaken 
cultures (blue) and O2-limited, closed, shaken flasks with a head-space ratio of 0.5 (red). The 
colours of the medium during the growth curve correspond to the colour of the resazurin in 
the medium (resazurin indicative colour chart). Wild-type E. coli began reducing resazurin 
after 6 h of aerobic incubation and achieved maximal density (OD600 ~ 1.5) after 42 h of 
aerobic incubation. During O2-limited growth, wild-type E. coli also began reducing 
resazurin after 6 h of incubation but reached highest density (OD600 ~ 0.44) after 12 h of 
incubation. Error bars represent ± SEM of each point. 
   Aerobic culture 
   O2-limited culture 
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2.3.7.2. Double-knockout E. coli (ML16) strain 
The growth of ML16 was monitored during both aerobic and O2-limited conditions 
(Figure 2.16). During the O2-limited growth and after 12 h of incubation, ML16 
reached the highest density with OD600 ~ 0.4 following reduction of Raz after 8 h of 
incubation. During aerobic growth, after 8 h of incubation, the colour of the Raz was 
reduced to dark orange/pink (Rru) and cells recorded the highest density (OD600 
~1.7) after 45 h of incubation. Notably, the ML16 growth rate appeared parallel to 
the wild-type E. coli as it also reached OD600 ~ 1.5 after 42 h of aerobic incubation. 
During both aerobic and O2-limited growth, ML16 seemed unable to maintain a 
stationary plateau.      
                                
 
Figure 2.16: Growth of ML16 supplemented with a redox indicator (resazurin) 
Growth was monitored by recording optical density (OD600) values of aerobic shaken 
cultures (blue) and O2-limited, closed, shaken flasks with a head-space ratio of 0.5 (red). The 
colours of the medium during the growth curve correspond to the colour of the resazurin in 
the medium (resazurin indicative colour chart).  During aerobic growth, ML16 began 
reducing resazurin after 8 h of incubation and attained highest density (OD600  ~ 1.7) after 45 
h of growth. The O2-limited growth of ML16 also began reducing resazurin after 8 h of 
incubation and reached maximal density (OD600 ~ 0.4) after 12 h of incubation. Error bars 
represent ± SEM of each point. 
   Aerobic culture 
   O2-limited culture 
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2.3.7.3. Transformed double-knockout E. coli (TML16) strain 
The growth of TML16 was monitored throughout aerobic and O2-limited growth 
conditions (Figure 2.17). During O2-limited growth, after 12 h of incubation, the 
colour of Raz was reduced to dark orange/pink (Rru) and TML16 attained the 
highest density after 16 h of incubation (OD600 ~ 0.22). TML16 was able to maintain 
a stationary plateau. During aerobic growth, reduction of Raz was observed after 12 
h of incubation. TML16 achieved its highest density (OD600 ~ 1.2) after 45 h of 
aerobic incubation and maintained a stationary plateau for about 15 h before starting 
to decline.   
 
Figure 2.17: Growth of TML16 supplemented with a redox indicator (resazurin) 
Growth was monitored by recording optical density (OD600) values of aerobic, shaken 
cultures (blue) and O2-limited, closed, shaken flasks with a head-space ratio of 0.5 (red). The 
colours of the medium during the growth curve correspond to the colour of the resazurin in 
the medium (resazurin indicative colour chart). During both aerobic and O2-limited growth 
of TML16, resazurin reduction began after 12 h of incubation. TML16 attained maximal 
density (OD600 ~ 1.2) after 45 h of aerobic incubation but reached highest density (OD600 ~ 
0.22) after 16 h of O2-limited incubation. Error bars represent ± SEM of each point. 
 
 
   Aerobic culture 
   O2-limited culture 
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2.4. Discussion 
The genes involved in the expression of the cytochrome bd-I oxidase are cydA and 
cydB, encoding subunits I and II of cytochrome bd-I oxidase. Nevertheless, cloning 
the whole operon cydABDC was a necessity due to the fact that the cydDC genes, 
located immediately downstream of cydAB genes, are implicated in the assembly of 
a functional bd-type oxidase (195, 243-247). This suggested a functional association 
between cytochrome bd-I oxidase and the ABC transporter owing to the adjacent 
location of Mtb cydAB and cydDC genes (221). The cydABDC organization in Mtb 
(148) is parallel to that observed in M. smegmatis (253) and Bacillus subtilis (215, 
307). However, Kana et al (2001) wrote that the cydDC genes in M. smegmatis may 
be expressed independently from cydAB owing to the intergenic space between 
cydAB and cydDC (253). Moreover, Green et al (1984) was able to express 
cytochrome bd-I oxidase in E. coli through cloning merely cydAB genes (308). In 
Geobacillus thermodenitrificans, a low GC Gram-positive bacterium, coexistance of 
the cytochrome bd-I and ABC transporter genes in the same plasmid was also not 
necessary (309). On the contrary, an aspect regarding the necessity of cydDC genes 
has been further emphasised recently in a study of Corynebacterium glutamicum, a 
high GC Gram-positive bacterium, that showed the importance of involving cydDC 
genes in the expression plasmid for cydAB overexpression (310).  
 
Essentially, using highly parallel Illumina sequencing, Griffin et al (2011)  precisely 
identified essential genes (151 genes) for Mtb viability. This study showed that all 
cyd-operon genes, cydABDC, are essential for Mtb viability (2). This contradicted a 
previous study which deemed only 81 genes to be essential through the use of 
microarrays, and which suggested that only cydB is essential for Mtb (116). 
Remarkably, Zhang et al (2012) who coupled high-density insertion libraries with 
deep sequencing showed a 97.1% level of agreement with the data of Griffin et al 
(2011) regarding essential Mtb genes (2, 166).    
 
With regards to the expression conditions, appropriate signalling of the regulatory 
components may lead to levels of cytochrome bd-I or bd-II, under specific growth 
conditions, that are significant to the cells. As previousely mentioned, in E. coli 
cytochrome bd-I has different expression conditions to that of cytochrome bd-II. The 
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expression of cytochrome bd-I both in E. coli and Mtb was recorded during both 
aerobic and microaerophilic growth conditions (20, 212) whereas cytochrome bd-II 
was expressed under anaerobic or starvation conditions (217, 218, 290, 292). Herein, 
expression studies of the recombinant Mtb cytochrome bd-I oxidase (Mtb bd-I) in an 
E. coli mutant used the low O2 tension as a stressful condition. The spectra data 
showed that Mtb bd-I was expressed moderately in aerobic conditions and 
excessively under oxygen-limiting conditions. The ratio of cytochrome d peak to the 
reference peak in TML16 was higher in O2-limited (0.3) condition than in aerobic 
conditions (0.13).  These findings are in accordance with previous observations of 
cytochrome bd-I expression conditions in E. coli (234, 311), in M. smegmatis (253) 
and in this study of the wild-type E. coli strain.  
 
The induction of cytochrome bd-I oxidase was suggested to be at 1% air saturation in 
M. smegmatis (253), at 7% air saturation in E. coli (246) and during transition to 
anaerobiosis state in B. subtilis (312). However, the present data suggest that the 
induction of Mtb bd-I is observed during both oxygen-rich and oxygen-limited 
conditions (i.e. aerobic and O2-limited). These results further contradict the 
suggestion of Shi et al (2005) that Mtb cytochrome bd-I is only induced at 1% air 
saturation (221).  
 
SDS-PAGE analysis of Mtb bd-I showed expression of two bands, which have 
protein mass of around 52 kDa. However, these bands were indistinguishable in 
terms of gene identity on SDS-PAGE since the molecular weights of all cydABDC 
genes are relatively close to each other. The protein masses of Mtb cydA, cydB, cydD 
and cydC subunits are 53.83 kDa, 37.63 kDa, 54.8 kDa and 59.5 kDa, respectively. 
Cytochrome bd-I  in E. coli, a transmembrane heterodimer protein, has one copy of 
each subunit with molecular weight of 58 kDa for subunit I and 43 kDa for subunit II 
(212). Therefore, according to the spectral analysis data that confirmed the 
expression of Mtb bd-I, we can suggest that the two expressed bands could represent 
Mtb bd-I subunits I and II. According to the transformed double-knockout (TML16) 
protein concentration, the proteins seemed to be overexpressed as even in a highly 
diluted sample, the proteins bands were clearly visible. This in turn confirmed the 
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aforementioned Kabashima et al (2009) finding that cydDC was necessary for cydAB 
over expression (310).         
 
Spectral properties showed different heme peaks and ratios according to growth 
conditions or strain differences. Reduced minus oxidized difference spectra recorded 
at room temperature were used to analyze the cytochrome content of wild-type E. 
coli BL21(DE3) pLysS. During both aerobic and O2-limited growth conditions, 
major absorbance peaks that were observed at 560, 596, and 629 nm were 
characteristic of b-, a1-, and d-type cytochromes, respectively that represent a 
‘normal’ E. coli spectrum (313, 314).  
 
Importantly, the spectra of ML16 mutant strain lacked the heme-d features but 
showed absorbance peaks at 528, 557, and a discrete peak at 602 nm, a finding 
consistent with specific disruption of cytochrome bd-I. The discrete peak at 602 nm 
was reported as cytochrome aa3 in other bacteria such as the Thiobacillus novellus 
(315), Rhizobium leguminosarum (316) and Bradyrhizobium japonicum (317). 
However, cytochrome aa3 in B. subtilis (318) and in M. smegmatis (253) has a peak 
at 600 nm rather than 602 nm. Essentially, wild-type E. coli BL21(DE3) did not 
possess the genes that code for cytochrome aa3 oxidase, qoxABCD. Siegel et al 
(1973) recorded similar peak at 602 nm during a study of NADPH-sulfite reductase 
of E. coli. However, it had not been designated to a specific cytochrome component 
(319). Accordingly, given that macromolecular reorganization of prosthetic groups 
and terminal oxidase subunits could give rise to alternate oxidases, terminal 
components of the respiratory chain cannot be inferred only from the genome 
sequence (253). Likewise, the bb’-type terminal oxidase in B. subtilis, which 
appeared to be bd-type (encoded by the cydAB genes), had the heme-d substituted by 
high spin heme-b (320). This might be the case for the present ML16 spectrum as 
despite the presence of endogenous cytochrome bd-II genes, the heme-d absorbance 
peak that was expected to be present at about 628 nm - 632 nm was not recorded 
(217, 218, 290, 292). 
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The ML16 strain was transformed with a plasmid carrying the entire Mtb cydABDC 
genes that led to restoration of heme-d631 absorbance peak, confirming that the Mtb 
cydABDC operon was able to functionally complement the cytochrome bd-I defect in 
the E. coli mutant (ML16) strain. Interestingly, Kana et al (2001) confirmed that the 
presence of a plasmid carrying Mtb cydABDC operon restored heme-d631 in a 
cytochrome bd-I defective M. smegmatis mutant strain (253).  The heme-d 
absorbance peak (about 628 nm - 632 nm) is a characteristic of the cytochrome bd-I 
oxidase in E. coli (263) and B. subtilis (Winstedt et al., 1998). The signals at 558 nm 
and at 595 nm were presumably due to the low-spin heme b558 and the high-spin 
cytochrome b595 component of the cytochrome bd-type oxidase complex, as were 
reported in the well-studied E. coli (313) and A. vinelandii (321) oxidases.    
 
A novel, but unexplained, observation is the red/brown pigmentation observed in 
TML16 cultures (aerobic and O2-limited). This could be explained by the 
overexpression of heme-containing cytochromes and porphyrins, which was 
supported by the expression studies of TML16 showing an over expression of 
functional recombinant Mtb cytochrome bd-I oxidase. Ratledge (1999) suggested 
that the presence of porphyrins was the main reason behind the red colour in 
mycobacteria (322). Significantly, a hypoxic culture of M. smegmatis, with 0.6% 
oxygen saturation, was accompanied by a change in the coloration of the cells from a 
light yellow pigmentation to a red pigmentation. In turn, this infers the induction of 
the cytochrome bd-I oxidase and the machinery needed for its assembly and 
synthesis (i.e. porphyrin/heme and cysteine biosynthesis) (289). 
 
Regarding the growth rate of the cells, during aerobic conditions, ML16 showed a 
higher growth rate, reaching its highest density (OD600 ~ 1.7) after 45 h compared to 
the BL21 (DE3) pLysS (reference strain) (OD600 ~ 1.5) after 42 h of incubation, and 
to the transformed strain TML16 that which hardly exceeded OD600 ~ 1.2 after 45 h 
of incubation. Nevertheless, the ML16 growth rate seemed more similar to the 
reference strain as it also reached OD600  ~1.5 after 42 h of incubation. Kana et al 
(2001) wrote that inactivation of M. smegmatis cydA and/or cydB genes had no 
discernible effect on the growth rate during exponential phase, when bacteria were 
grown aerobically at 21 or 5% air saturation. However, Kana et al (2001) observed a 
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significantly lower growth rate of M. smegmatis cydA mutant than that of wild-type, 
when bacteria were grown at 0.5 and 1% air saturation (253). Moreover, Cohen 
(2011) suggested that the reduction in the growth rate could be attributed to exposing 
the cells to oxygen limiting conditions (294). In contrast, data showed that during 
O2-limited conditions, Ml16 demonstrated a similar growth rate to the reference 
strain reaching an OD600 of ~ 0.4 after 12 h of incubation. Therefore, results 
suggested that the air saturation inside the flasks during O2-limited condition could 
be more than 1%. In turn, TML16 cells under oxygen-limiting condition exhibited a 
low growth rate in comparison with both mutant and reference strains, as it reached 
the highest density (OD600 ~ 0.22) after 16 h of incubation. The slow growth rate of 
TML16 during both oxygen-rich and oxygen-limited conditions might be due to the 
adaptation of the cells to synthesize a functional recombinant Mtb cytochrome bd-I 
oxidase alongside growing under oxygen limited condition.  
 
To qualitatively evaluate the contribution of cytochrome bd-I to respiration in 
aerobic and O2-limited conditions, resazurin was used as a visual indicator of the 
oxygen depletion in cultures (305) and as an indicator of the respiratory function. 
Raz reacts in the presence of oxygen, acids and functional dehydrogenases and 
oxidoreductases of viable organisms. Raz could be reduced by strict aerobes, 
facultative anaerobes such as E. coli, aerotolerant and microaerophile organisms, but 
not by strict anaerobes (305, 323, 324).  
 
ML16 and the wild-type strain cultures were shown to reduce resazurin earlier than 
TML16. During both aerobic and O2-limited growth conditions, the reduction of Raz 
was detected respectively after 8 h and 6 h post-inoculation for ML16 and the 
reference strain. TML16 cell cultures were observed to reduce Raz slower, taking 12 
h of incubation to reduce during both O2-limited and aerobic growth conditions. The 
oxygen depletion in TML16 culture was delayed due to the fact that the host cells 
needed longer time to express functional cytochrome bd-I. Geckil et al (2001) noted 
that oxygen uptake might be particularly strict when recombinant cells are involved. 
This is due to the fact that the presence of the plasmid is considered a burden 
because of the cellular resources required for maintaining and expressing plasmid 
genes. In addition, the plasmid may cause perturbations in cellular metabolism (325). 
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However, the presence of a plasmid (pLysS) in the reference strain did not hold it 
back from reducing Raz during earlier time of growth rate. This could be attributed 
to the fact that pLysS has no noticeable effect on growth rate (303). Expectedly, 
ML16 reduced Raz later than the wild-type due to the lack of cytochromes bo3 and 
bd-I in ML16 cells. Notably, although ML16 did not show a heme-d absorbance 
peak of cytochrome bd-II, it demonstrated normal oxygen utilization with a 
colourless Raz in the medium observed, which might indicate aerobic respiration.  
 
Significantly, the demand for oxygen uptake was sustained in TML16, resembling 
that of the reference strain. However, ML16 showed a short period of oxygen uptake 
demand before it reached the regular oxygen uptake phase. The ability of the Mtb 
bd-I to restore the reference strain phenotype (oxygen consumption) is attributed to 
its high affinity for oxygen. Bekker et al (2009) showed that cytochrome bd-I has a 
10- and 20-fold-higher affinity for oxygen than cytochrome bd-II and cytochrome 
bo3, respectively (290). Moreover, the high demand for O2 by both TML16 and the 
reference strain could also be attributed to a potential factor related to its harbouring 
a plasmid construct (325). In accordance with the present data, Khosravi et al (1990) 
wrote that recombinant cells require more oxygen than plasmid-free cells (326). 
There are other factors that could affect the oxygen depletion in cultures, and in turn 
the resazurin status. For instance, the mode and vigour of agitation (33) were found 
to have an effect on the Raz status as well as the intense light (i.e. bright sunlight), 
which could lead to rapid photochemical decay of resazurin (327). However, these 
factors could be ruled out as they were fixed throughout this study experiments and 
intense light exposure was avoided. 
 
Regarding the stationary phase (non-replicating phase) viability, unlike the reference 
strain, both aerobically and O2-limited grown ML16 seemed to exhibit a stationary-
phase viability defect as observed in cyd mutant strains of E. coli (295) and of A. 
vinelandi (328). Remarkably, TML16 cells did display a restoration of the loss of 
stationary phase viability, emphasising the significance of cytochrome bd-I during 
stationary phase. The ability of Mtb bd-I to restore cells viability during stationary 
phase was further confirmed in different heterologous expression system, the 
TMB44 system (Chapter IV). In addition, the mycobacterial bd-I oxidase was 
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required specifically for growth under extreme microaerophilia (253). Interestingly, 
this observation might indicate the involvement of Mtb bd-I in persister cell 
viability. Persister cells are non-replicating subpopulation of microbes that exist 
during the stationary phase and have the ability to survive exposure to bactericidal 
antibiotics (4). Nevertheless, significant expression of Mtb bd-I during aerobic 
conditions could indicate the ability of this enzyme to compensate the loss of other 
terminal oxidases.  
 
In summary, the spectroscopic evidence provided herein confirms the presence of 
Mtb heme-d-containing cytochrome in the E. coli mutant strain, ML16. In this and 
other respects, the high affinity cydAB-encoded cytochrome bd-I oxidase of Mtb 
displayed spectral features analogous to the well-characterized E. coli cytochrome 
bd-I (213). In addition, cytochrome bd-I oxidase demonstrated its role as an essential 
oxygen scavenger and as an important respiratory component of Mtb with respect to 
maintaining cell viability during stationary phase. Stationary phase could include 
slowly-replicating, non-replicating and/or persister cells. This is in agreement with 
the Griffin et al (2011) sequencing study that confirmed Mtb cytochrome bd-I 
oxidase essentiality (2) for Mtb viability, and with Dhar and McKinney (2010) who 
identified cydDC essentiality for persister cells (24, 52).  
 
Regarding limitation and recommendations of this chapter, monitoring oxygen 
consumption in the cultures was limited to visual qualitative assessment using Raz. 
Ideally, measuring the O2 saturation of the cultures using an O2 electrode sensor or 
rotometer would be recommended. Moreover, growing cells in a chemostat could act 
as an alternative way of culturing TML16 whereby all the parameters in the system 
could be monitored, including the dissolved O2 tension (253). Initial 
characterizations of the recombinant Mtb cytochrome bd-I oxidase including steady 
state kinetic and drug susceptibility studies are described in the following chapter.   
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Chapter III 
Biochemical and pharmacological characterization 
of Mycobacterium tuberculosis cytochrome bd-I 
oxidase 
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3.1. Introduction  
The purpose of this study was to explore the kinetic properties of recombinant 
Mycobacterium tuberculosis cytochrome bd-I oxidase (Mtb bd-I) and to highlight 
the potential of this enzyme as a novel drug target, thus, optimistically, fuelling the 
drug discovery pipeline. 
 
The respiratory chain of Mtb can function with a variety of different membrane-
bound NADH dehydrogenases, including NDH-1, NDH-2, NDH-2A, and SDH as 
well as LDH, G3PDH, MDH and PDH dehydrogenases, on the electron input side. 
In contrast, the electron accepting components of the respiratory chain include two 
terminal oxidases (cytochrome bc1-aa3 super complex and cytochrome bd-I oxidase) 
as well as reductases (NRs and FRD). The link between the electron donating and 
the electron accepting enzymes are the membrane mobile quinones. Donor:quinone 
oxidoreductases (i.e. NADH:quinone oxidoreductase) and quinol:acceptor 
oxidoreductase, such as quinol:oxygen oxidoreductase for bd, are coupled together to 
generate simple electron transport chains, producing a PMF. Quinones are small 
membrane-entrapped lipophilic molecules that are freely diffusible, which can carry 
two electrons and two protons in the fully reduced state (quinol) (329). 
Decylubiquinol (dQH2), ubiquinol-1 (Q1H2) and ubiquinol-2 (Q2H2) are examples of 
synthetic quinols that are frequently utilised in enzymological studies (Figure 3.1). 
 
 
Figure 3.1: Structures of decylubiquinone, ubiquinone-1 and ubiquinone-2 and their 
reduced quinol counterparts 
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It is well known that utilization of quinol as an electron donor by cytochrome bd-I 
oxidase (bd-I) is species-specific. For example, bd-I can only oxidize menaquinol 
(MQH2) in B. stearothermophilus and ubiquinol (UQH2) in A. vinelandii. In contrast, 
E. coli bd-I can oxidize both UQH2 and MQH2 (255, 256), as upon changes from 
aerobic to anaerobic growth conditions, bd-I replaces UQH2 by MQH2 (330). 
Menaquinone (MQ) is the substrate in Mtb, consisting of nine isoprene units (MQ-9) 
while in E. coli it contains 8 units (MQ-8) (195, 202, 331). In vitro, beside the 
physiological substrates, short chain ubiquinols such as dQH2, Q1H2 and Q2H2 as 
well as artificial electron donors, N,N,N′,N′-tetramethyl-p-phenylenediamine 
(TMPD) can be oxidized  by bd-I (53, 212, 213).      
    
Viewing the reaction pathway or catalytic cycle of an enzyme helps in understanding 
the enzyme catalysis and thus in planning the best inhibition mechanism of the 
enzyme. Cytochrome bd-I oxidase is an integral membrane protein with exposed 
surfaces to cytoplasmic and periplasmic compartments. Cytochrome bd-I oxidase is 
a terminal oxidase that oxidizes quinol/menaquinol and reduces O2 to water. Three 
hemes (heme b558, heme b595 and heme d) form the enzyme. Heme b558 is associated 
with subunit I of bd-I and is involved in QH2 oxidation. Heme d is the site for 
capturing and, subsequently, reducing O2 to H2O and is predicted to be located in the 
second subunit (subunit II) of bd-I, near the periplasmic surface (195, 257, 332). 
Both heme b595 and heme d are located close to each other forming a di-heme active 
site and potentially can bind ligands; heme d has a higher affinity for ligands than 
heme b595, resulting in binding of ligands to heme d (211, 333). The chemistry 
catalyzed by the enzyme is simple: 
                           
The electron transfer sequence in cytochrome bd-I is thought to be QH2 → heme b558 
→ [heme b595 → heme d] → O2. Four protons per O2 are taken up from the 
cytoplasmic side and four are released to the periplasmic side, thus the H
+
/e
-
 ratio is 
1. Simultaneously, reduction of O2 to water and oxidation of quinol to quinone, 
performed along with the transfer of four electrons through heme b558 and b595 to the 
O2 reducing site, result in the generation of a PMF by trans-membrane charge 
separation, which subsequently may drive ATP synthesis by the ATP synthetase 
(332). Generation of a PMF by trans-membrane charge separation is a consequence 
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of releasing protons, generated from the quinol oxidation, into the positive 
(periplasmic) side of the membrane, and taking protons, used to convert O2 to H2O, 
from the negative (cytoplasmic) side (205, 206). The proposed model of cytochrome 
bd-I oxidase catalytic mechanism is depicted in the following figure (Figure 3.2). 
 
                                      
 
Figure 3.2: Proposed cytochrome bd-I model adapted from (211) 
 
 
Enzyme reactions can be studied under steady state conditions. Steady state kinetics 
refers to a balance situation between the rate of Enzyme-Substrate (ES) formation 
and the rate of ES complex disappearance. During the initial phase of an enzyme 
reaction, the initial velocity, a slope of the product (or substrate) concentration 
versus time plot, typically lasts until about 10 to 15% of the initial substrate 
concentration has been converted into product; afterwards the velocity slows down. 
Enzymes can catalyse monosubstrate, bisubstrate and multiple substrate reactions. 
Monosubstrate reaction, the most simple enzyme reaction, involves converting a 
single substrate to a single product. A bisubstrate reaction involves two substrates, 
utilized to form one or more products. A multiple substrate reaction includes more 
than two substrates combining to form products (334, 335).          
 
Under physiological conditions cytochrome bd-I activity varies; the detergent nature 
in which the purified enzyme is solubilised has an influence on its activity. For 
instance, solubilising E. coli bd-I in octylglucoside detergent rendered the enzyme 
inactive. However, E. coli bd-I shows high activity in Tween-20 (211, 336). 
101 
 
Concerning the importance of the pH profile, pH is known to affect the charges on 
the amino acids residues within the active site, resulting in structural changes of the 
catalytic side. Subsequently, the substrate may no longer fit into enzyme active site. 
Moreover, changes in pH could break the ionic bonds that stabilize the functional 
structure of the enzyme (194, 335). The conserved amino acids residues in the bd-
family are His19, His186 and Met393, Arg448, and Glu99, Glu107, Ser140, Lys252 
and Glu257, of which the latter two residues are involved in QH2 binding (211, 337). 
The conserved amino acids residues in the bd-family could participate in critical 
proton transfer reactions and in stabilizing charges during the transition state (334).    
 
Inhibiting the electron transport chain components of Mtb is an attractive 
chemotherapeutic goal as demonstrated by the diarylquinoline: TMC207 drug, 
targeting the mycobacterial ATP synthase complex (4, 274, 338, 339). The fact that 
Mtb bd-I, has no counterparts in mammalian mitochondria, and that it is essential for 
Mtb viability renders this component attractive as a drug target (Chapter 2.4) (2, 
211).  
 
Different classes of inhibitors were found to be potent against quinol oxidases, such 
as the natural antibiotic gramicidin S and the quinolone-type inhibitors, aurachins C 
and D (Figure 3.3). Derivatives of aurachin compounds showed that the critical core 
of the compounds is the ring structure. The compounds’ effectiveness is maintained 
upon replacing the natural polyisoprenyl side chain with a simpler saturated aliphatic 
side chain; as the chain length of the R group increased, little systematic variations 
of inhibitor potency were observed (264, 265). A relatively similar scenario was 
adopted in a drug discovery programme with the objective of identifying hit 
compounds against Plasmodium falciparum NADH:ubiquinone oxidoreductase 
(PfNDH2) (340, 341).  Based on structure-activity relationship (SAR) development, 
this program succeeded in identifying a novel quinolone-type inhibitor against 
PfNDH2. A further programme (MtbNDH2 programme) ensued with the objective 
of identifying selective inhibitors against NDH-2: NADH dehydrogenase, a novel 
enzyme target within the Mtb bacilli, adopting the same strategy as the PfNDH2 
programme.  
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Figure 3. 3: A) aurachin C structure. B) aurachin D structure 
 
1-hydroxy-2-dodecyl-4(1H) quinolone (HDQ) is a known inhibitor of PfNDH2 and 
was the core for initiating the chemoinformatics approach with the purpose of 
selecting compounds for high-throughput screening (HTS) (342). Therefore, 
quinolone-type compounds (from in house libraries) were examined against Mtb bd-I 
and Mtb H37Rv. The quinolone core (Figure 3.4) of these compounds has been the 
key target for SAR development investigating, the relationship between the chemical 
structure of a compound and its biological or pharmacological activity. SAR can be 
considered by viewing a series of molecules, each with a slightly different structure, 
and then observing the biological activity with each structural variation.   
 
   
 
 
 
 
 
 
 
Figure 3.4: A) HDQ structure. B) The quinolone core 
 
Eliminating the pathogenic organism is the ultimate clinical outcome of any drug 
designed for this purpose. Therefore, studying the pharmacokinetic and the 
pharmacodynamics of inhibitors as well as the kinetics of inhibitor interaction with 
the enzyme provides a meaningful prediction of drug efficacy in vivo. In this work, 
basic kinetic parameters of the Mtb cytochrome bd-I catalytic reaction were 
measured and compared to cytochrome bd-I from previously studied bacteria. 
Moreover, the IC50s of quinolone-type inhibitors against Mtb bd-I and the inhibitor-
enzyme interaction were studied. 
A) B) 
            
 
    
 
A) B) 
                           
A B 
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3.2. Material and methods 
3.2.1. Membrane preparations 
Following the protocol of Fisher et al (2009), membrane preparations were carried 
out as detailed in Chapter (2.2.17) (209). It is worth mentioning that all assays were 
carried out using the membranes of the TML16 strain, grown under O2-limited 
conditions, as it has the highest catalytic activity. The Mtb bd-I of the TML16 strain, 
grown under aerobic condition, was also examined for steady-state kinetics with 
dQH2 to evaluate Mtb bd-I under both growth conditions (Figure 3.6, B).  
 
3.2.2. Preparation of 50 mM KPi, 2 mM EDTA, pH 7.5 buffer  
For kinetic assays 50 mM KPi, 2 mM EDTA, pH 7.5 buffer was used throughout 
experiments, unless otherwise stated. This buffer was prepared following the 
previously described protocol (section 2.2.16).  
 
3.2.3. Preparation of decylubiquinol (dQH2) and ubiquinol-2 (Q2H2)  
Preparation of both dQH2 and Q2H2 were performed according to the protocol of 
Fisher et al (2004) (343). Briefly, 10 mg of 2,3-dimethoxy-5-methyl-n-decyl-1,4-
benzoquinone (decylubiquinone) or 10 mg of 2,3-dimethoxy-5-methyl-6-geranyl-
1,4-benzoquinone (ubiquinone-2) (Sigma Aldrich, UK), were dissolved in 400 µl of 
nitrogen-saturated hexane.  An equal volume of aqueous 1.15 M sodium dithionite 
was added, and the mixture shaken vigorously until colourless.  The upper, organic 
phase was collected, the dQH2 or Q2H2 were extracted off hexane and the solvent 
was evaporated under N2. Subsequently, dQH2 or Q2H2 were dissolved in 100 µl of 
96% ethanol (acidified with 10 mM HCl). Concentrations of dQH2 or Q2H2 were 
determined spectrophotometrically on a Cary 300 Bio UV/visible spectrophotometer 
(Varian, UK) from absolute spectra, using          = 4.14 mM
-1
.cm
-1
. Both dQH2 
and Q2H2 were stored at -80 
o
C and used within two weeks. 
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3.2.4. Preparation of ubiquinol-1 (Q1H2)  
Preparation of Q1H2 was based on the protocol of Kihira et al (2012) (344) with 
modification where 1 ml of 40 mM ubiquinone-1 (Sigma Aldrich, UK) solubilised in 
DMSO was diluted 3-fold with 100 mM potassium phosphate buffer (KPi, pH 7.5). 
Sodium dithionite powder was added to this solution to reduce ubiquinone-1 until 
the yellow colour disappeared. The Q1H2 formed was extracted with hexane and the 
solvent was evaporated under N2. Q1H2 was dissolved in 100 µl of 96% ethanol 
(acidified with 10 mM HCl). The concentration of Q1H2 was calculated 
spectrophotometrically on a Cary 300 Bio UV/visible spectrophotometer (Varian, 
UK) from absolute spectra, using          = 4.14 mM
-1
.cm
-1
. Q1H2 was stored at -80 
o
C and used within two weeks. 
 
3.2.5. Steady state kinetic assays  
Oxidation of quinols (dQH2, Q1H2 and Q2H2) by Mtb bd-I was measured 
spectrophotometrically at 283 nm on a Cary 300 Bio UV/visible spectrophotometer 
(Varian, UK). Total reaction volume in a 1 cm pathlength quartz cuvette was 700 µl, 
containing 698 µl of (50 mM KPi, 2 mM EDTA, pH 7.5) buffer and 2 µl of the crude 
recombinant membrane to a final concentration of 3 μg.ml-1. Following thorough 
agitation of the cuvette contents and recording the absorption spectrum, quinol was 
added (to a final concentration of 5 - 98 µM) and kinetic data collected for 4 min. 
Initial rates (computer-fitted as zero-order kinetics) were measured as a function of 
quinone concentration, using      = 8.1 mM
-1
cm
-1
.  Plots of initial velocity as a 
function of substrate concentration were fitted using the Michaelis-Menten equation 
(dQH2 and Q1H2):  
                                                                  
        
      
 
 
However, for Q2H2 oxidation, a modified ping-pong bi-bi mechanism was used for 
Mtb bd-I as per Matsumoto et al (2006) (345). The formula was established by Dr. 
Nick Fisher. 
                                     
     ( S ) 
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Data were analysed using a Michaelis-Menten hyperbola and a modified ping-pong 
bi-bi mechanism equation in order to determine Km and Vmax values using Origin 8.5 
(OriginLab Corp., USA). The mathematical term Vmax refers to the maximal velocity 
obtained at infinite substrate concentration whereas Km (commonly stated to as the 
Michaelis constant) refers to the substrate concentration that leads to half saturation 
of the enzyme active sites under steady state conditions (334, 335).      
 
3.2.6. pH assay 
To investigate the role of acid base catalysis in Mtb bd-I oxidase-catalyzed reactions, 
the pH dependence of kinetic parameters was determined by measurement of dQH2 
oxidation rates across the pH range of 5.5 - 8.5, employing a mixed buffer system 
containing 2-(N-morpholino)ethanesulfonic acid (MES), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), and N-Tris(hydroxymethyl)methyl-3-
aminopropanesulfonic acid (TAPS). UV-visible spectroscopic analysis of freshly 
prepared membranes was carried out on a Cary 300 Bio UV/visible 
spectrophotometer (Varian, UK). Total reaction volume in a 1 cm pathlength quartz 
cuvette was 700 µl, which contained 2 µl of membrane (final concentration 3 μg.ml-
1
)
 
suspended in 698 µl of different pH (40mM HEPES/MES/TAPS) buffer. 
Following thorough agitation of the cuvette contents, a UV-visible absorption 
spectrum was recorded at 283 nm, to which a fixed concentration of 50 μM dQH2 
was added to initiate the reaction. Specific catalytic activity (μmol.min-1.mg-1) was 
calculated using      = 8.1 mM
-1
.cm
-1
. 
 
3.2.7. Detergent assays 
The effect of detergents on Mtb bd-I oxidation rates of dQH2 were measured 
spectrophotometrically using a Cary 300 Bio UV/visible spectrophotometer (Varian, 
UK) and a quartz cuvette of pathlength 1 cm. Assays of total reaction volume 700 µl 
containing 698 µl of (50 mM KPi, 2 mM EDTA, pH 7.5) buffer, 2 µl of the 
membranes (final protein concentration of 11.3 μg.ml-1) and 0.01% (v/v) of 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), n-dodecyl-β-D-
maltopyranoside (DDM), cholate, deoxycholate, Triton X-100 or Tween-80 
detergents. Following thorough agitation of the cuvette contents and recording of a 
UV-visible absorption spectrum at 283 nm, 2.3 µl of 15 mM dQH2 (final 
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concentration of 50 μM dQH2) was added to the cuvette to initiate the reaction. 
Specific catalytic activity (μmol.min-1.mg-1) was calculated using      = 8.1 mM
-
1
.cm
-1
. 
 
3.2.8. Chemoinformatics compound selection 
The best 18 compounds against PfNDH2 of the mitochondrial ETC of Plasmodium 
falciparum (340) were tested against Mtb bd-I and Mtb H37Rv. Subsequently, 5 
more compounds were chosen arbitrarily from a program established to identify hits 
against NDH2 complex of Mycobacterium tuberculosis, which were RKA-259, 
SCR-8-12, RKA-307, RKA-310 and MTD-403.  
 
3.2.8.1. Preparation of inhibitor stock solutions 
10 mM inhibitor stocks were prepared according to their solvent solubility (Table 
3.1).  Inhibitor stocks were prepared and kept at -20 
o
C for no longer than 1 month. 
Final dilutions were made with culture medium (7H9 MiddleBrook) or with DMSO 
and freshly prepared prior to studies being carried out. Final concentration of DMSO 
was maintained below 1% throughout experiments unless otherwise stated. 
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Table 3.1: List of the inhibitors used in inhibition studies for phenotypic profiling of 
H37Rv strain of Mtb 
 
Compound 
Molecular weight 
(g.mol
-1
) 
Solvent Source 
Isoniazid 137.14 DMSO Sigma Aldrich, UK 
Rifampicin 822.94 DMSO Sigma Aldrich, UK 
Ethambutol 277.23 DMSO Sigma Aldrich, UK 
Streptomycin 728.69 H2O Sigma Aldrich, UK 
Metronidazole 171.15 DMSO Sigma Aldrich, UK 
CK-2-63 411.37 DMSO 
In house synthesis in collaboration 
with Prof Paul O’Neill, Department 
of Chemistry, Uni. of Liverpool) 
CK-3-22 412.36 DMSO In house synthesis 
CK-2-88 325.40 DMSO In house synthesis 
CK-3-23 339.43 DMSO In house synthesis 
CK-3-14 346.35 DMSO In house synthesis 
RKA-307 318.41 DMSO In house synthesis 
RKA-310 348.44 DMSO In house synthesis 
RKA-259 442.39 DMSO In house synthesis 
RKA-41 602.72 DMSO In house synthesis 
RKA-70 395.37 DMSO In house synthesis 
RKA-73 411.37 DMSO In house synthesis 
SCR-8-12 361.32 DMSO In house synthesis 
LT-9 343.39 DMSO In house synthesis 
SL-2-25 396.36 DMSO In house synthesis 
WDH-1U-10 403.86 DMSO In house synthesis 
WDH-1W-5 385.34 DMSO In house synthesis 
WDH-2A-9 399.37 DMSO In house synthesis 
GN-171 467.44 DMSO In house synthesis 
OB-231 428.41 DMSO In house synthesis 
OB-258 444.41 DMSO In house synthesis 
PG-128 381.35 DMSO In house synthesis 
PG-203 411.37 DMSO In house synthesis 
1-hydroxy-2-dodecyl-
4(1H) quinolone 
329.48 Methanol In house synthesis 
Potassium cyanide 65.12 Methanol Sigma Aldrich, UK 
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3.2.8.2. Enzyme inhibition assays  
Determination of IC50s values for the inhibitors against Mtb bd-I were performed 
using a Cary 300 Bio UV/visible spectrophotometer (Varian, UK), and a quartz 
cuvette of pathlength 1 cm. Assays, of total volume 700 μl, were carried out at room 
temperature containing assay buffer (50 mM KPi, 2 mM EDTA, pH 7.5) and fixed 
concentration of membranes (3 μg.ml-1) and inhibitors, which were added prior to 
reaction initiation with 50 μM dQH2. IC50 values were calculated from plots of log 
dose vs oxidation rate using a four parameter logistic function (y = m1+(m2-
m1)/(1+(m0/m3)^m4); m1=0.1; m2=150; m3=1; m4=1), using Origin 8.5 software 
(OriginLab Corp., USA) and initial rates were measured as a function of quinone 
concentration, using      = 8.1 mM
-1
cm
-1
. 
 
3.2.8.3. Competition assays, Lineweaver-Burk and Eadie-Hofstee Plots  
Determination of Km and Vmax values of Mtb bd-I in the presence of two different 
inhibitor concentrations were performed using the aforementioned steady-state 
kinetic assays (section 3.2.5) with and without the addition of fixed concentration of 
inhibitors prior to reaction initiation. In order to examine the type of some inhibitors, 
i.e. whether they were competitive, non-competitive or uncompetitive inhibitors, 
Lineweaver-Burk and Eadie-Hofstee plots were generated.  The Lineweaver-Burk 
plot is generated by plotting the reciprocal velocity (1/v) against the reciprocal 
substrate concentration (1/S) at two or more values of inhibitor concentrations. In 
contrast, the Eadie-Hofstee plot is generated by plotting the initial velocity (v) 
against the value of initial velocity over substrate concentration (v/[S]) at two or 
more values of inhibitor concentrations. Both Lineweaver-Burk and Eadie-Hofstee 
plots linearize the Michaelis–Menten equation and are considered useful means to 
present data graphically and thus identify the type of inhibition. However, the Eadie-
Hofstee plot, unlike the Lineweaver-Burk plot, distributes points evenly by giving 
equal weight to data points in any range of substrate concentration or reaction 
velocity (194, 335).    
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3.2.9. Culture of Mycobacterium tuberculosis  
3.2.9.1. Preparation of media: 
3.2.9.1.1. Middlebrook 7H9 broth 
Middlebrook 7H9 Broth (BD Diagnostic, UK) was enriched with 0.2% (v/v) 
glycerol, 0.05% (v/v) Tween
®
 80 and 10% (v/v) ADC (Albumin Dextrose Catalase) 
before being filtered through a sterile bottle top filter unit with a 0.22 μm membrane 
(Fisher Scientific, UK). ADC is an enrichment supplement composed of albumin, 
dextrose and catalase, constituents essential for mycobacterial growth.  
 
3.2.9.1.2. Middlebrook 7H11 agar plate medium 
Middlebrook 7H11 Agar (BD Diagnostic, UK) plates were supplemented with 0.2% 
(v/v) glycerol. 10% (v/v) OADC (Oleic Albumin Dextrose Catalase) was added 
when the medium had cooled below 50 °C, but prior to setting. OADC is an 
enrichment supplement composed of oleic acid, albumin, dextrose and catalase, 
constituents essential for mycobacterial growth. 
 
3.2.9.2. General considerations regarding Mtb culturing 
The Advisory Committee on Dangerous Pathogens (ACDP) has categorized 
Mycobacterium tuberculosis as hazard group 3. Within a containment Level 3 
laboratory, a Nuaire Labguard Class II biological safety cabinet (Nuaire, USA) was 
for all work involving viable Mtb.  
 
Mtb cultures were safely contained inside a Bio Transport
TM
 Carrier box (Nalgene
®
, 
USA) inside the incubator and during moving the cultures from the incubator to the 
safety cabinet and vice versa. All waste generated was immersed in a solution of 5%  
(v/v) of Surfanios before being autoclaved. Surfanios (Anios lab, France) was used 
as disinfectant due to its superior ability to sterilise mycobacteria.  
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3.2.9.2.1. Mtb strain and growth media 
Mtb strain H37Rv (ATCC#25618) was maintained in Middlebrook 7H9 Broth or 
Löwenstein-Jensen slopes (BD Diagnostic, UK) at 37 °C in a 5% CO2 HERACell 
150 CO2 incubator (Thermo Scientific, UK). The continuous sub-culture of Mtb in 
solid or liquid medium was avoided as in vitro culture mutations might occur 
frequently due to prolonged incubation (346). 
 
3.2.9.2.2. Culturing Mtb from frozen stocks 
Mtb was retrieved from -20 °C and allowed to defrost at room temperature. 50 μl of 
Mtb stock was inoculated directly into 10 ml of Middlebrook 7H9 broth. 
Simultaneously, a pre-warmed Löwenstein-Jensen slope was inoculated using a 10 
μl disposable loop (NUNC, UK) as a cell reservoir and to eliminate the presence of 
any contamination. Mtb cultures were incubated at 37 °C in a 5% CO2 HERACell 
150 CO2 incubator (Thermo Scientific, UK). Following 2-3 weeks growth, an 
isolated Mtb colony was transferred from the slope into a 50 ml Falcon tube 
containing 10 ml of Middlebrook 7H9 both. The culture was vortexed and 
subsequently incubated for a minimum of 2 weeks before being used. The remaining 
Mtb in the defrosted vial were discarded in 5% (v/v) Surfanios.   
 
3.2.9.2.3. Mtb aerobic cultures 
Mtb inoculum (100 μl) was transferred to a 50 ml Falcon tube containing 10 ml of 
Middlebrook 7H9 broth. The culture was vortexed and incubated for a minimum of 2 
weeks at 37 °C in a 5% CO2 incubator before being used. The aerobic culture was 
discarded after 8 weeks of incubation. 
 
3.2.9.2.4. Hypoxia model of growth: cultures grown in limited oxygen condition 
The Wayne model of growth was adapted for Mtb growth in oxygen limited 
conditions (347). The creation of a microaerophilic environment (limited aeration) 
was attained through reducing the head-space ratio to 0.5, and 375 μl of the log-
exponential phase Mtb were cultured in 50 ml Falcon tubes containing 37.5 ml of 
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Middlebrook 7H9 Broth. Each tube contained an autoclaved Polytetrafluoroethylene-
coated (PTFE-coated) magnetic stirring bar (VWR International) with 8 × 5 mm 
dimensions. Subsequently, tube was closed tightly and sealed with Parafilm
®
 
(Pechiney Plastic Packaging Company, USA). Cultures were incubated in a 5% CO2 
incubator at 37 °C, stirring at 120 rpm on a Biostir 4 magnetic stirrer (Wheaton 
Industries Inc, USA) (282). 
 
3.2.9.2.5. Mtb growth curves  
In order to plot growth curves for aerobic Mtb cultures (Chapter 3.2.9.2.3), the 
culture turbidity was monitored twice a week at 600 nm using a WPA CO 8000 
Biowave cell density meter (Biochrom, UK). The generation time, defined as the 
time for Mtb cells to double in number, was assessed by plotting a curve of time 
versus the OD600 values of the culture.  
 
With the purpose of monitoring the growth of Mtb hypoxic cultures, a set of 19 
cultures were made following the aforementioned method (section 3.2.9.2.4) and 
used to monitor the growth of the hypoxic culture. At selected times, one tube was 
opened and an aliquot of culture was collected before checking the turbidity at OD600 
using the portable WPA CO 8000 Biowave cell density meter (Biochrom, UK). 
Once the culture was opened and used, it was discarded.  
 
Assuring the same provenance of bacteria, a 2 week culture of Mtb at OD600 ~ 0.9 
was selected and used throughout all experiments. The generated growth curves 
(Appendix I, Figures A - D) were used as additional information about the growth 
rate of aerobic and hypoxic Mtb cultures that were used in this thesis. 
 
3.2.10. Mycobacterium tuberculosis drug sensitivity assays  
Mtb drug sensitivities were determined using Mtb drug sensitivity assay,  microplate 
alamar blue assay (MABA assay) as per Hartkoorn et al (2007) and Warman et al 
(2012) (282, 348) with modification. All compounds were initially prepared in 400 
μM in DMSO. Serial dilutions of each compound were made in DMSO, of which 2.5 
μl were plated in triplicate to wells of a 96-well microplate (NUNC, UK) containing 
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47.5 μl growth medium. Compounds were plated alongside drug-free controls 
containing growth medium with 2.5% DMSO and positive controls containing supra-
IC90 concentrations of isoniazid. Outer wells of assay plates contained sterile H2O 
with the purpose of reducing the evaporation over the course of the experiment.  
 
Subsequently, Mtb culture (aerobic or hypoxic) was diluted to the turbidity of a 
McFarland Standard number 1 (Pro-Lab Diagnostics, UK) (OD600 = 0.3), 
corresponding to a bacterial concentration of 3×10
8
 colony forming units per ml 
(cfu.ml
-1
), which was further diluted to obtain a final concentration of 1×10
7
 cfu.ml
-
1
. All dilutions were made using Middlebrook 7H9 Broth. Mid-log phase Mtb diluted 
to 1x10
7
 cfu.ml
-1
 (50 μl) were plated in all wells, except the wells that contained 
sterile H2O. Plates were incubated for 7 days at 37 °C in a CO2 incubator.  
 
Afterwards, 20 μl 2:1 alamarBlue®:Tween 80 was added to the plates and further 
incubated for 24 hours. AlamarBlue
®
 solution (ABD Serotec, USA) was used as 
indicator of Mtb growth as growth can be observed as a change in the colouration of 
the alamarBlue
®
 solution. Afterwards, 10% paraformaldehyde (Sigma Aldrich, UK) 
was freshly prepared and filtered through a 0.22 μm pore filter before being added to 
each well of sterilise plates.  It is important to filter 10% paraformaldehyde solution 
in order to eliminate particles that could affect the photometric reading of the plate. 
Following two hours of plate incubation with 10% paraformaldehyde, plates were 
wiped thoroughly with 5% (v/v) Surfanios and assay results were determined by 
measurement of well absorbance at 570 nm and 600 nm using an Opsys MR
TM
 
Microplate Reader (Dynex Technologies, USA). Using these data and drug-free 
wells data, the half-maximal inhibitory concentration (IC50) for each compound was 
calculated. The IC50 represents the concentration of a drug which causes 50% of 
growth inhibition. The IC90 (90% inhibitory concentration) refers to the 
concentration of drug which causes 90% of growth inhibition. IC50 values were 
calculated from plots of log dose vs. percentage of growth fitted with a four 
parameter logistic function (Origin 8.5 software). 
For anaerobic cultures, plates were prepared as described for aerobically grown Mtb 
and subsequently were sealed within GasPak EZ pouches (BD, UK) containing an 
indicator to confirm the maintaining of anaerobic conditions over the course of the 
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experiment. Afterwards, plates were incubated anaerobically at 37 °C in a CO2 
incubator for 7 days and subsequently were moved to an aerobic environment and 
incubated for a further 7 days. Plates were assayed (addition of alamarBlue
® 
and 
10% paraformaldehyde) as previously described for aerobic cultures. In addition to 
isoniazid controls, metronidazole controls were included to confirm anaerobic 
conditions had been achieved (139). IC50 values of anaerobic cultures were 
calculated in the same manner as for aerobic cultures. 
 
3.2.11. Time-kill studies  
Time-kill studies were carried out using the method of Warman et al (2012) (282). A 
mid-log phase aerobic Mtb H37Rv culture (Chapter 3.2.9.2.3) was diluted to approx. 
1x10
7
 cfu.ml
-1
 and subsequently added to equal volumes of drug-containing growth 
medium in the wells of a 24-well plate. Drugs were present at a final concentration 
of 5x IC90 (90% inhibitory concentration), as determined from modified MABA 
assays (Tables 3.3 and 3.5). A drug-free control was included in order to monitor 
normal culture growth. After 1, 2, 4, and 7 days, aliquots of the cultures were 
withdrawn and centrifuged at 10,000 g for 10 min. Pelleted materials were 
resuspended in drug free Middlebrook 7H9 media (lacking Tween-80 and ADC). 
Subsequently, serial dilution (1:10 - 1:10
6
)
 
were made before plating to solid growth 
medium (Middlebrook 7H11 agar plates) (Becton Dickinson UK Ltd, Cowley, 
Oxford, UK) supplemented with 10% OADC, 0.2% (v/v) glycerol, and 0.05% (v/v) 
Tween-80). An aliquot of day 0 drug-free inoculum was similarly processed to 
determine the initial bacterial load of all wells. After 14 days of incubation at 37 °C 
in a CO2 incubator, cfu.ml
-1
 values were determined by colony counting. 
 
3.2.12. Statistical analysis 
To study the significance of the presence of different detergents on Mtb bd-I activity, 
Mann-Whitney U test was applied whereas spearman’s correlation function was 
applied to study the association between aerobically cultured Mtb H37Rv and 
enzyme IC50 data using GraphPad 5 Software (USA).   
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3.3. Results 
3.3.1. Detergent assay 
The activity of Mtb bd-I was examined in the presence of different detergent types. 
There was an increase in Mtb bd-I activity in the presence of 0.01% of cholate, 
deoxycholate, CHAPS and DDM whilst the presence of Triton X-100 and Tween-80 
led to noticeable decreases in activity (Figure 3.5). The effects of these detergents 
were assessed for the double-knockout E. coli strain (ML16) as well and showed that 
detergents did not have any effect on dQH2 oxidation activity, confirming the 
expression of Mtb bd-I in the transformed double-knockout E. coli strain (TML16).       
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Figure 3.5: The effect of detergents on Mtb bd-I activity in 50 mM KPi, 2 mM EDTA, 
pH 7.5 buffer 
The transformed double-knockout E. coli strain, TML16 (dark grey bars), showed increases 
of Mtb bd-I activity in the presence of 0.01% cholate, deoxycholate, CHAPS or DDM but a 
notable decrease in the presence of Triton X-100 and Tween-80. The effect of detergents 
was also examined on the double-knockout E. coli strain, ML16 (light grey bars). The values 
are the average of experimental triplicates ± SEM. The data showed no significant effect 
between the presence and the absence of detergent (P > 0.05) (GraphPad 5 Software, USA). 
 
 
 
 
 
115 
 
3.3.2. pH assay 
To determine the most favourable conditions for kinetic studies of Mtb bd-I, the 
optimum pH was examined (Figure 3.6). The pH dependence of the dQH2 Mtb bd-I 
oxidase activity showed a bell-shaped curve from which the greatest Mtb bd-I 
activity was at pH 7.5, but low activity values were recorded at more acidic and 
alkaline pH values. 
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Figure 3.6: pH dependence of Mtb bd-I activity. 
The rate of dQH2 oxidation by Mtb bd-I was determined in a mixed buffer system containing 
40 mM HEPES/MES/TAPS. The optimal activity of Mtb bd-I was observed at pH 7.5 but it 
decreased at more acidic and alkaline pH. The values were obtained by calculating an 
average of two independent replicate experiments ± SEM (Origin 8.5 software). 
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3.3.3. Kinetic characterization of Mtb bd-I 
Initial kinetic characterisation of crude Mtb bd-I membranes revealed a typical 
biphasic activity with a fast linear phase followed by a second slower phase in 
presence of dQH2 and Q1H2 substrates (Figures 3.7, A and 3.8 respectively). In 
contrast, Mtb cytochrome bd-I showed sigmoidal behaviour with low concentrations 
of Q2H2 (Figure 3.9), in agreement with previous studies (345, 349).  
 
Mtb bd-I demonstrated a preference for dQH2. Apparent Km data for substrate 
analogues were determined spectrophotometrically (Figures 3.7 – 3.9) identifying a 
rank order preference for dQH2 > Q1H2 > Q2H2 with Km values of 19.25 ± 1.3, 51.55 
± 8.9, and 65.21 ± 15.31 µM respectively. Examining Mtb bd-I membranes of 
TML16 strain, grown in aerobic conditions revealed similar Km data (21.52 ± 3.57 
µM) to that from O2-limited condition (19.25 ± 1.3 µM). The specific catalytic 
activity values of Mtb bd-I during O2-limited condition was 9.01 ± 0.23 μmol.min-
1
.mg
-1
 and during aerobic condition was 5.1 ± 0.29 μmol.min-1.mg-1 (Table 3.2). 
 
Given the fact that the assay was performed in an oxygen-rich environment, for ‘air-
oxidized’ cytochrome bd-I (i.e. the oxygen reduction rate almost constant) the 
oxidation rate of quinols was not affected. Therefore, the data gave a monophasic 
shape although bd-I was expected to exhibit a bisubstrate catalytic reaction. The  
Michaelis-Menten equation for dQH2 and Q1H2 oxidation was applied. However, 
under oxygen-limiting growth conditions, enzyme kinetics may be affected as the 
oxidation of quinols would be tightly coupled to dioxygen reduction rate (345). 
 
Table 3.2: Kinetic parameters of Mtb bd-I activity 
 Km ± SEM (μM) 
specific catalytic activity ± SEM 
 (μmol.min-1.mg-1) 
dQH
2  (O2-limited)
 19.25 ± 1.3 9.01 ± 0.23 
dQH
2  (aerobic)
 
21.52 ± 3.57  5.1 ± 0.29 
Q
1
H
2
 
51.55 ± 8.9 5.26 ± 0.52 
Q
2
H
2
 
65.21 ± 15.31 8.65 ± 2.5 
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3.3.3.1. Decylubiquinol (dQH2) 
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Figure 3.7: Steady-state decylubiquinol:Mtb bd-I activity 
Steady-state kinetics of Mtb bd-I were measured spectrophotometrically at 283 nm.  The 
oxidation of decylubiquinol (dQH2) by the Mtb bd-I (closed circles) was analysed using the 
Michaelis-Menten equation. The apparent Km (µM) and specific catalytic activity (µmol.min
-
1
.mg
-1
) values were calculated to be respectively A) 19.25 ± 1.3 and 9.01 ± 0.23, during O2-
limited growth condition and B) 21.52 ± 3.57 and 5.1 ± 0.29 during aerobic growth 
condition. ML16 (open circles) was tested as a negative background. The reactions were 
initiated by the addition of dQH2 (5 - 98 µM). The points are the mean initial rates of 
experimental duplicate obtained at each dQH2 concentration indicated. Data were fitted 
using the Michaelis-Menten function using rectangular hyperbola (Origin 8.5 software). 
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3.3.3.2. Ubiquinol-1 (Q1H2) 
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Figure 3.8: Steady-state ubiquinol-1:Mtb bd-I activity 
Steady-state kinetics of Mtb bd-I were measured spectrophotometrically at 283 nm. The 
oxidation of ubiquinol-1 (Q1H2) by the Mtb bd-I (closed circles) was analysed using the 
Michaelis-Menten equation. The apparent Km (µM) and specific catalytic activity (µmol.min
-
1
.mg
-1
) values were calculated to be 51.55 ± 8.9 and 5.26 ± 0.52 respectively. ML16 (open 
circles) was tested as a negative background. The reactions were initiated by the addition of 
Q1H2 (5 - 98 µM). The points are the mean initial rates of experimental duplicates obtained 
at each Q1H2 concentration indicated. Data were fitted using the Michaelis-Menten function 
(Origin 8.5 software). 
 
3.3.3.3. Ubiquinol-2 (Q2H2) 
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Figure 3.9: Steady-state ubiquinol-2: Mtb bd-I activity 
Steady-state kinetics of Mtb bd-I were measured spectrophotometrically at 283 nm. The 
oxidation of ubiquinol-2 (Q2H2) by Mtb bd-I (closed circles) was analysed using the 
modified ping-pong bi-bi mechanism for cytochrome bd-I. The apparent Km (µM) and 
specific catalytic activity (µmol.min
-1
.mg
-1
) values were calculated to be 65.21 ± 15.31 and 
8.65 ± 2.5 respectively. ML16 (open circles) was tested as a negative background. The 
reactions were initiated by the addition of Q2H2 (5 - 98 µM). The points are the mean initial 
rates of experimental duplicates obtained at each Q1H2 concentration indicated. Data were 
fitted using a modified ping-pong bi-bi function (Origin 8.5 software).  
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3.3.4. Drug sensitivity assays  
3.3.4.1. Growth inhibition studies 
Growth inhibition assays were performed to confirm the phenotypic profiles of the 
current DOTS therapeutic drugs against Mtb H37Rv strain (Table 3.3). Owing to lab 
to lab data variations, this experiment provides personal data for time to kill and 
metabolic experiments. Literature data of DOTS drugs indices were reported in 
number of studies (348, 350, 351). In this experiment, first line anti-TB agents were 
all effective against Mtb strain H37Rv, (Figure 3.10) as an example. The 
metronidazole data served as validation of the adaptation of the Wayne model and 
the achievement of hypoxic conditions. Metronidazole does not have a significant 
inhibitory effect against aerobic Mtb but has a bactericidal effect against Mtb grown 
under severe hypoxia (139). Pyrazinamide was not included as it is completely 
inactive at a neutral pH (i.e. the pH of standard drug sensitivity assays) and is known 
to be effective only in acidic pH (130).  
Table 3.3: Bactericidal IC50s and IC90s values of inhibitor compounds tested against 
Mycobacterium tuberculosis 
 
The IC50s values were established using the modified MABA assay. The values are mean ± 
SEM of two independent replicate experiments. IC50s values were calculated using a four 
parameter logistic function (Origin 8.5 software). IC90 values were calculated along with 
IC50 determinations. 
 ND-not determined. 
Compound 
Mtb H37Rv  
(aerobic) 
Mtb H37Rv  
(Wayne model) 
IC50 ± SEM (μM) IC90 (μM) IC50 ± SEM (μM) 
Rifampicin 1×10
-3 
± 0.004×10
-3 
    2.21×10
-3 
  3×10
-3 
± 0.003×10
-3
  
Ethambutol 2.15 ± 0.24  4.61 2.14 ± 0.07 
Isoniazid 1.66 ± 0.21  2.38 1.67 ± 0.40  
Streptomycin 0.14 ± 0.01  0.23 80 ×10
-2
 ± 0.08 ×10
-2
  
Metronidazole ND - 80 ± 10.70 
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Figure 3.10: IC50 determination of isoniazid concentrations against Mtb aerobic growth 
The percentages of growth were calculated, utilizing control wells to represent 100 % 
growth. The IC50 for isoniazid was calculated as 1.66 ± 0.21 μM using a four parameter 
logistic function (Origin 8.5 software).  The values are mean ± SEM of two independent 
replicate experiments.  
 
3.3.4.2. Enzyme and growth inhibition studies, quinolone-type compounds   
As a step towards identifying and validating a novel Mtb bd-I inhibitor, a collection 
of quinolone-type inhibitors (in house compounds) were tested against Mtb bd-I. The 
flow of Mtb bd-I and Mtb H37Rv inhibition studies is depicted in Figure 3.11 that 
shows the rank order of compound potency against Mtb bd-I and Mtb H37Rv, 
ranging from the least potent to the most potent. Inhibition studies with these 
inhibitors showed significant attenuations of quinol oxidation activity in a 
concentration-dependent manner (as an example see Figure 3.12). The IC50s values 
were determined for 23 compounds with each compound screened at 8 
concentrations (with 3-fold dilution steps between points), all of which were 
replicated. Generally, IC50 values ranged between approximately 3 x 10
-3
 and 70 μM 
(Table 3.4). In order to examine SAR of these compounds, the inhibitors were 
classified into groups according to their structures. Hundreds of compounds were 
screened through a single point inhibition screening assay. In this screening, all 
compounds were examined at final concentration of 5 μM and processed normally 
using the MABA assay (Mtb) in aerobic condition. Consequently, those compounds 
that showed 50% or more inhibition processed to a full IC50 modified MABA assay 
(Mtb). The in house labratory data of single point screening assay at 5 μM 
concentration of quinolone-type compounds using the modified MABA assay (Mtb) 
is shown in Table (3.4). ClogP values of all quinolone-type inhibitors were 
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calculated; ClogP is a well-established measure of the compound's hydrophilicity 
from which high ClogP value indicates low hydrophilicity and thus poor absorption 
or penetration (Table 3.4).  
 
            
 
Figure 3.11: The quinolone-type compounds flow chart of potency against Mtb bd-I 
and Mycobacterium tuberculosis H37R 
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Table 3.4: The physical characteristics of the quinolone-type compounds used in this 
study 
Compound Structure ClogP 
 bd-I, IC50 
± SEM 
(μM) 
Growth of 
Mtb H37Rv 
(aerobic) at 5 
μM of 
[compounds] 
(%)* 
CK-3-22 
 
5.49 
0.14 ± 
0.02 
19.52 
CK-3-14 
 
4.12 
10.6 ± 
6.58 
100 
RKA-259 
 
5.36 3.6 ± 1.67 12.61 
RKA-307 
 
4.06 
0.44 ± 
0.08 
1.83 
RKA-310 
 
3.96 1.4 ± 0.17 No growth 
MTD-403 
 
4.38 
0.27 ± 
0.06 
No growth 
SCR-8-12 
 
3.62 3.55 ± 1.1 No growth 
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Table 3.4: (continued) 
 
CK-2-88 
 
5.14 
0.02 ± 
0.01 
90.51 
CK-3-23 
 
6.67 3.6 ± 0.57 6.62 
CK-2-63 
 
6.11 
3 x 10
-3 
± 1 
x 10
-4
 
37.81 
PG-203 
 
5.23 
0.07 ± 
0.02 
100 
RKA-70 
 
6.32 
0.75 ± 
0.36 
100 
RKA-73 
 
6.18 
0.31 ± 
0.06 
100 
LT-9 
 
5.30 0.1 ± 0.02 34.74 
RKA-41 
 
3.68 
70.3 ± 
29.98 
ND 
SL-2-25 
 
5.33 
0.29 ± 
0.07 
88.91 
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Table 3.4: (continued) 
WDH-1U-
10 
 
4.95 
0.012 ± 1 
x 10
-3
 
82.22 
WDH-1W-
5 
 
4.29 
15.8 ± 
1.23 
61.31 
WDH-2A-
9 
 
4.64 6.5 ± 2.26 97.42 
GN-171 
 
6.34 
0.25 ± 
0.09 
100 
OB-231 
       
4.55 7.8 ± 1.64 93.42 
OB-258 
       
4.42 8.8 ± 2.87 94.81 
   PG-128 
 
3.82 
4.47 ± 
0.86 
95.63 
 
 
The quinolone-type compounds were grouped according to their chemical structures along 
with their code, ClogP values and the mean of IC50s values against  Mtb bd-I ± SEM of 
experimental duplicates. Values were determined spectrophotometrically (Mtb bd-I). IC50s 
values were calculated using a four parameter logistic function (Origin 8.5 software).           
* In house laboratory data of a single point screening assay at 5 μM concentration of 
quinolone-type compounds using the modified MABA assay (Mtb H37Rv). 
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The in house laboratory data of the quinolone-type inhibitors were used in this study 
to show the full phenotypic profiles of these compounds. Growth inhibition assays 
were determined against Mtb H37Rv, using the modified MABA assay, under 
aerobic and anaerobic growth conditions for the quinolone-type inhibitors. Out of 23 
compounds tested against Mtb bd-I and screened through single point screening 
assay, 9 compounds showed ≤ 50% of growth at 5 μM concentration, all of which 
were examined through a full IC50 modified MABA assay (Mtb) (Table 3.5).  
 
Table 3.5: IC50s values from growth inhibitory assays of quinolone-type compounds 
 
 
Values were calculated spectrophotometrically (Mtb bd-I) or using the modified MABA assay (Mtb). 
The values are the mean of at least two replicates. IC50s values were calculated using a four parameter 
logistic function (Origin 8.5 software). 
* In house laboratory data.      ND-not determined.     NA-not applicable as aerobic IC50 was > 10 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 
 Mtb bd-I Mtb H37Rv (aerobic) 
Mtb H37Rv  
(Wayne model) 
IC50 ± SEM (μM) IC50 ± SEM (μM)* IC90 (μM) IC50 (μM)* 
LT-9 0.1 ± 0.02 >10 ND NA 
CK-3-22 0.14 ± 0.02 1.97 ± 0.05 4.95 >10 
SCR-8-12  3.55 ± 1.12 3.45 ± 0.15 4.55 6.41  
CK-3-23  3.6 ± 0.57 2.89 ± 0.11 6.53 1.63  
CK-2-63  3 x 10
-3 
± 0.1 x 10
-3
 3.7 ± 0.19 6.73 1.61  
RKA-259  3.6 ± 1.67 1.03 ± 0.03 2.08 1.42  
RKA-307  0.44 ± 0.08 1.57 ± 0.03 3.11 3.92  
RKA-310  1.4 ± 0.17 0.81 ± 0.04   1.96 0.61  
MTD403  0.27 ± 0.06 0.27 ± 0.01 0.85 0.41  
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The following graphs (Figure 3.12) show examples of the inhibitory effects of two 
quinolone-type compounds tested against Mtb bd-I.  
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Figure 3.12: Determination of the IC50s for CK-2-63 and MTD-403 against Mtb bd-I 
activity 
The IC50s values for A) CK-2-63 and B) MTD-403 in the decylubiquinol:Mtb bd-I assay 
were determined spectrophotometrically at 283 nm.  The IC50s values are 3 x 10
-3 
± 0.1 x 10
-3 
μM and 0.27 ± 0.06 μM for CK-2-63 and MTD-403, respectively. The values are the 
average of experimental duplicates ± SEM at each point. The data were fitted using a four 
parameter logistic function (Origin 8.5 software). 
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The following Table (3.6) shows other compounds used for characterization of Mtb 
bd-I. Heme ligands (e.g., cyanide, azide or nitric oxide) are known to act at the O2 
binding/reducing site of the cytochrome bd-I oxidase (211). Thus, the IC50 of 
potassium cyanide (KCN) was calculated to be 429.11 ± 126.85 μM against Mtb bd-
I.  In addition, the IC50 of HDQ, a quinolone-like inhibitor that has high affinity for 
alternative NADH dehydrogenases, was calculated to be 231.93 ± 116.4 μM.  
 
Table 3.6: The IC50s determination of KCN and HDQ against Mtb bd-I activity 
Compound Structure ClogP  Mtb bd-I, IC50 ± SEM (μM) 
KCN 
      
ND 429.11 ± 126.85 
HDQ 
 
6.52 231.93 ± 116.43 
 
The IC50s values for KCN and HDQ in the decylubiquinol:Mtb bd-I assay were determined 
spectrophotometrically at 283 nm. IC50s values are the mean ± SEM of experimental 
duplicates. IC50s values were calculated using a four parameter logistic function (Origin 8.5 
software). 
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3.3.5. Correlation Study 
Scatter trends in activity for the compounds were observed with regards to 
aerobically cultured Mtb H37Rv and enzyme IC50 data. This is most clearly 
demonstrated by a plot of Mtb bd-I IC50 against aerobically cultured Mtb H37Rv 
IC50 (Figure 3.13) in which no significant correlation was apparent (Table 3.5). 
However, excluding LT-9, CK-3-22, CK-2-63 and RKA-259 resulted in a two star 
(**) significant correlation (P value < 0.01). 
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Figure 3.13: Scatter plot of the IC50s of quinolone-type compounds against Mtb bd-I 
and aerobically cultured Mycobacterium tuberculosis H37Rv 
The IC50s of MTD-403 (closed circle), RKA-307 (closed square), CK-3-22 (open square), 
RKA-310 (open diamond), CK-3-23 (closed diamond),  SCR-8-12 (open circle), CK-2-63 
(closed inverted triangle), LT-9 (open inverted triangle), and RKA-259 (cross) compounds 
against Mtb bd-I and aerobically cultured Mtb H37Rv were plotted using a correlation 
function in GraphPad Prism (GraphPad 5 Software, USA). The data showed no significant 
correlation between enzyme inhibition and in vitro antitubercular activity (P > 0.05). The 
values are the IC50s of the compounds are detailed in Table 3.5.  
 
3.3.6. Time-kill studies  
According to the in vitro definition, bacteriostatic agents inhibit bacterial growth 
whereas bactericidal agents kill bacteria. The bactericidal/static nature of 8 
quinolone-type inhibitors was determined by time-dependent kill kinetic studies 
(Figure 3.14, compounds were presented at 5 x IC90). Whilst untreated Mtb showed 
significant growth over 7 days, all quinolone-type compounds showed bacteriostatic 
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activities with the exception of SCR-8-12, CK-3-22 and CK-3-23. SCR-8-12 
revealed a significant reduction in viable counts (cfu.ml
-1
) of Mtb within the first 4 
days and by day 7 no viable organisms remained. SCR-8-12 activity is similar to the 
bactericidal activity of streptomycin (STR). In particular, CK-3-22 and CK-3-23 did 
not exhibit any significant reduction in viable counts over 7 days while RKA-310 
displayed lower viable counts than control over 7 days but without any significant 
decline. LT-9, RKA-307 and MTD-403 demonstrated nearly the same bacteriostatic 
nature where viable counts of bacteria started to decline by day 7. This phenomenon 
is more obvious in CK-2-63 activity, which showed reduction of Mtb viable count 
by day 7. Ethambutol (EMB) reduced the viable counts significantly over 7 days but 
it failed to completely attenuate growth. The bactericidal/static nature of RKA-259 
was not determined due to time limitation.  
 
Figure 3.14: Time-kill curves for untreated and drug-treated Mtb H37Rv 
Time-kill curves for untreated cells, ethambutol, streptomycin, CK-2-63, CK-3-22, CK-3-23, 
LT-9, MTD-403, SCR-8-12, RKA-310, and RKA-307. Compounds were present at 5 x IC90 
(established from MABA assays) and cfu.ml
-1
 were determined at the appropriate time points.  
Points are the mean of experimental duplicates. Error bars represent ± SEM of each point. 
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3.3.7. The mechanism of inhibition of Mtb bd-I activity by quinolone-type 
inhibitors 
To study the mechanism of inhibition and to distinguish the interaction between Mtb 
bd-I and the substrate, dQH2 and quinolone-type inhibitors, the steady state kinetics 
of Mtb bd-I were studied with respect to the substrate and inhibitors. The main 
division of inhibitors are irreversible and reversible inhibitors. The enzyme catalytic 
activity is completely destroyed by irreversible inhibitors but completely restored 
following reversible inhibitors removal. Most drugs bind to their enzyme target 
through reversible interactions. The enzymatic reaction begins with the reversible 
binding of substrate (S) to the free enzyme (E) to form the enzyme-substrate (ES) 
complex.  Inhibitors (I) can bind directly to the free form of the enzyme, to an ES 
complex, or to both. To describe S binding to the enzyme-inhibitor (EI) complex, a 
constant α must be used. The constant α defines the degree to which inhibitor 
binding affects the affinity of the E for S. According to the inhibitors influence on 
enzyme kinetic behaviour and parameters, inhibitors were divided into three types, 
competitive, non-competitive and uncompetitive inhibitors (335, 352). Matsumoto et 
al (2006) described that competitive inhibition is characterised by no alteration of the 
maximum velocity (Vmax) while non- and un-competitive inhibition cause attenuation 
of Vmax (345). Reversible modes of inhibitor interactions with enzymes and their 
effect on the S binding affinity and consequently on kinetic parameters are depicted 
in Table 3.7.   
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 Table 3.7: Diagnostic signatures and binding features of reversible inhibition modalities (335, 345, 352, 353)  
Inhibition 
modality 
Diagnostic signature in 
Lineweaver-Burk  plot 
 
Diagnostic signature in 
Eadie-Hofstee plot 
Enzyme-Inhibitor binding Affinity of EI complex to S 
Effect on parameters 
 Km Vmax 
Competitive, α = 
∞ 
Intersecting lines that 
converge at the y-axis 
lines intersecting the y-
axis at Vmax 
Inhibitor binds exclusively 
to the free enzyme 
EI complex excludes further S 
binding 
Increase No effect 
Non-competitive, 
α > 1 
Intersecting lines that 
converge to the left of the y-
axis and above x-axis 
P
ar
al
le
l 
li
n
es
 
Inhibitor binds to the free 
enzyme 
EI complex decreases affinity of 
S binding 
Increase Decrease 
Non-competitive, 
α = 1 
Intersecting lines that 
converge to the left of the y-
axis and on the x-axis 
Inhibitor binds to the free 
enzyme and ES complex 
equally 
EI complex has no change in 
affinity of S binding 
No effect Decrease 
Non-competitive, 
α < 1 
Intersecting lines that 
converge to the left of the y-
axis and below the x-axis 
Inhibitor binds with greater 
affinity to the ES complex 
EI complex augments affinity of 
S binding 
Decrease Decrease 
Uncompetitive, α Parallel lines 
lines intersecting the x-
axis at Vmax/ Km 
Inhibitor binds exclusively 
to the ES complex 
Inhibitor requires the prior 
formation of the ES complex for 
binding and inhibition  
Decrease Decrease 
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In order to uncover the mechanism of inhibition of Mtb bd-I by CK-2-63, SL-2-25, 
MTD-403, PG-203 and SCR-8-12, the data were first fitted using the Michaelis-
Menten function to calculate Km and Vmax (converted to specific catalytic activity) 
parameters. Then data were transformed to Lineweaver-Burk plot and Eadie-Hofstee 
plots with view to examine the properties as depicted in Table 3.7. The mode of 
quinolone-type compound inhibition is summarized in the following Table 3.8 and 
the data for each inhibitor are depicted in Figures 3.15 - 3.19. The 5 quinolone-type 
compounds were selected arbitrarily.         
 
Table 3.8: Mechanism of inhibition of Mtb bd-I by quinolone-type inhibitors in 
presence of varying concentrations of dQH2 substrate 
 
Inhibitor 
Km ± SEM 
(μM) 
Specific catalytic activity 
± SEM (μmol.min-1.mg-1) 
Mechanism of inhibition 
CK-2-63 
4 nM  25.8 ± 3.5 6.95 ± 0.42 Non-competitive, α > 1 
Or mixed-type of inhibition 12 nM  28.3 ± 5.2 5.93 ± 0.55 
SCR-8-12 
3 μM 12.3 ± 1.1 8.85 ± 0.23 
Competitive 
9 μM 10.2 ± 1.3 8.62 ± 0.27 
MTD-403 
110 nM 8.5 ± 0.9 8.45 ± 0.22 
Competitive 
330 nM 7.9 ± 0.7 8.5 ± 0.18 
SL-2-25 
110 nM 7.4 ± 3.4 6.0 ± 0.46 
Uncompetitive 
330 nM 7.7 ± 0.7 4.45 ± 0.91 
PG-203 
110 nM 7.7 ± 1.5 4.1 ± 0.17 
Uncompetitive 
330 nM 8.7 ± 1.6 2.88 ± 0.13 
 
Steady-state kinetics of treated Mtb bd-I were measured spectrophotometrically at 283 nm. 
The oxidation of dQH2 by Mtb bd-I in the presence of inhibitors was analysed using the 
Michaelis-Menten equation. The apparent Km (µM) and specific catalytic activity (µmol.min
-
1
.mg
-1
) values were calculated. The reactions were initiated by the addition of gradient 
concentration of dQH2 (5 - 98 µM). The values are the mean initial velocity of experimental 
duplicates obtained at each point. The data were fitted using the Michaelis-Menten function 
(Origin 8.5 software). The Km and specific catalytic activity parameters were compared to 
untreated Mtb bd-I parameters of dQH2 substrate oxidation (Km = 19.25 ± 1.3 µM, specific 
catalytic activity = 9.01 ± 0.23 µmol.min
-1
.mg
-1
).   
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3.3.7.1. Inhibition mechanism of Mtb bd-I by CK-2-63 
                       A) 
                            
B)  C) 
  
 
Figure 3.15: Substrate titration of steady state velocity for Mtb bd-I in the presence of 
the CK-2-63 inhibitor 
A) Steady-state kinetics of Mtb bd-I at varying dQH2 (5-98 µM) concentration with no 
inhibitor (closed circle), with 4 nM CK-2-63 (open diamond) and with 12 nM CK-2-63 
(closed diamond) were fitted using the Michaelis-Menten function (Origin 8.5 software). B) 
Data as in (A) were fitted using the double reciprocal Lineweaver Burk plot. CK-2-63 shows 
a non-competitive (α > 1) mode of inhibition with intersecting lines that converge to the left 
of the y-axis and above x-axis. C) Data as in (A) were fitted using the Michaelis-Menten 
function Eadie-Hofstee plot. CK-2-63 shows a mixed mode of inhibition; the lines are not 
parallel neither intersecting at Vmax values. The points are the mean initial velocity of 
experimental duplicates obtained at each dQH2 concentration indicated. The data were fitted 
using Kalidagraph (Synergy software).   
 
134 
 
3.3.7.2. Inhibition mechanism of Mtb bd-I by SCR-8-12 
                       A) 
                            
B)  C) 
 
 
 
Figure 3.16: Substrate titration of steady state velocity for Mtb bd-I in the presence of 
the SCR-8-12 inhibitor 
A) Steady-state kinetics of Mtb bd-I at varying dQH2 (5-98 µM) concentration with no 
inhibitor (closed circle), with 9 μM SCR-8-12 (closed diamond) and with 3 μM SCR-8-12 
(open diamond) were were fitted using the Michaelis-Menten function (Origin 8.5 software). 
B) Data as in (A) were fitted using the double reciprocal Lineweaver Burk plot. SCR-8-12 
shows a competitive mode of inhibition with intersecting lines that converge at the y-axis. C) 
Data as in (A) were fitted using the Eadie-Hofstee plot. SCR-8-12 shows a competitive 
mode of inhibition with intersecting lines at Vmax values. The points are the mean initial 
velocity of experimental duplicates obtained at each dQH2 concentration indicated. The data 
were fitted using Kalidagraph (Synergy software).  
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3.3.7.3. Inhibition mechanism of Mtb bd-I by MTD-403 
                        A) 
                             
B)  C) 
  
 
Figure 3.17: Substrate titration of steady state velocity for Mtb bd-I in the presence of 
the MTD-403 inhibitor 
A) Steady-state kinetics of Mtb bd-I at varying dQH2 (5-98 µM) concentration with no 
inhibitor (closed circle), with 330 nM MTD-403 (closed diamond) and with 110 nM MTD-
403 (open diamond) were were fitted using the Michaelis-Menten function (Origin 8.5 
software). B) Data as in (A) were fitted using the double reciprocal Lineweaver Burk plot. 
MTD-403 shows a competitive mode of inhibition with intersecting lines that converge at 
the y-axis. C) Data as in (A) were fitted using the Eadie-Hofstee plot. MTD-403 shows a 
competitive mode of inhibition with intersecting lines at Vmax values. The points are the mean 
initial velocity of experimental duplicates obtained at each dQH2 concentration indicated. 
The data were fitted using Kalidagraph (Synergy software).    
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3.3.7.4. Inhibition mechanism of Mtb bd-I by SL-2-25 
                       A) 
                            
B)  C) 
  
 
Figure 3.18: Substrate titration of steady state velocity for Mtb bd-I in the presence of 
the SL-2-25 inhibitor 
A) Steady-state kinetics of Mtb bd-I at varying dQH2 (5-98 µM) concentration with no 
inhibitor (closed circle), with 330 nM SL-2-25 (closed diamond) and with 110 nM SL-2-25 
(open diamond) were fitted using the Michaelis-Menten function (Origin 8.5 software). B) 
Data as in (A) were fitted using the double reciprocal Lineweaver Burk plots. SL-2-5 shows 
an uncompetitive mode of inhibition with parallel lines. C) Data as in (A) were fitted using 
the Eadie-Hofstee plot. SL-2-5 shows an uncompetitive mode of inhibition with intersecting 
lines at Vmax /Km values. The points are the mean initial velocity of experimental duplicates 
obtained at each dQH2 concentration indicated. The data were fitted using Kalidagraph 
(Synergy software).    
 
 
137 
 
3.3.7.5. Inhibition mechanism of Mtb bd-I by PG-203 
                        A) 
                            
B)  C) 
  
 
Figure 3.19: Substrate titration of steady state velocity for Mtb bd-I in the presence of 
the PG-203 inhibitor 
A) Steady-state kinetics of Mtb bd-I at varying dQH2 (5-98 µM) concentration with no 
inhibitor (closed circle), with 330 nM PG-203 (closed diamond) and with 110 nM PG-203 
(open diamond) were fitted using the Michaelis-Menten function (Origin 8.5 software). B) 
Data as in (A) were fitted using the double reciprocal Lineweaver Burk plot. PG-203 shows 
an uncompetitive mode of inhibition with parrallel lines. C) Data as in (A) were fitted using 
the Eadie-Hofstee plot. PG-203 shows an uncompetitive mode of inhibition with intersecting 
lines at Vmax /Km values. The points are the mean initial velocity of experimental duplicates 
obtained at each dQH2 concentration indicated. The data were fitted using Kalidagraph 
(Synergy software). 
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3.4. Discussion 
A detailed understanding of the drug target and the mechanism of drug-target 
binding helps immensely in developing a lead. An initial characterization of 
recombinant Mtb cytochrome bd-I oxidase (Mtb bd-I) will be discussed in this 
chapter. There are several aspects of enzymes characterizations that merit 
consideration, some of which will be discussed here. The pH and detergent 
influences on Mtb bd-I activity were considered. In addition, substrate preference, 
catalytic behaviour and potential of Mtb bd-I as a drug target were studied.       
A heterologous expression system (TML16) for Mtb bd-I characterization was 
developed using an Escherichia coli bo3/bd-I knockout strain (ML16; recA, cydAB, 
cyoABCDE::Cm
r
). Steady-state kinetics of Mtb bd-I for dQH2 oxidation were 
performed using crude recombinant membrane of TML16 strain that was grown 
aerobically and under O2-limited condition. The apparent Km (µM) and specific 
catalytic activity (µmol. min
-1
.mg
-1
) values were calculated to be respectively 19.25 
± 1.3 and 9.01 ± 0.23, during O2-limited growth condition and 21.52 ± 3.57 and 5.1 
± 0.29 during aerobic growth condition. The Km values of Mtb bd-I from both 
growth conditions were similar, but not the specific catalytic activity values. This 
was justified through the fact that Km is a characteristic of an enzyme for its substrate 
and is independent of the enzyme concentration used in the experiment. However, 
catalytic activity value varies with the amount of enzyme used and hence it has no 
absolute value (335). Therefore, all the experimental assays in this chapter were 
performed using crude recombinant membranes from O2-limited grown TML16 as it 
had the highest catalytic activity.  
 
Steady-state kinetics of Mtb bd-I oxidase revealed a substrate preference for dQH2 
over Q1H2 and Q2H2 (Km = 19.25 μM, 51.5 μM and 65.2 μM). The reported Km value 
of dQH2 oxidation in E. coli (85 µM) (290) is much higher than that of Mtb bd-I, 
indicating the high affinity of dQH2 for Mtb bd-I. Q1H2 is the preferred substrate for 
studying cytochrome bd-I in various organisms, recording a broad range of Km 
values. The apparent Km values estimated for cytochrome bd-I Q1H2 oxidation by E. 
coli, Azotobacter vinelandii, Klebsiella pneumonia, Cyanobacterium synechocystis 
and Photobacterium phosphoreum range from 40 µM to 280 µM. The initial steady-
state kinetics of Mtb bd-I were consistent with previous studies whereby Mtb bd-I 
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conclusively catalyses the conversion of quinol to quinone with concomitant O2 
reduction. Importantly, the catalytic behaviours of Mtb bd-I in oxidation of dQH2 
and Q1H2 were similiar to its counterparts in other bacteria, following a 
monosubstrate reaction (described by the Michaelis-Menten equation) (212, 213, 
321, 336, 345, 349, 354-357).  
 
Regarding the enzyme kinetics of Q2H2 oxidation, different Km values were reported 
for the E. coli cytochrome bd-I, 50 µM (356), 60 µM (358) and 42 µM (345). 
Cyanobacterium synechocystis cytochrome bd-I had a Km value of 8 µM for Q2H2 
oxidation (349). Although Mtb bd-I showed comparable kinetic to E. coli bd-I, it 
seemed to have the lowest affinity for the Q2H2 substrate. Notably, kinetic analysis 
with a wide range of substrate concentrations revealed that the oxidase activity of 
Mtb cytochrome bd-I showed sigmoidal concentration dependence at low 
concentrations of Q2H2, and marked substrate inhibition at high concentrations of 
Q2H2. In a structure-function study on the ubiquinol-2 analogs, the substrate 
inhibition of E. coli bd-I oxidase was related to the 6-diprenyl group and to the 3-
methoxy group on the quinone ring (345). The peculiar kinetics were considered as a 
unique feature of bd-type quinol oxidase since in a similar Q2H2 concentration range, 
the alternative E. coli terminal oxidase, the cytochrome bo3 heme-copper quinol 
oxidase, never exhibits such sigmoidality or substrate inhibition (358, 359). Vladimir 
(2003) noted that the substrate inhibition is often observed in the nonphysiological 
reaction and at high substrate concentrations where the substrates usually act as 
uncompetitive inhibitors and forming a dead-end complex (335, 352).  In agreement 
with the Matsumoto et al (2006) study, the kinetic mechanism of Q2H2 oxidation by 
Mtb bd-I can be explained by a modified Ping-Pong bi-bi mechanism (following a 
bisubstrate reaction) (345). 
 
The reaction of ‘air-oxidized’ Mtb bd-I with dQH2 and Q1H2 substrates generated a 
monophasic kinetic plot, whereas with Q2H2 a biphasic kinetic plot was observed. 
Mtb cytochrome bd-I oxidase kinetic beheviour is in agreement with previously 
recorded kinetic behaviour in E. coli (211, 290, 345). However, there is discord 
between the orders of substrate preference (dQH2 > Q1H2 > Q2H2, this study, and 
Q2H2 > Q1H2 > dQH2, (345)). Importantly, the discrepancies in the kinetic parameter 
values and the substrate preference are referred to species-specificity and to the type 
140 
 
of protein used (recombinant or purified protein). Morover, further differences 
according to the degrees of the protein purification were recorded as well (345, 358). 
Steady-state kinitics of Mtb bd-I signified the uniqueness of cytochrome bd-I 
mechanism for the substrate oxidation and dioxygen reduction in accordance with 
previous studies.  
 
Studying optimum conditions for enzyme activity and determination of those in 
which Mtb cytochrome bd-I oxidase was highly active was essential for future 
biophysical characterization. Regarding the pH significance, Wilson (2010) wrote 
that the enzyme activity is pH dependent. Therefore, the pH dependence of Mtb bd-I 
dQH2 oxidase activity was studied, showing the highest activity of the enzyme 
(optimum pH of Mtb bd-I) at pH 7.5, with lower activity was observed at more 
acidic and alkaline pH values. Similarly, Lorence et al (1984) found that ubiquinol-1 
oxidase activity of E. coli cytochrome bd-I oxidase had a broad optimum pH at and 
above pH 7.5 but low enzyme activity at acidic pH 6.5 - 5.5 (336). These effects of 
pH could be results of a combination of factors, the ionization state of amino acids 
residues of the catalytic side, the binding of substrate to enzyme, the ionization of 
substrate and the alteration of protein structure (particularly at extremes of pH) (194, 
335).  
 
Furthermore, the specific activity of Mtb bd-I was affected differently by detergents. 
High ubiquinol oxidase activity was observed in the presence of cholate, or 
deoxycholate, CHAPS, or DDM. However, in the presence of Triton X-100 or 
Tween-80, the decylubiquinol oxidase activity was notably reduced. In contrast, 
there was high ubiquinol-1 oxidase activity of E. coli cytochrome bd-I oxidase in the 
presence of γ-palmitoyl-L-α-alysophosphatidylcholine, or Tween-20, but it was 
totally inactive in presence of octylglucoside, cholate, or high concentrations of 
Triton X-100 (336). It is noteworthy that CHAPS, cholate and deoxycholate are 
ionic detergents while Tween-80, Triton X-100 and DDM are non-ionic detergents. 
Importantly, substrate binding, product formation and release can be critically 
affected by the ionization of different groups on the enzyme (334). 
 
The cytochrome bd-family, as mentioned before (section 1.5.4.2), is subdivided into 
the A-subfamily with a long Q-loop, such as E. coli bd-I, and the B-subfamily with a 
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short Q-loop, such as Bacillus stearothermophilus and Mtb (215, 360). However, the 
functional role of different sizes of the Q-loop is not clear yet (211). Importantly, 
some of the short Q-loop cytochrome bd-I oxidase are cyanide insensitive oxygen 
reductases (CIO) such as Pseudomonas aeruginosa bd-I, which is distinguished by 
low heme d content (216). Herein, recombinant Mtb cytochrome bd-I was found to 
be a cyanide sensitive oxidase with an IC50 of 429.11 μM. These data are in 
comparable with the short Q-loop B. stearothermophilus enzyme that showed a 
similar IC50 value (~500 μM) against the duroquinol oxidase activity of the purified 
cytochrome bd-I (360). The long Q-loop purified E. coli bd-I was shown to be 
cyanide sensitive with an IC50 of 2 mM (213). 
 
It worth mentioning that cyanide is a known bacterial cytochrome bd-I inhibitor, 
likely to act at the site of oxygen reduction. However, it does not have a potent 
inhibition activity (211, 213). Therefore, identifying a novel inhibitor that acts on the 
quinol oxidation site was the main focus of the current research. 
 
HDQ, the core of quinolone-type inhibitors, is a known cytochrome bd-I inhibitor as 
seen in Desulfovibrio vulgaris Hildenborough (DvH) (210). Correspondingly, the 
HDQ data showed an inhibition effect of Mtb bd-I activity with an IC50 of 231 μM. 
Therefore, a total of 23 quinolone-type inhibitors were examined against both Mtb 
bd-I and the Mtb H37Rv strain (single-point screening at 5 μM of inhibitor 
concentration), from which the potency screen produced 9 compounds with an IC50 < 
4 μM against Mtb bd-I.  
 
Medicinal chemistry manipulation of the core template was the basis of inhibitor 
development with a view to maximize solubility and activity. The best 18 hits in the 
PfNDH2 programme were tested against Mtb bd-I, in addition to 5 more compounds, 
which were chosen arbitrarily from the MtbNDH2 programme. Some of these 
compounds are structurally related. The first structurally related group is the CK-3-
22 (the primary template), RKA-259 and CK-3-14 group. CK-3-22 (ClogP = 5.49) 
has a nitrogen in ring C to improve solubility, which showed an IC50 of 140 nM 
against Mtb bd-I and good inhibition of Mtb H37Rv growth at 5 μM single-point 
screening. Furthermore, CK-3-22 has the trifluoromethoxy (OCF3) group, 
acknowledged to improve the stability and lipophilicity of biologically active 
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molecules and hence improve in vivo uptake and transport (361, 362).   Regarding 
RKA-259, although adding 7-methoxy into the CK-3-22 template enhanced inhibitor 
potency against Mtb H37Rv, it reduced RKA-259 effectiveness against Mtb bd-I 
with IC50 of 3.6 μM. In CK-3-14, replacing the OCF3 group with fluorine (F) 
decreased the ClogP value (4.12). Fluorine is probably the next most favourite 
hetero-atom after nitrogen for incorporation into small molecules. However, 
inhibitor potency against both Mtb bd-I (IC50 = 10.6 μM) and Mtb H37Rv was 
reduced. In contrast, in the RKA-307, MTD-403 and RKA-310 group, adding 5,7-
difluoro into RKA-307 (the primary template, ClogP = 4.06), which had a good 
activity against both Mtb bd-I (440 nM) and Mtb H37Rv, led to increased inhibitor 
potency in the MTD-403 compound without marked changes in the ClogP value. 
MTD-403 had a potent activity against both Mtb bd-I (IC50 = 270 nM) and Mtb 
H37Rv. This highlights the fact that fluorine as a substituent in active ingredients 
plays a significant role (361). Notably, although adding 7-methoxy into the RKA-
307 template enhanced RKA-310 potency against Mtb H37Rv, it decreased RKA-
310 activity against Mtb bd-I with an IC50 of 1.4 μM.  
 
CK-2-88 is a primary template for 6 other compounds, which are CK-2-63, CK-3-23, 
RKA-70, RKA-73, PG-203 and LT-9. Although CK-2-88 (ClogP = 5.14) exhibited a 
potent activity against Mtb bd-I (IC50 of 20 nM), a weak inhibition effect against 
Mtb H37Rv was observed. Addition of OCF3 into CK-2-88, as seen in previous 
compounds, conferred a potent CK-2-63 compound with IC50 of 3 nM against Mtb 
bd-I and a good inhibition profile against Mtb H37Rv. However, the solubility of 
CK-2-63 was decreased slightly as demonstrated in its ClogP value (ClogP = 6.11). 
On the other hand, swapping the substitution pattern in CK-2-63 at the 2 and 3 
positions resulted in a more soluble PG-203 compound (ClogP = 5.23) with less 
potency against Mtb bd-I (IC50 of 70 nM) and with no inhibition activity against Mtb 
H37Rv. CK-3-23 (ClogP = 6.67) is CK-2-88 with the addition of 4-methoxy group, 
the compound was active but less potent and less soluble than CK-2-63. To improve 
the activity of CK-2-63, the replacement of O with CH2 and H at the 3-position with 
CH3 gave RKA-70 (ClogP = 6.32) with low effectiveness against both Mtb bd-I and 
H37Rv. Moreover, addition of N-hydroxy into the RKA-70 template to give RKA-73 
did not show any significant improvement. LT-9 is CK-2-88 with F in the side chain 
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that showed better activity against Mtb H37Rv. However, this addition did not result 
in any significant improvement against Mtb bd-I from that of CK-2-88.  
SCR-8-12 was developed as a bc1 inhibitor against malaria and it showed good 
inhibition activity against both Mtb bd-I and H37Rv. Fluoroquinolone type 
compounds are used for the treatment of TB and currently constitute the second line 
of anti-TB therapy as they play a key part in the treatment of MDR-TB (147). 
However, RKA-41, a fluoroquinolone type compound, did not reveal good inhibitory 
activities against Mtb bd-I. SL-2-25 has an OCF3 group and nitrogen as well to 
improve solubility. It showed a good activity against Mtb bd-I with an IC50 of 290 
nM but was not active against Mtb H37Rv. WDH-1W-5 has a pyrazole in the side 
chain and gave poor activity against both Mtb bd-I and H37Rv. WDH-2A-9 is 
WDH-1W-5 with an addition of methyl at the 3-position to improve solubility. This 
addition improved WDH-2A-9 activity against Mtb bd-I with an IC50 of 6.5 μM, but 
retained poor inhibition activity against Mtb H37Rv. WDH-1U-10 has an ester group 
at the 3-position and Cl in the side chain, which confered potent activity against Mtb 
bd-I with an IC50 of 12 nM, but poor activity against Mtb H37Rv. GN-171 has an 
OCF3 group instead of a Cl, this showed good activity with an IC50 of 250 nM 
against Mtb bd-I, but poor activity against Mtb H37Rv. Although PG-128 has an 
extra nitrogen in its side chain to improve solubility, it did not exhibit good activity 
against H37Rv and had an IC50 of 4.47 μM against Mtb bd-I. OB-231 has an 
extended side chain and its analogue OB-258 has a N-hydroxy group to look at its 
effect on activity. Both compounds showed poor activity against Mtb bd-I and 
H37Rv with IC50 values of 7.8 μM and 8.8 μM respectively, against Mtb bd-I. 
 
From the quinolone-type inhibitors, a total of 9 inhibitors discussed above showed 
generally an acceptable inhibition profile with IC50 < 4 μM against Mtb bd-I and 
with 50% or more inhibition against Mtb H37Rv (single-point screening at 5 μM 
inhibitor concentration). These inhibitors were submitted for full IC50 evaluation 
during both aerobic (replicating Mtb H37Rv) and anaerobic, Wayne model, (non-
replicating Mtb H37Rv) conditions. Some of these compounds showed a poor 
activity against replicating Mtb H37Rv, such as LT-9 although it had good activity 
against Mtb bd-I. Further, CK-3-22 showed good activity against both Mtb bd-I and 
replicating Mtb H37Rv, but not against non-replicating Mtb H37Rv. SCR-8-12 
showed a similar IC50 (~ 3.5 μM) against both Mtb bd-I and replicating Mtb H37Rv, 
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but it was less potent against non-replicating Mtb H37Rv. Although CK-2-63 was 
more potent than CK-3-23 against Mtb bd-I, both inhibitors exhibited largely similar 
inhibition profiles with regard to replicating/non-replicating Mtb H37Rv. The 
similarity of growth inhibition assays might be due to the fact that both CK-2-63 and 
CK-3-23 were developed from the same template (CK-2-88). The potency of RKA-
259 against replicating/non-replicating Mtb H37Rv was significantly better than that 
of RKA-307, although the latter was more potent than RKA-259 against Mtb bd-I. 
The phenotypic profile of RKA-310 against replicating/non-replicating Mtb H37Rv 
was even better than the previous compounds. RKA-310, following chemistry 
refinement, was replaced by an optimised version of the quinolone-type inhibitor, 
MTD-403. MTD-403 showed a potent inhibition profile against both Mtb bd-I and 
Mtb H37Rv. It should be noted that there was no significant correlation between Mtb 
bd-I and Mtb H37Rv growth inhibition assays. This might be due to the fact that the 
solubility and permeability characteristics of these inhibitors against bacteria would 
have an impact on how inhibitors behave (341); in addition to the possibility that 
these compounds may have multiple targets which would also confound a direct 
correlation with Mtb kill.  
 
Interestingly, although there was no significant correlation between Mtb bd-I and 
Mtb H37Rv growth inhibition assays, excluding LT-9, CK-3-22, CK-2-63 and RKA-
259 resulted in a highly significant correlation (P value < 0.01) with the remaining 
compounds. The significant correlation might suggest that Mtb bd-I (an ETC 
component) is a potential target for the tested quinolone-type inhibitors. This 
suggestion is further enforced by HepG2 data for mitochondrial toxicity assessment 
where CK-3-22, CK-3-23, CK-2-63, RKA-259, RKA-307, RKA-310 and MTD-403 
showed much lower IC50s in HepG2 cells cultured in galactose-containing media 
than that cultured in glucose-containing media (personal communication with Dr. 
Gemma Nixon). Therefore, HepG2 assays proved that inhibitors targeting the ETC. 
Briefly, IC50s values of quinolone-type inhibitors were determined using HepG2 cells 
that were cultured in the presence of glucose or galactose. If the inhibitors target a 
mitochondrial component, HepG2 cultured in glucose-containing media will 
continue growing as they adapt to produce ATP through glycolysis while cells 
growing in the presence of galactose will be attenuated as ATP production will be 
through oxidative phosphorylation (363). Interestingly, SCR-8-12 did not show any 
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difference of IC50 values during both assays (with glucose or galactose), suggesting 
that SCR-8-12 had a different mode of action than other inhibitors, as also 
demonstrated by the time-kill data.            
 
Bactericidal inhibitors are superior to bacteriostatic ones in reducing resistance 
development and in shortening the treatment period. However, the clinical 
importance of in vitro bactericidal inhibitors is rarely observed (364). The 
bactericidal/static nature of inhibitors on extra-cellular Mtb (Mtb grown in liquid 
culture) could be affected by various factors such as time scale of incubation, the 
metabolic state of Mtb (replicating or non-replicating Mtb), and the physiological 
conditions of the experiment (364-366). Evaluating the bactericidal/static nature of 
the quinolone-type inhibitors showed no bactericidal activity over 7 days with the 
exception of SCR-8-12. CK-3-22 and CK-3-23 treated Mtb exhibited almost 
identical behaviour to untreated Mtb over 7 days. In contrast, RKA-310 treated Mtb 
showed a low number of viable bacteria compared to that of untreated Mtb but 
without significant decline of viable count over 7 days of incubation. The 
bacteriostatic activities of LT-9, RKA-307, CK-2-63 and MTD-403 showed 
reduction of viable counts by day 7. These quinolone-type inhibitors, in addition to 
RKA-310, might display similar bactericidal/bacteriostatic activities, as 
demonstrated by the diarylquinoline TMC207, a selective inhibitor of mycobacterial 
ATP synthase. It is worth mentioning that the bactericidal nature of the TMC207 is 
characterized by a bacteriostatic phase in the first 7 days followed by a dose-related 
bactericidal phase (365). Therefore, the bactericidal/static nature of CK-3-22 and 
CK-3-23 might be apparent if the time scale of drug incubation exceeded 14 days. 
Significantly, SCR-8-12 showed a bactericidal activity that is similar to the standard 
drugs, streptomycin and isoniazid (366-369). SCR-8-12 seemed to operate by a 
different mode of action than other quinolone-type inhibitors, as supported by the 
aforementioned HepG2 data. Noticeably, de Steenwinkel et al (2010) found that 
isoniazid displayed a concentration-dependent killing manner while rifampicin was 
revealed to be a strongly time-dependent killing agent (366). Dhillon et al (2010) 
wrote that the bactericidal activity of TMC207 on extra-cellular Mtb was time but 
not dose-dependent for at least the first 12 days of drug incubation. Moreover, 
TMC207 killing was observed to be faster in tuberculous lesions than in aerobic 
culture, and it increased as treatment continued (365). 
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Examining the classification and mechanism of enzyme inhibition is of importance 
in terms of studying the mechanism by which an enzyme promotes its catalytic 
activity and revising how the inhibitor structures might be modified to increase their 
potency (335). The double reciprocal Lineweaver Burk data revealed that CK-2-63 is 
a non-competitive inhibitor implying that CK-2-63 might bind to the free enzyme 
that consequently might result in reducing substrate affinity binding. However, the 
Eadie-Hofstee plot of CK-2-63 was not conclusive, suggesting that CK-2-63 may 
exhibit a mixed-type of inhibition. SCR-8-12 and MTD-403 appeared to be 
competitive inhibitors. Competitive inhibitors are known to bind exclusively to the 
free enzyme, which subsequently leads to exclusion of any further substrate binding. 
Competitive inhibition is usually reflected by affecting the apparent value of Km but 
not the value of Vmax  (353). However, SCR-8-12 and MTD-403 showed a decrease 
in the Km value rather than an increase which means that the affinity of Mtb bd-I for 
the substrate increased; hence inhibitors seemed not to be binding to the quinol 
oxidation site. Copeland (2005) wrote that inhibitors that displayed the kinetic 
signatures of competitive inhibitors are not necessarily bound to the enzyme active 
site (353). SL-2-25 and PG-203 (CK-2-63 substitute) are reported to be 
uncompetitive inhibitors. This, in turn, suggests that as uncompetitive inhibitor they 
may exclusively bind to the enzyme substrate complex (353). 
 
Identifying and developing potential Mtb bd-I and Mtb H37Rv quinolone-type 
inhibitors as novel therapeutic agents is conceivable. To this end, MTD-403 has been 
found to be the optimum compound. MTD-403 displayed an excellent therapeutic 
index (no toxicity) and permeability (well absorbed in gut). However, it was found to 
be metabolized very quickly. Hence, further optimisation work to improve the drug 
metabolism and pharmacokinetics (DMPK) properties of the template is ongoing 
(personal communication with Dr. Gemma Nixon). Moreover, further medicinal 
chemistry quantitative structure–activity relationship models (QSAR models) are 
needed to improve MTD-403.   
 
Studying the enzyme active site in terms of the binding of a substrate(s) to the 
enzyme catalytic site and the subsequent conversion of the substrate(s) to product(s) 
is critical to gain a complete understanding of the way enzymes work. To gain such 
understanding, a wide range of strategies could be adopted in future, such as X-ray 
147 
 
crystallographic studies, irreversible inhibitor with radioisotope studies and kinetic 
studies.  In addition to the kinetics studies of Mtb bd-I that were carried out in this 
study, measuring the oxygen affinity of Mtb bd-I is considered one of the basic 
kinetic characterizations of this enzyme. Unfortunately, lack of laboratory facilities 
hindered this investigation (231, 370-372).  
 
Regarding the limitations of this study, although time-kill data were informative, 
increasing the time scale from 7 days to at least 14 days is recommended. Moreover, 
as carried out by Dhillon et al (2010) using various concentration of inhibitors is 
advised to examine the dose effect on eliminating Mtb (365). 
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Chapter IV 
 Generation and characterisation of a heterologous 
expression system for Mycobacterium tuberculosis 
cytochrome bd-I oxidase in an E. coli respiratory 
knockout (bo3/bd-I/bd-II) mutant strain 
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4.1. Introduction 
The aim of this chapter was to construct an additional expression system for 
Mycobacterium tuberculosis cytochrome bd-I terminal oxidase (Mtb bd-I) 
characterization. This system was used as a validation tool for the main Mtb bd-I 
biochemical features, obtained through using the ML16 strain.     
 
Mtb bd-I characterization was accomplished using ML16, an E. coli bo3/bd-I 
knockout (Chapter II and III). Owing to the challenges of expressing Mtb bd-I, an E. 
coli bo3/bd-I/bd-II knockout strain (MB44) was used in order to have an additional 
possibility of successful expression of Mtb bd-I (Figure 4.1). However, although 
successful expression of Mtb bd-I using the MB44 strain was achieved, 
characterization studies of Mtb bd-I were carried out using the ML16 strain since the 
MB44 strain was too weak and difficult to grow to form the foundation of robust 
Mtb bd-I characterization studies. 
 
 
Figure 4.1: Components of the electron transport chain of MB44, an E. coli mutant 
strain  
The chain has the entire electron donors found in wild type E. coli and only FRD-fumarate 
reductase, TMAORD-TMAO reductase and NR-nitrate reductase as electron acceptors. 
Chain components also include the F0F1 ATP synthase (complex V), MQ-8-menaquinone-8 
and MQH2-menaquinol. P and n correspond to the positive (periplasmic) and negative 
(cytoplasmic) sides of the respiratory membrane with respect to proton translocation. Proton 
movements are indicative only and do not represent H
+
/e
-
 ratios for the respective 
complexes. The orientation and topology of the subunits are indicative only.   
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MB44 is a mutant E. coli BW25113 strain (∆cydB::Kanr ∆cyoB ∆appB ∆nuoB) 
lacking all three E. coli terminal quinol oxidases, cytochrome bo3, cytochrome bd-I 
and cytochrome bd-II, encoded by the cyoABCDE, cydAB and appBC operons, 
respectively. Cytochrome bd-I and cytochrome bd-II are under the cytochrome bd-
family in E. coli and have similar spectral signatures. However, as discussed earlier 
(Chapter 2.4), they have different expression conditions. Moreover, Bekker et al 
(2009) recorded different Km values of quinol oxidation by cytochrome bd-I and 
cytochrome bd-II, which were 85 μM and 250 μM respectively (211, 290). 
 
Bekker et al (2009) constructed MB44 with a kanamycin marker for selectivity. 
MB44 has phenotypic characteristics which require growth in LB medium enriched 
with 50 mM glucose and 50 µg.ml
-1
 kanamycin. Moreover, MB44 has no significant 
respiratory activity; but in aerobic conditions, it catabolises glucose as an energy 
source by full homolactic fermentation into lactate. In contrast, it exhibits mixed acid 
fermentation in oxygen-limited conditions, producing lactate, acetate and succinate 
(194, 290).  
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4.2. Materials and methods 
4.2.1. Preparation of competent cells 
Competent cells were constructed using MB44, an E. coli bo3/bd-I/bd-II knockout 
strain, donated by Dr. Martijn Bekker, University of Amsterdam, Nieuwe. The 
MB44 strain lacked all forms of quinol:oxygen oxidoreductase (i.e. cytochrome bo3, 
cytchrome bd-I and cytchrome bd-II terminal oxidases). Following the protocol of 
Datsenko and Wanner (2000), MB44 was constructed to contain a kanamycin 
resistance cassette (300). Dr. Martijn Bekker informed me that MB44, a derivative of 
E. coli K-12 strain MG1655, grew in the presence of 50 µg.ml
-1
 kanamycin and 50 
mM glucose (290). 
 
Competent MB44 cells were produced by the magnesium chloride/calcium chloride 
method. The aerobic culture condition was as follows: inoculation of overnight 
MB44 culture into 200 ml LB medium (in a 500 ml flask) enriched with 50 mM 
glucose and 50 µg.ml
-1
 kanamycin, and incubated at 37 °C in a shaking incubator at 
200 rpm. Generation of the O2-limited culture involved inoculation of an overnight 
MB44 culture into 375 ml LB medium enriched with 50 mM glucose and 50 µg.ml
-1
 
kanamycin (in a 500 ml flask), sealed with a rubber plug with a head-space ratio of 
0.5 and incubated at 37 °C in a shaking incubator at 200 rpm.  
 
Competent cell preparations were performed according to the standard protocols of 
Sambrook and Russell (297). 100 ml of the cultures were centrifuged at 4000 g for 
10 min at 4 °C once cell density reached OD600 ~ 0.25. Subsequently, cells were 
processed as described earlier in section 2.2.13. The competent cells were designated 
as AnMB44 (Anaerobic growth MB44) and AMB44 (Aerobic growth MB44). 
 
4.2.2. Transformation of pTMA into MB44 competent cells 
A volume of 200 µl of AnMB44 and AMB44 competent cells were transformed with 
the pTMA (10 µl) and processed as described previously (Chapter 2.2.14), with the 
exception of plating the cells to LB agar plates enriched with 50 mM glucose, 100 
µg.ml
-1
 ampicilin and 50 µg.ml
-1
 kanamycin. Antibiotics were added to sustain 
plasmid transformant growth. Plates were incubated overnight at 37 °C aerobically 
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and anaerobically. After 3 days of incubation, colonies were picked from the plates 
and grown in 5 ml LB medium containing an appropriate concentration of antibiotic 
at 37 °C in a shaking incubator at 200 rpm. These cultures were then used for 
making glycerol stocks of the plasmid-containing cells and for larger scale cultures 
and plasmid preparation. The positive transformed cells were designated as TMB44 
(O2-limited growth TMB44) and ATMB44 (Aerobic growth TMB44).  
 
Importantly, as experienced earlier with ML16 transformation (2.2.14), 
transformation of pTMA to AMB44 gave a strain that was less effecient to continue 
with; it took 3-4 days to grow on agar plates and about 3 days to grow in 5 ml LB 
medium over both growth conditions (aerobic and anaerobic). Importantly, 
transformation of pTMA to AnMB44 was successful for both growth conditions 
(aerobic and anaerobic).  
 
4.2.3. Optimization of Mtb bd-I expression conditions  
The general growth conditions were as follow: aerobic growth involved 200 ml of 
LB (in a 500 ml flask), containing 100 µg.ml
-1
 ampicilin and 50 µg.ml
-1
 kanamycin. 
The selective O2-limited condition involved 375 ml of LB (in a 500 ml flask), 
containing 100 µg.ml
-1
 ampicilin and 50 µg.ml
-1
 kanamycin, sealed with a rubber 
plug with a head-space ratio of 0.5. Cultures were incubated at 37 °C in a shaking 
incubator at 200 rpm.   
 
At first, the growth condition of TML16 that led to successful expression of Mtb bd-
I (Chapter 2.2.15) was applied to TMB44 cells with a difference in medium 
supplementation (i.e. addition of 50 mM glucose). This growth condition included an 
addition of 1 mM IPTG along with inoculum and a total incubation time of 19 h. 
However, these parameters did not lead to successful expression of Mtb bd-I. 
Therefore, increasing the incubation time to 48 h was applied because the MB44 
growth curve showed a continuation of growth up to 48 h (Figure 4.7), which will be 
discussed later. Simultaneously, the time of induction using IPTG was changed 
(induction after 24 h of incubation) due to the length of the incubation period, as 
extended IPTG inductions may result in protein degradation (personal 
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communication with Dr. Ashley Warman). Nevertheless, no successful expression of 
Mtb bd-I was detected. Optimization of the glucose concentration was the next step. 
Different glucose concentrations were used; 25 mM, 10 mM, 5 mM and 1 mM. The 
successful expression of Mtb bd-I was observed at 1 mM glucose. The final growth 
parameters were incubating for 48 h, addition of IPTG after 24 h of incubation and 
supplementation of the medium with 1 mM glucose.  
 
It worth mentioning that after optimizing the glucose concentration and having 
successful expression of Mtb bd-I, TMB44 cells were grown in 1 mM glucose for 19 
h and with addition of IPTG at the beginning along with inoculum, resembling the 
TML16 expression condition. However, no successful expression of Mtb bd-I was 
detected.        
 
4.2.4. Large-scale culture of TMB44, AnMB44 and BL21(DE3)pLysS strains  
The successful transformation colonies (TMB44) were grown in selective O2-limited 
conditions, 375 ml of LB enriched with 1 mM glucose (in a 500 ml flask), containing 
100 µg.ml
-1
 ampicilin and 50 µg.ml
-1
 kanamycin, sealed with a rubber plug with a 
head-space ratio of 0.5. IPTG was added after 24 h of incubation to 1 mM final 
concentration. Cultures were incubated at 37 °C in a shaking incubator at 200 rpm 
for 48 h. A negative control (untransformed MB44 competent cells) was grown in 
the same selective O2-limited condition but without the addition of ampicilin. The 
inoculum size was 0.2% of 375 ml LB broth. Hereafter, the positive transformed 
cells were designated as TMB44 whereas the negative untransformed cells were 
designated as MB44.  
 
Also, the same successful transformation colonies were grown in aerobic conditions, 
using 200 ml of LB enriched with 1 mM glucose (in a 500 ml flask) containing 100 
µg.ml
-1
 ampicilin and 50 µg.ml
-1
 kanamycin. IPTG was added after 24 h of 
incubation to 1 mM final concentration. Cultures were incubated at 37 °C in a 
shaking incubator at 200 rpm for 48 h.  A negative control (untransformed MB44 
competent cells) was grown in the same selective O2-limited condition, but without 
the addition of ampicilin. The inoculum size was 0.2% of 375 ml LB broth.  
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BL21(DE3) pLysS was cultured as wild-type E.coli strain following similar 
aforementioned aerobic and O2-limited growth conditions, supplemented with only 
34 µg.ml
-1
 chloramphenicol.  
 
4.2.5. Membrane preparations  
Membrane preparations were carried out following the protocol of Fisher et al 
(2009) which was described previously in detail (section 2.2.17) (209).  
 
4.2.6. Determination of protein concentration  
The Bradford assay (304) was carried out as described in detail previously (section 
2.2.18).  
 
4.2.7. Initial spectroscopic study of Mtb cydABDC operon 
Initial UV-visible spectroscopic analysis of freshly prepared membranes was carried 
out on a Cary 300 Bio UV/visible spectrophotometer (Varian, UK) following a 
previously described methodology (Chapter 2.2.19). Reduced minus oxidized spectra 
of the wild-type E. coli BL21 (DE3) LysS strain, MB44 and TMB44 cells were 
recorded over only O2-limited conditions. Difficulties with having a decent volume 
of crude membrane from aerobically grown MB44 and TMB44 cells hampered the 
process of obtaining spectra.     
 
4.2.8. Growth curves  
Growth was monitored by measuring the optical density at 600 nm using a Thermo 
Spectronic instrument (Genesys, UK) over a time course (hours) under the above 
mentioned aerobic and O2-limited growth conditions (section 4.2.4). A redox 
indicator (resazurin) was used following the previously explained protocol (section 
2.2.20). 
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4.2.9. Preparation of dQH2, Q1H2 and Q2H2 
Preparation of both dQH2 and Q2H2 were performed according to the protocol of 
Fisher et al (2004) (343). Preparation of Q1H2 was based on the protocol of Kihira et 
al (2012) (344) with modification. Detailed methods were previously presented 
(section 3.2.3. and 3.2.4).  
 
4.2.10. Steady-state kinetic assays  
Quinol oxidation (dQH2 and Q1H2) by Mtb bd-I was measured 
spectrophotometrically at 283 nm on a Cary 300 Bio UV/visible spectrophotometer 
(Varian, UK). The method was described previously (section 3.2.5).   
 
4.2.11. Enzyme inhibition assay                 
Determination of an IC50 value for MTD-403 against Mtb bd-I was performed using 
a Cary 300 Bio UV/visible spectrophotometer (Varian, UK) following the previously 
described protocol (section 3.2.8.2).   
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4.3. Results 
4.3.1. The effect of recombinant Mtb cytochrome bd-I on cell pigmentation 
During the membrane preparation process the transformed triple-knockout cells 
(TMB44) showed a colour change to a red/brown pigmentation following 
harvesting aerobic and O2-limited cultures. In contrast, the triple-knockout cells 
(MB44) had a light yellow pigmentation following isolation from both aerobic 
and O2-limited cultures (Figure 4.2).   
                        
Figure 4.2: Effect of recombinant Mtb cytochrome bd-I expression on cell pigmentation 
A) Harvested triple-knockout cells (MB44) and transformed triple-knockout cells (TMB44).  
B) The cell pellets of MB44 and TMB44 were resuspended in buffer (50 mM KPi, 2 mM 
EDTA, pH. 7.5). MB44 had a light yellow pigmentation whereas TMB44 (expressing the 
recombinant Mtb cytochrome bd-I) was accompanied by a change in the coloration of the 
cells to a red/brown pigmentation.  
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4.3.2. Initial spectroscopic study of the Mtb cydABDC operon 
Reduced minus oxidized spectra of the wild-type E. coli BL21 (DE3) LysS strain, 
MB44 and TMB44 cells, growing at O2-limited condition, were recorded at room 
temperature using sodium dithionite as reductant and potassium hexacyanoferrate 
(III) as oxidant (Figures 4.3 - 4.5). The presence of a distinctive peak at 631 nm was 
the significant difference between TMB44 and MB44 spectra which corresponded to 
that of the heterologous Mtb cytochrome bd-I in TMB44. 
 
4.3.2.1. Wild–type E. coli BL21(DE3) pLysS strain 
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Figure 4.3: Reduced minus oxidized spectrum of wild-type E.coli BL21(DE3) pLysS 
strain 
Reduced minus oxidized spectra of the wild-type E. coli BL21 (DE3) LysS strain was 
recorded at room temperature using sodium dithionite as reductant and potassium 
hexacyanoferrate (III) as oxidant. There are three distinct features spectra recorded in O2-
limited grown E. coli, which are cytochrome b at 561 nm, cytochrome a1 at 596 nm and 
cytochrome d at 629 nm. The cells were grown for 48 h using closed shaken flasks with a 
head-space ratio of 0.5 and induced with 1 mM IPTG after 24 h of incubation. The ratio of 
heme d (629 nm) with respect to heme b560 as a reference peak is 0.71 in O2-limited 
conditions. These peaks have been normalized according to the following equation (Value-
min/max-min). The final protein concentration of the membranes was approximately 6.3 
mg.ml
-1
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4.3.2.2. Triple-knockout E. coli (MB44) strain 
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Figure 4.4: Reduced minus oxidized spectra of MB44 
Reduced minus oxidized spectra of MB44 were recorded at room temperature using sodium 
dithionite as reductant and potassium hexacyanoferrate (III) as oxidant. The cells were 
grown in O2-limited condition for 48 h using closed shaken flasks with a head-space ratio of 
0.5 and induced with 1 mM IPTG after 24 h of incubation. A), B) and C) are spectra of 
MB44 crude membranes from different cultures batches. There are consistent peaks at ~ 528 
nm and 560 nm in all membranes. A) and B) show a broad peak at ~600 nm that is not 
present in C) crude membranes. The final protein concentrations of A, B and C membranes 
were approximately 1, 1.3 and 2 mg.ml
-1 
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4.3.2.3. Transformed triple-knockout E. coli (TMB44) strain 
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Figure 4.5: Reduced minus oxidized spectrum of TMB44 
A reduced minus oxidized spectrum of TMB44 was recorded at room temperature using 
sodium dithionite as reductant and potassium hexacyanoferrate (III) as oxidant. Cytochrome 
d at 631 nm is recorded as distinct feature of recombinant Mtb cytochrome bd-I. The cells 
were grown in O2-limited conditions for 48 h using closed shaken flasks with a head-space 
ratio of 0.5 and induced with 1 mM IPTG after 24 h of incubation. The ratio of heme d (631 
nm) with respect to heme b558 as a reference peak is 0.34 in O2-limited condition. These 
peaks have been normalized according to the following equation (Value-min/max-min). The 
final protein concentration of membrane was approximately 3 mg.ml
-1
 
 
4.3.3. Assessment of growth phenotypes  
To qualitatively assess the contribution of Mtb cytochrome bd-I to respiration, 
monitoring the growth of wild-type, mutant and transformed cells was performed to 
identify the differences between E. coli BL21 (DE3) LysS, MB44 and TMB44 
strains, respectively. Resazurin (Raz), a redox indicator, showed a qualitative result 
for the bacterial respiratory state, as discussed previously (2.3.7).  
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4.3.3.1. Wild–type E. coli BL21(DE3) pLysS strain 
The growth of BL21(DE3) pLysS (wild-type E. coli) was monitored through both 
aerobic and O2-limited growth conditions (Figure 4.6). During O2-limited growth, 
the colour of the Raz was changed to dark orange/pink (Rru) after 6 h of incubation, 
during the exponential phase. Cells achieved highest density after 48 h incubation 
(OD600 ~ 0.5) and maintained a stationary plateau for about 12 h. Similarly, during 
the aerobic growth, the colour of Raz was changed to dark orange/pink after 6 h of 
incubation. Wild-type E. coli reached its highest density (OD600 ~1.6) after 48 h of 
aerobic incubation and maintained a stationary plateau for 12 h before starting to 
decline.   
 
  
Figure 4.6: Growth of BL21(DE3) pLysS (wild-type E. coli) in vitro supplemented with 
resazurin. 
Growth was monitored by recording optical density (OD600) values of aerobic, shaken 
cultures (blue) and O2-limited, closed, shaken cultures with a head-space ratio of 0.5 (red). 
The colours of the medium during the growth curve correspond to the colour of the resazurin 
in the medium (resazurin indicative colour chart). During both aerobic and O2-limited 
growth, wild-type E. coli began reducing resazurin after 6 h of incubation and achieved 
maximal density after 48 h with OD600 ~ 1.6 and OD600 ~ 0.5 for aerobic and O2-limited 
incubation, respectively.  
   Aerobic culture 
   O2-limited culture 
 
161 
 
4.3.3.2. Triple-knockout E. coli (MB44) strain 
The growth of MB44 was assessed during aerobic and O2-limited growth conditions 
(Figure 4.7). During both growth conditions, MB44 reached highest density after 48 
h incubation with OD600 ~ 0.26 and started reducing Raz, after 10 h incubation. 
MB44 did not maintain a stationary plateau during both growth conditions and 
started to decline just after reaching its highest density.                 
           
 
Figure 4.7: Growth of MB44 in vitro supplemented with resazurin 
Growth was monitored by recording optical density (OD600) values of aerobic, shaken 
cultures (blue) and O2-limited, closed, shaken flasks with a head-space ratio of 0.5 (red). The 
colours of the medium during the growth curve correspond to the colour of the resazurin in 
the medium (resazurin indicative colour chart). During both aerobic and O2-limited growth 
conditions, MB44 began reducing resazurin after 10 h incubation and attained highest cell 
density (OD600 ~ 0.26) after 48 h of growth.  
 
 
 
 
 
   Aerobic culture 
   O2-limited culture 
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4.3.3.3. Transformed triple-knockout E. coli (TMB44) strain 
The growth of TMB44 was observed all through aerobic and O2-limited growth 
conditions (Figure 4.8). Similar behaviours were observed during both growth 
conditions, the colour of the Raz was changed after 8 h incubation. TMB44 achieved 
highest density after 44 h incubation (OD600 ~ 0.53) and succeeded in maintaining a 
stationary plateau for about 14 h.  
 
 
Figure 4.8: Growth of TMB44 in vitro supplemented with resazurin 
Growth was monitored by recording optical density (OD600) values of aerobic, shaken 
cultures (blue) and O2-limited, closed, shaken flasks with a head-space ratio of 0.5 (red). The 
colours of the medium during the growth curve correspond to the colour of the resazurin in 
the medium (resazurin indicative colour chart). During both aerobic and O2-limited growth 
conditions, resazurin reduction began after 8 h incubation and cells attained highest density 
(OD600 ~ 0.53) after 44 h incubation.   
 
 
 
 
   Aerobic culture 
   O2-limited culture 
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4.3.4. Kinetic analysis of the recombinant Mtb cytochrome bd-I oxidase 
Initial kinetic characterisation of crude TMB44 membranes was performed as per 
TML16 in order to compare the Mtb bd-I data from two different expression 
systems. Examining Mtb bd-I in TMB44 membranes revealed similar Km data to that 
of TML16 (section 3.3.3). Apparent Km data for substrate analogues were 
determined spectrophotometrically (Figure 4.9) identifying a rank order preference 
for dQH2 > Q1H2 with Km values of 22.57 ± 2.1 µM and 51.83 ± 6.1 µM 
respectively. The specific catalytic activity values of Mtb bd-I for dQH2 oxidation 
was 6.21 ± 0.51 µmol.min
-1
.mg
-1
 and for Q1H2 was 1.74 ± 0.26 µmol.min
-1
.mg
-1
 
(Table 4.1). The kinetic parameters of Q2H2 oxidation were not determined due to 
limited quantities of the membrane preparations and time restrictions. However, 
preliminary data for Q2H2 showed that TMB44 demonstrated similar kinetics to 
TML16 (section 3.3.3.3), i.e. substrate inhibition at high Q2H2 concentrations. Due to 
limited quantities of MB44 membrane preparations and time restrictions, full 
kinetics studies were not performed. However, MB44 did not show any quinol 
oxidation activity at 50 µM dQH2 or Q1H2.       
  
Table 4.1: Kinetic parameters of Mtb bd-I activity 
 
 Km ± SEM (μM) 
Specific catalytic activity ± SEM  
(μmol.min-1.mg-1) 
dQH
2  TML16
 19.25 ± 1.3 9.01 ± 0.23 
dQH
2  TMB44
 22.57 ± 2.1 6.21 ± 0.51 
Q
1
H
2  TML16
 51.55 ± 8.9 6.27 ± 0.53 
Q
1
H
2  TMB44
 51.83 ± 6.1 1.74 ± 0.26 
 
The kinetic parameters of Mtb bd-I in both expression systems, TML16 and TMB44, are 
presented.     
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Figure 4.9: Steady-state decylubiquinol/ubiquinol-1: Mtb bd-I activity 
Steady-state kinetics of Mtb bd-I were measured spectrophotometrically at 283 nm. A) The 
oxidation of dQH2 was analysed and the apparent Km (µM) and specific catalytic activity 
(µmol.min
-1
.mg
-1
) values were calculated to be 22.57 ± 2.1 and 6.21 ± 0.51 respectively. B) 
The oxidation of Q1H2 was analysed  and the apparent Km (µM) and specific catalytic 
activity (µmol.min
-1
.mg
-1
) values were calculated to be 51.83 ± 6.1 and 1.74 ± 0.26 
respectively. The reactions were initiated by the addition of different concentrations of dQH2 
/Q1H2 (5 - 98 µM). The points are the mean initial rates of experimental duplicate obtained 
at each dQH2/Q1H2 concentration indicated. Data were fitted using the Michaelis-Menten 
function using rectangular hyperbola (Origin 8.5 software). 
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4.3.5. Drug sensitivity assays  
Inhibition studies of quinolone-type inhibitors against the recombinant Mtb 
cytochrome bd-I oxidase revealed a number of potent compounds against both Mtb 
bd-I and Mtb H37Rv. Herein, the most potent compound so far (MTD-403) was 
tested against Mtb bd-I from the TMB44 expression system (Figure 4.10). MTD-403 
gave a similar IC50 value (330 ± 160 nM) to that obtained from the TML16 
expression system (270 ± 60 nM) against Mtb bd-I (Chapter 3.3.4.2).   
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Figure 4.10: Determination of the IC50 for MTD-403 against Mtb bd-I activity  
The IC50 value for MTD-403 in the decylubiquinol:Mtb bd-I assay was determined 
spectrophotometrically at 283 nm.  The IC50 value is 0.33
 
± 0.16
 μM. The value is derived 
using averages of experimental duplicates ± SEM at each point. The data were fitted using a 
four parameter logistic function (Origin 8.5 software). 
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4.4.  Discussion 
The aforementioned phenotypic features of the MB44 strain were observed during 
expression studies of Mtb bd-I. MB44 was able to grow only in the presence of 
glucose and although the medium was enriched with a high concentration of glucose 
(50 mM), this mutant could only attain a low cell density (OD600 ~ 0.26) during the 
process of competent cells preparations. In accordance with these observations, 
Dassa et al (1991) showed that a triple E. coli mutant strain, SBS2019 
(∆cyo∆cyd∆appB::TnphoA), was not able to grow without the presence of a 
fermentative carbon source (glucose) and displayed drastic growth inhibition in the 
presence of oxygen. This growth inhibition was attributed to the accumulation of 
ROS in the cells. Moreover, SBS2019 was observed to form micro-colonies after 
prolonged incubation (291). Furthermore, it has been reported that ECOM3 
(MG1655, ∆(cydAB appBC cyoABCD)::FRT-kan-FRT) is another triple E. coli 
mutant strain which was only capable of growth in the presence of glucose (373). 
These observations confirm that MB44 exhibited similar phenotypes to its 
counterparts of triple-knockout strains. 
 
Regarding the expression conditions of Mtb bd-I, appropriate signalling of the 
regulatory components of cytochrome bd-I was discussed previously (section 2.4). 
Although appropriate expression conditions of Mtb bd-I were achieved in the 
double-knockout E. coli (ML16) strain, applying similar conditions to transformed 
MB44 (TMB44) was not successful in expressing Mtb bd-I. This observation was 
attributed to the strain phenotype differences. As mentioned above, MB44 
demonstrates weak growth which leads to the extended incubation time of 48 h and 
induction of cells after 24 h of incubation, but these changes were not sufficient to 
express Mtb bd-I. Therefore, enlightened by the observation of Bekker et al (2009), 
enhancing the expression of cytochrome bd-II in E. coli in glucose-limited condition, 
limiting glucose supplementation in the medium was applied (290). Remarkably, 
Mtb bd-I was successfully expressed in MB44 cells under glucose limited conditions 
(1 mM glucose) and induction after 24 h of the 48 h incubation time. Since MB44 
cells were slow growing cells, leaving MB44 to grow for the first 24 h without the 
stress of induction was the reason behind addition of IPTG after 24 h of incubation, 
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besides avoiding protein degradation as a result of long IPTG exposure (personal 
communication with Dr. Ashley Warman). 
 
According to growth conditions or strains phenotypes, spectral analysis revealed 
different heme peaks. Reduced minus oxidized difference spectra recorded at room 
temperature were used to analyze the cytochrome content of MB44, TMB44 and 
wild-type E. coli BL21 (DE3) pLysS (reference strain). Difficulties in generating 
good yields of membrane severely limited the scope of further studies. Although 
there were differences in growth conditions, the reference strain which was induced 
after 24 h of incubation (reference strain-2) showed similar absorbance peaks of b-, 
a1- and d-type cytochromes (at 560, 596, and 629 nm) to that studied previously, the 
reference strain that was induced at the beginning of incubation (reference strain-1) 
(section 2.4). These data were also comparable to the literature for “normal” wild-
type E. coli BL21 spectra (313, 314).  
 
Regarding MB44 spectra, although this mutant was harvested from relatively large 
cultures (27 L), the absorbance peaks were not always discernable due to poor 
membrane yields; a consequence of low cell density. However, there were two 
consistent peaks at 528 and 560 nm, which are characteristic peaks of E. coli b-type 
cytochromes (313, 314). Some of the MB44 membranes demonstrated peaks at 593 
and 605 nm. MB44 does not have endogenous cytochromes (unlike ML16 which has 
cytochrome bd-II). Therefore, these unexpected peaks in MB44 could be attributed 
to the background noise of the spectra. Significantly, TMB44 spectra revealed 
similar spectral signatures to that of TML16 (Chapter 2.4), confirming the Mtb bd-I 
expression. The heme-d absorbance peak (approx. 628 - 632 nm) is a characteristic 
feature of the cytochrome bd-I oxidase in M. smegmatis, in E. coli and in B. subtilis 
(253, 263, 307). 
 
TMB44 cultures displayed red/brown pigmentation as observed with TML16 cells 
(Chapter 2.4). This observation was attributed to the increased expression of heme-
containing cytochromes; hence confirming the expression of cytochrome bd-I 
oxidase (289). 
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With regards to the growth rate, the reference strain-2 showed a relatively slow 
growth rate during O2-limited conditions, compared to reference strain-1 (Chapter 
2.4). Reference strain-2 reached its highest density (OD600 ~ 0.5) after 48 h 
incubation whereas reference strain-1 recorded the maximum at 12 h incubation with 
OD600 ~ 0.44. The growth delay in reference strain-2 induction could be attributed to 
a combination of factors, oxygen limitation and delayed IPTG induction. During 
aerobic conditions there were no significant differences between reference strain-1 
and -2.  
 
As expected, MB44 growth rate was too weak and slow during both growth 
conditions (aerobic and O2-limited) in comparison with reference strain-2 and the 
ML16 strain (Chapter 2.4). MB44 hardly reached an OD600 ~ 0.26 while ML16 
exceeded an OD600 ~ 1.7 and OD600 ~ 0.4 during aerobic and O2-limited growth, 
respectively. MB44 data were in agreement with the findings of previous studies in 
which quinol oxidase mutant strains were reported to have weak and slow growth 
phenotypes, which in turn could be explained by the toxic effect of oxygen-derived 
compounds accumulating in the cells (290, 291, 373).  
 
Significantly, TMB44 exhibited a more “healthy” growth rate than MB44 cells and 
restored the reference strain-2 growth rate during O2-limited growth condition. 
During aerobic growth, although TMB44 showed a higher growth rate (maximal 
OD600 ~ 0.5) than MB44 (maximal OD600 ~ 0.26), expression of Mtb bd-I did not 
restore reference strain-2 growth rate (maximal OD600 ~ 1.6). This might be due to 
the adaption of the cells to synthesize a functional recombinant Mtb cytochrome bd-I 
oxidase, i.e. TMB44 cells under additional pressure of harnessing cellular resources 
to maintain and express plasmid genes. In addition, the plasmid may cause 
disruption in cellular metabolism which might hold back cell growth (325). 
Moreover, the time of IPTG induction might have an influence on cell growth. 
 
To evaluate the contribution of cytochrome bd-I to respiration during growth, 
resazurin was used as a visual qualitative indicator of oxygen depletion in cultures 
and respiratory function (305). Reference strain-2 showed a similar initial resazurin 
reduction to the previously discussed reference strain-1 (Chapter 2.4). However, as 
169 
 
reference strain-2 was induced after 24 h of incubation unlike reference strain-1 
(induction was at the beginning of the incubation), reference strain-2 showed a 
normal O2 uptake state during O2-limited growth conditions. The absence of IPTG 
pressure during the first 24 h of cell replication could be a justification for this 
observation. Remarkably, during aerobic and O2-limited growth conditions, TMB44 
started reducing resazurin (after 8 h of incubation) earlier than TML16 (12 h during 
O2-limited and aerobic incubation). However, TMB44 showed similar resazurin 
colouration to that of TML16, which indicates a high demand on O2 consumption 
(Chapter 2.4). During both growth conditions, the reduction of resazurin by MB44 
was noticed after 10 h of incubation. The colour of resazurin during MB44 cultures 
was not a representation of O2 uptake, but of the presence of acids (305, 323, 324). 
As mentioned earlier, MB44 during aerobic conditions operates full homolactic 
fermentation, producing lactate, and during oxygen-limited conditions it has a mixed 
acid fermentation that could explain the reduction of resazurin (218, 290).   
 
With regards to the stationary phase (non-replicating phase) viability, the MB44 
strain exhibited a stationary-phase viability defect. However, TMB44 during both 
aerobic and O2-limited conditions was able to restore the loss of viability in the 
stationary phase similar to reference strain-2 and to the TML16 strain. The defect of 
MB44 in maintaining a stationary phase was in accordance with cyd mutant strains 
ML16 (this study, section 2.4) in E. coli (295) and an A. vinelandi cydAB mutant 
(328). These findings again confirm the importance of cytochrome bd-I during the 
non-replicating stage and the ability of Mtb bd-I to compensate for the loss of other 
terminal oxidases. 
  
Importantly, steady-state kinetics of Mtb bd-I oxidase from TMB44 showed similar 
kinetic parameters (Km values) for dQH2 and Q1H2 and substrate preference (dQH2 > 
Q1H2) to that of TML16 (section 2.4). These data confirm Mtb bd-I oxidase 
characteristics for dQH2 and Q1H2 substrates. As discussed before, the variance in 
Vmax values was due to the differences in the amount of enzyme used (335). 
Moreover, MTD-403, the optimum quinolone-type inhibitor against Mtb to date, was 
tested against Mtb bd-I oxidase from the TMB44 membrane preparation in order to 
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further confirm Mtb bd-I characterization. The IC50 of MTD-403 was similar to that 
obtained using the TML16 strain. 
In summary, Mtb bd-I was successfully heterologously expressed in an E. coli triple-
knockout system. The steady state kinetic features and inhibitory profile were 
consistent with those previously observed using the double-knockout system 
(TML16), supporting the validity of the latter. The slow growth rate and poor yields 
derived from the TMB44 and MB44 lines, however, make these systems unsuitable 
for large scale use, as is required for drug discovery or protein purification. 
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Chapter V 
Pharmaco-metabolomics of Mycobacterium 
tuberculosis  
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5.1. Introduction 
The objective of this chapter was to begin to study the pharmaco-metabolomics of 
Mtb first line and developing drugs. The broader objective is to generate a 
metabolomics fingerprint for drugs with validated modes of action (MoA) and to 
determine whether the fingerprints are consistent with proposed MoA of new drugs.   
 
Metabolomics is a systematic study that quantitatively and/or qualitatively profiles 
the living system metabolome. The metabolome gives a holistic view of the living 
system when combined with other ‘‘omics’’ approaches, transcriptomics and 
proteomic (374, 375). Considering the global increasing rates of MDR-and XDR-TB 
(143, 144), expanding the knowledge of the drug MoA will allow more rational 
development of new drugs to bypass resistance to current TB therapy. Knowledge of 
the Mtb response at the transcriptomic, proteomic or metabolomic level to novel 
compounds, as well as to the clinically used drugs, usually offers a credible proof of 
the affected metabolome pathways and thus understanding their MoA. Moreover, 
important secondary effects of antimicrobial drug action would be revealed, which in 
turn allows for the development of co-drugs that target such secondary responses as 
a new direction of antimicrobial therapy (376).   
 
Metabolic changes signal the organism response to a drug’s perturbation and the 
ability of the organism to adapt to the disruption. However, envisaging targets that 
would have a cidal effect on replicating and non-replicating Mtb is hampered by 
incomplete understanding of such metabolic responses to target disruption by new 
drugs and by the current anti-TB therapies (241). Moreover, this process is also 
limited by a lack of complete understanding of drugs MoA. Most of the studies on 
anti-TB drugs MoA have centred on the primary target and its associated mutations 
that count for emerging resistant strains. The MoAs of current TB drugs (DOTS) on 
the Mtb metabolome are not well characterized. Studying the perturbations of the 
Mtb metabolome by DOTS are limited to transcriptional and proteomic studies (241, 
376). 
 
In this chapter, the front line anti-TB drugs (isoniazid (INH), rifampicin (RIF), 
ethambutol (EMB) and streptomycin (STR) were examined along with two of the 
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previously tested Mtb bd-I in house quinolone-type inhibitors, CK-2-63 and RKA-
307, and trifluoperazine (TPZ), a phenothiazine-based compound, targeting type II 
NADH:quinone oxidoreductase, to understand various metabolic alterations of Mtb 
bacilli upon exposure to these drugs. The mode of action of these inhibitors was 
previously described (Chapter 1.4.1) and is depicted in Figure (5.1). The central 
carbon metabolites were included in this study owing to their critical roles during TB 
infection (Chapter 1.5.2, Figure 1.14). Moreover, redox couples, bioenergetic 
couples and some of the amino acid metabolites were also included. As the Mtb rely 
on lipids in vivo (172-175), some key metabolites that link fatty acids metabolism 
with TCA cycle and glyoxylate shunt were included such as acetyl-CoA, propionyl-
CoA, succinyl-CoA and methylmalonyl-CoA (16). However, other metabolites of 
fatty acid metabolism were not incorporated due to method limitation, which will be 
discussed later in this chapter.   
 
 
Figure 5.1: Schematic diagram of the proposed mode of action of DOTS and Mtb 
respiratory inhibitors 
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Recently, high-resolution mass spectrometers have emerged in the field of microbial 
metabolomics, driving the research towards obtaining profiles of a large number of 
low-molecular-weight compounds (metabolites) in highly complex biological 
samples. Metabolites, the intermediates of biochemical reactions, have a critical role 
in linking different operating metabolic pathways within the living cells that generate 
a tight controlled metabolic network. Liquid chromatography-mass spectrometry 
(LC-MS)-based metabolomics experiments have different approaches, targeted 
analysis or non-targeted profiling. Targeted analysis aims at measuring a predefined 
set of known metabolites whereas non-targeted profiling is based on identification 
and quantitation of unknown metabolites (374, 377).     
 
The metabolome of living cells has a large variety of metabolites that differ in 
chemical structures and properties. The metabolome complexity is a result of wide-
ranging chemical compounds that range from hydrophilic carbohydrates, volatile 
alcohols and ketones, amino and non-amino organic acids, hydrophobic lipids, and 
complex natural products to ionic inorganic species which makes identifying the 
complete metabolome at the same time virtually unfeasible (378). 
 
Studying the metabolome is a multiple-step process which typically includes cell 
growth, metabolism quenching, metabolome extraction, and sample concentration, 
metabolites detection by LC-MS or another advanced method and finally data 
analysis (378). The quenching step is based on arrest of all metabolic activities that 
exist in living cells and typically accomplished through quick alteration in 
temperature or pH (379). There are different approaches for quenching the 
metabolism of cells grown in liquid culture (the common physiological condition of 
most microbes) that have been reviewed in details by Rabinowitz (2007), of which 
the quench the harvest method was applied in this study (380). Here, quenching and 
extraction are combined as a 40:40:20 acetonitrile:methanol:water solution results in 
extraction of the intracellular metabolites because of disruption of the cell wall, as 
well as metabolism quenching. Importantly, at the metabolome quenching step, 
isotopic internal standards can be added to the quenching solvents in order to obatin 
precise quantitaive data (377).  
175 
 
Regarding the extraction step, an ideal extraction aims to extract all or most of the 
metabolites in their original state (i.e., the extraction solvent should stop any further 
physical and chemical alterations of the metabolites) and in a quantitative manner. 
More than one solvent is usually used as one mixture during the extraction procedure 
in order to be compatible with all types of metabolites. For instance, polar solvents 
like methanol or methanol–water mixtures are used to extract polar metabolites, 
whereas non-polar solvents like chloroform or hexane are used for lipophilic 
compounds extraction (377, 381).  
 
Prior to sample analysis, a concentration step is required to remove all the solvent(s) 
from the samples due to high sample dilutions that result in lower concentration of 
metabolites, although risking of metabolome alterations is expected. Therefore, 
removing solvents is needed to enhance metabolite signals at the detection phase and 
to avoid any interference of these solvents with the subsequent analysis. There are 
different methods of metabolite concentration, of which the most efficient and 
common one is through using a nitrogen gas stream to evaporate solvent (378).  
 
In terms of metabolites detection and analysis, a highly sensitive and selective 
technique, liquid chromatography-tandem mass spectrometry (LC-MS/MS), was 
applied. LC-MS/MS is an analytical chemistry technique that combines physical 
separation, ionization and characterization of one or more compounds using tandem 
mass spectrometry. LC-MS includes three essential steps which are liquid 
chromatography separation, ionization, and separation and quantitation of the ions by 
mass spectrometry. This method is able to profile over a hundred cellular metabolites 
in a single chromatographic separation. The mass spectrometry spectrum presents 
masses of the ionized molecule and its fragments which are the total of the 
component atoms masses. Specificity arises from two orthogonal dimensions of 
separation: chromatographic retention time (RT) and mass-to-charge ratio (m/z), and 
in modern instruments the specificity is further increased by multiple rounds of MS 
(‘‘tandem mass spectrometry’’ or ‘‘MS/MS’’) (377, 382). 
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5.2. Material and methods 
5.2.1. Preparation of targeted metabolomics solutions 
5.2.1.1. Solvents and Chemicals 
Water (H2O; VWR International Ltd, UK), acetonitrile (CH3CN; Fisher Scientific, 
UK) and methanol (CH3OH; Fisher Scientific, UK) were all HPLC grade. 
Ammonium acetate (C2H3O2NH4) was purchased from VWR International Ltd (UK). 
Mass spectroscopy grade formic acid (CH2O2, ≥ 98%) and ammonium hydroxide 
(NH4OH) were obtained from Sigma Aldrich (UK).    
 
5.2.1.2. Quenching solution 
The quenching solution consisted of 40:40:20 acetonitrile (ACN): Methanol 
(MeOH): water (H2O) + 0.1 M formic acid and was spiked with 200 μM of internal 
standards, β-alanine and DL-arabinose for positive and negative modes, respectively. 
Solutions were prepared and stored at -20 °C (383).  
 
5.2.1.3. Extraction solution 
The extraction solution consisted of only 40:40:20 ACN:MeOH:H2O and was 
prepared in a similar manner to the quenching solution (section 5.2.1.1).  
 
5.2.1.4. Mobile phase solvents 
The mobile phase solvent consisted of two main solvents, solvent A [20 mM 
ammonium acetate + 20 mM ammonium hydroxide in 95:5 water: acetonitrile (pH 
9.45)] and solvent B (acetonitrile, ACN). Before use, the mobile phase was filtered 
through a sterile bottle top filter unit with a 0.22 μm membrane (Fisher Scientific, 
UK), sonicated and degassed using a sonicator (Fisher Scientific, UK) for 15 min. 
This mobile phase was used due to its compatibility with the luna aminopropyl 
column used in this study, as tested by Rabinowitz’s lab (384, 385).   
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5.2.2. Preparation of inhibitor stock solutions 
10 mM inhibitor stocks were prepared according to their solvent solubility as 
detailed before in section 3.2.8.1.  10 mM stock solutions were prepared and kept at -
20
o
C for no longer than 1 month. Final dilutions were made with culture medium 
(7H9 MiddleBrook) and freshly prepared prior to studies being carried out (Table 
4.1). The effect of DOTS drugs, isoniazid, ethambutol, rifampicin and streptomycin, 
on Mtb H37Rv metabolites were examined along with quinolone-type inhibitors, 
CK-2-63 and RKA-307. 
 
5.2.3. Culture of Mycobacterium tuberculosis  
Cultures of Mycobacterium tuberculosis H37Rv were carried out as described 
previously (section 3.2.9). Briefly, aerobic cultures of Mtb H37Rv were grown to 
mid-log phase at 37 °C in 10 ml growth medium (Middlebrook 7H9 broth) 
supplemented with 10% (v/v) ADC, 0.2% (v/v) glycerol, and 0.05% (v/v) Tween
®
 
80. 
 
5.2.4. Protocol for sampling metabolites from Mtb H37Rv culture 
Currently, the protocol for microbial metabolomics analysis is still in the proof-of-
concept stage, thus protocols are typically developed for a specific study (379). 
There are several protocols used to extract metabolites from bacteria. The most 
common used are filter-based cell culture, batch liquid culture and chemostats. 
Filter-based cell culture and chemostats were excluded due to CTL3 facilities 
limitation. The metabolite extraction processes involve two main steps, metabolism 
quenching and metabolites extraction. Quenching metabolism was accomplished 
using a cold quenching solution, 40:40:20 ACN:MeOH:H2O. This mixture was 
found to be effective in quenching metabolism and in extracting nucleotide 
triphosphates from E. coli. Metabolite extraction was attained by centrifugation (380, 
382).   
 
Following the protocol of Rabinowitz (2007), metabolite sampling from Mtb H37Rv 
liquid culture was applied with modification (380). The quenching solution 40:40:20 
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ACN:MeOH:H2O was acidified with 0.1 M formic acid and spiked with 200 μM of 
internal standards, β-alanine and DL-arabinose. The addition of formic acid in the 
quenching solution helps protecting nucleotide triphosphates against degradation. 
This quenching solution was used to simultaneously quench metabolism and initiate 
the extraction process. Moreover, it is worth mentioning that 40:40:20 
ACN:MeOH:H2O solution was used for Mtb H37Rv metabolite extraction because it 
was verified to kill all viable Mtb H37Rv where it has been used in previous Mtb 
studies (160, 241).  To further confirm this before commencing the experiment, the 
following ratios 1:6, 1:8 and 1:10 of Mtb H37Rv culture: 40:40:20 ACN:MeOH:H2O 
solution were cultured grown on 7H11 agar plates and incubated at 37 °C in a 5% 
CO2 HERACell 150 CO2 incubator (Thermo Scientific, UK). After 5 weeks of 
incubation, no colony growth was recorded at all ratios. Therefore, 1:8 (Mtb H37Rv 
culture: quenching solution) ratio was used for quenching process in this study. 
Importantly, the 40:40:20 ACN:MeOH:H2O mixture at cold temperature is 
considered a general efficient quenching and appropriate solvent for metabolite 
extraction due to its compatibility to hydrophilic interaction liquid chromatography 
(HILIC) compounds which cover most of the polar and some of the non-polar 
metabolites  (241, 378, 383, 384).    
 
5.2.4.1. Experiment set-up 
Drug-containing growth medium was placed in the wells of 24-well plates. Drugs 
were present at a final concentration of IC90 (90% inhibitory concentration), as 
determined from modified MABA assays (section 4.3.4, Tables 4.3 and 4.5). The 
IC90 value of TPZ (36.02 µM) was obtained from the Warman et al (2012) study 
(282). With a view to capture the primary effects of the drugs/inhibitors on Mtb 
metabolic, IC90 was chosen as the final concentration rather than using IC50 through 
consulting previously published studies (241, 386). A drug-free control (vehicle 
control) was included in order to monitor normal culture growth. Exponentially 
growing Mtb H37Rv cells were harvested at an OD600 of ~1 by centrifugation at 0 
°C, using an Eppendorf 5804R refrigerated centrifuge (Eppendorf, UK), at 5000 g 
for 10 min. Pelleted materials were resuspended in a cold drug free Middlebrook 
7H9 Broth (lacking glycerol, Tween
®
 80 and ADC). Subsequently, the culture was 
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added to equal volumes of drug-containing growth medium (final concentration of 
culture corresponded to OD600 of 0.5, 1 x 10
8
 cfu.ml
-1
) in the wells of 24-well plates. 
The final concentration of culture was chosen following the protocol of Griffin et al 
(2012) (184). The 24-well plate was incubated at 37 °C in a 5% CO2 HERACell 150 
CO2 incubator (Thermo Scientific, UK). ampho 
 
5.2.4.2. Metabolites extraction  
Following pre-determined incubations of 0, 1, 2, 3, 6 and 7 days, aliquots of the 
cultures were withdrawn and the extraction step initiated.  The Mtb H37Rv culture 
was quenched using cold quenching solution in ratio 1:8 (culture: quenching 
solution). Subsequently, samples were vortexed for 30 s before centrifugation at 
5000 g for 15 min at 0 °C using an Eppendorf 5804R refrigerated centrifuge 
(Eppendorf, UK). Afterward, supernatants were collected in a sterilized tube and the 
remaining pelleted materials were resuspended in a cold extraction solution 
(40:40:20 ACN:MeOH:H2O). In similar manner, samples were vortexed, centrifuged 
and supernatants were pooled with the preceding supernatant. Pooled supernatant 
was filtered using a 0.22 μM Millex® filter unit (Millipore, UK). The samples were 
transferred to the LC-MS/MS lab and stored at -80 °C to be processed through LC-
MS/MS no later than a week from sampling.  
 
5.2.5. LC-MS/MS samples preparation 
According to the protocol of Biagini et al (2012), samples were transferred to glass 
vials and dried under a stream of nitrogen. Mobile phase solvent A (pH 9.45) was 
used to resuspend the dried samples. Afterwards, samples were vortexed, filtered 
using a 0.22 μM filter unit (Phenomenex-RC, UK) and transferred to Chromacol LC-
MS/MS glass vials (Chromacol, Thermo Fisher Scientific Inc., UK) (387). 
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5.2.6. Preparation of standards stock for calibration curve standards 
Following the protocol of Biagini et al (2012) that was established by PhD student 
Murad Mubaraki, standards stocks were prepared according to their solvent 
solubility at specific concentrations for each metabolite (Sigma Aldrich, UK) (Table 
5.1). Consequently, 100 μl of each metabolite was merged in one standard mixture 
before the preparation of 16 serial dilutions of the standard mixture, which was 
carried out using HPLC grade water. These 16 standard levels were processed 
through the extraction step and prepared for LC-MS/MS analysis in a similar manner 
to that described earlier (section 5.2.4.2 and 5.2.5). These standard levels were 
analysed through LC-MS/MS (section 5.2.7) before generating the calibration curves 
by plotting the area ratio of the metabolite standard (The area under the curve (AUC) 
of metabolite divided by AUC of internal standard) against its concentration. The 
linearity for each metabolite was evaluated by using linear regression.     
 
Table 5.1: Metabolite primary stocks concentration for calibration curve standards 
Metabolites MW (g.mol
-1
) 
Primary Stock 
Concentration (mM) 
Solvent 
Glucose 180.16 11.10 H2O 
Fumarate 116.07 17.23 H2O 
Succinate 118.09 16.93 H2O 
Malate 134.09 14.91 H2O 
α-ketoglutarate 146.11 13.68 MeOH 
(Iso)-Citrate 192.12 10.41 MeOH 
PEP, Phosphoenolpyruvate 168.04 11.90 H2O 
G-3-P,  Glycerol-3-phosphate 170.05 11.62 H2O 
Hypoxanthine 136.12 14.70 DMSO 
Lactate 90.08 44.40 H2O 
DHAP, Dihydroxyacetone 
phosphate 
170.06 23.52 H2O 
Oxaloacetate 132.07 151.43 H2O 
Acetyl-CoA 809.57 12.35 MeOH 
Succinyl-CoA 867.60 5.76 H2O 
Propionyl-CoA 823.60 6.07 H2O 
Methylmalonyl-CoA 867.61 2.31 H2O 
Alanine 89.09 22.44 H2O 
Asparagine 132.12 15.13 H2O 
Aspartate 133.1 15.02 H2O 
Glutamine 146.14 13.68 H2O 
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Table 5.1 (Continued) 
 
 
 
           
             
Metabolites MW (g.mol
-1
) 
Primary Stock 
Concentration (mM) 
Solvent 
Glutamate 147.13 13.59 H2O 
Arginine 174.2 11.48 MeOH 
Proline 115.13 17.37 H2O 
Serine 105.09 19.03 H2O 
Valine 117.15 17.07 H2O 
Threonine 119.12 16.78 H2O 
Cysteine 121.16 33.02 H2O 
(Iso)-leucine 131.17 15.24 H2O 
Lysine 146.19 13.68 H2O 
Methionine 149.21 13.40 H2O 
Histidine 155.15 12.89 DMSO 
Phenylalanine 165.19 12.10 MeOH 
Tryptophan 204.23 9.79 H2O 
Tyrosine 181.19 11.03 H2O 
Ornithine 132.19 15.13 MeOH 
Citrulline 175.19 11.41 H2O 
NAD 663.43 3.01 H2O 
NADH 664.43 3.00 DMSO 
GSH, Glutathione 307.32 6.50 H2O 
GSSG, Glutathione disulfide 612.63 3.26 H2O 
NADP 744.41 2.69 H2O 
NADPH 745.41 2.68 DMSO 
FAD, flavin adenine 
dinucleotide 
785.55 2.54 MeOH 
Carbamoyl-l-aspartate 176.12 11.35 MeOH 
Orotate 156.10 12.81 DMSO 
Dihydroorotate 158.11 12.64 MeOH 
Carbamoyl-P 141.02 212.76 DMSO 
UMP, Uridine monophosphate 324.18 6.16 H2O 
UDP, Uracil diphosphate  404.16 4.94 H2O 
UTP, Uridine triphosphate 484.14 4.13 H2O 
CTP, Cytidine triphosphate 483.15 4.13 MeOH 
TTP, Thymidine triphosphate 482.16 4.14 H2O 
AMP, Adenosine 
monophosphate 
347.22 5.76 H2O 
ADP, Adenosine diphosphate 427.20 4.68 H2O 
ATP, Adenosine triphosphate 507.18 3.94 H2O 
GTP, Guanosine triphosphate 523.18 3.82 H2O 
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5.2.7. Analysis using LC-MS/MS 
Following the protocol of Biagini et al (2012) an Accela Autosampler HPLC system 
(Thermo Fisher Scientific) was used with modification for the metabolites separation 
using an Luna aminopropyl column (250 × 2 mm with a 5-μm particle size) 
(Phenomenex, USA) (387). The mobile phase consisted of solvent A [20 mM 
ammonium acetate + 20 mM ammonium hydroxide in 95:5 water:acetonitrile (pH 
9.45)], prepared as described before and solvent B (acetonitrile). The 
chromatographic gradients were as follows: t = 0, 15% A; t = 15 min, 100% A; t = 
33 min, 100% A; t = 35 min, 15% A; t = 45 min, 15% A. Injection volume, flow 
rate, column temperature, and autosampler temperature were set at 20 μl, 150 μl.min-
1
, 15 °C, and 15 °C, respectively. 
 
For metabolite detection, a TSQ Quantum Access Triple-Stage Quadrupole mass 
spectrometer (Thermo Electron Corporation) was used. Electrospray ionization (ESI) 
was employed for the metabolite detection and analysis of metabolites. ESI spray 
voltage was 4000 V and 5500 V for positive and negative modes, respectively. 
Nitrogen was used as sheath gas at 30 psi and as the auxiliary gas at 10 psi. Argon 
was used as the collision gas at 1.5 mTorr. The capillary temperature was 320 °C and 
270 °C for positive and negative modes, respectively. Scan time for each single 
reaction monitoring (SRM) event transition was 0.1 s with a scan width of 1 m/z. 
Xcalibar (Thermoscientific) software was applied to conduct the instrument control, 
data acquisition, and data analysis. LC-MS/MS parameters including retention time 
(RT), product and precursor mass, and collision induced dissociation (CID) are 
presented in Appendix II (Tables 1 and 2). The linearity (R
2
), linearity range and 
limit of detection (LOD) are presented in Appendix II (Table 3). 
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5.2.8. Data treatment and analysis          
Using known concentrations of standards for each of the 56 SRMs, calibration 
curves were generated and thus metabolite concentrations levels were quantified. 
AUC of the integrated peak represented the signal for each metabolite. Figure 5.2 
shows an example of a LC-MS/MS chromatogram of the AMP metabolite. An 
example of calibration curve of AMP is shown in Figure 5.3. Calibration curves of 
all metabolites are presented in Appendex III (Figures 1-19). Each metabolite signal 
was normalized to the signal of the internal standard DL-arabinose (negative mode) 
or β-alanine (positive mode) in the same sample.  
 
Principal component analysis (PCA), partial least squares-discriminant analysis 
(PLS-DA) and heat maps were generated through the MetaboAnalyst web server 
(http://www.metaboanalyst.ca/MetaboAnalyst/faces/Home.jsp) (388). Afterwards, 
data were plotted using GraphPad prism 5 Software Inc. for each metabolite in order 
to determine the important results.              
        
 
Figure 5.2: LC-MS/MS chromatogram of AMP 
A) Chromatographic separation of AMP peak shows retention time (RT) at ~22.8 min. B) 
SRM scan of ionized AMP shows the detection of its product ion at a mass-to-charge (m/z) 
of 136. 
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Figure 5.3: Standard calibration curve of AMP  
The line of best fit for the calibration curve was generated using equal weighted linear 
regression as the mathematical model of best fit, showing R
2 
> 0.99. AMP concentration in 
experimental samples was calculated from the resulting area ratio and the regression 
equation of the calibration curve.              
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5.3. Results 
Generated data were initially processed using the MetaboAnalyst web server (388) 
where multivariate statistical analysis using PCA and PLS-DA was performed on the 
ratio of log2 transformed datasets. All data were expressed as the normalized levels 
of metabolites to the number of Mtb cells in untreated and drug-treated samples. 
Afterwards, datasets were analyzed through hierarchical cluster analysis generating a 
heatmap. Finally, the importance of drug-treated metabolite versus untreated 
metabolites (vehicle control) was examined for each metabolite individually 
(GraphPad prism 5 Software Inc.). Out of 56 metabolites examined by LC-MS/MS, 
only 25 metabolites were analysed by the MetaboAnalyst web server. All redox 
couples, bioenergetics metabolites and some of amino acid metabolites: asparagine, 
arginine, serine and cysteine were not detected by LC-MS/MS as they were below 
LOD. Moreover, 7 CCM metabolites: PEP, DHAP, lactate, acetyl-CoA, succinyl-
CoA, methylmalonyl-CoA and propionyl-CoA were not detected (below LOD, 
Appendix II, Table 2).     
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5.3.1. PCA and PLS-DA 
Comparative analyses of metabolomics data are greatly facilitated by using PCA and 
PLS-DA. PCA converts high dimensional data into lower-dimensional plots without 
loss of information through developing a small number of artificial variables 
(principal components). PCA is a commonly used unsupervised technique, as it 
requires no a priori knowledge of class of the sample. PCA is usually presented in 
terms of component scores that account for most of the variance in the observed 
variables of the data. Similarly, PLS-DA uses a supervised technique to determine 
pattern on the original data. PLS-DA classifies the data into two blocks, one between 
class variation and the other within class. Thus, PLS-DA separates the more 
meaningful data from the less meaningful (388, 389). 2-D PCA showed that RKA-
307-treated Mtb H37Rv clusters away from the untreated Mtb H37Rv and other 
drugs/inhibitors treated clusters (Figure 5.4, A), which is also observed with the 3-D 
PCA. The TPZ-treated Mtb H37Rv cluster was more defined with the 3-D PCA 
(Figure 5.4, B). PLS-DA was applied to further improve and refine the clustering and 
positioning of the variables and to assess the significance of class discrimination. 2-
D PLS-DA (Figure 5.5, A) displayed discrimination of clusters for the CK-2-63-, 
TPZ- and RKA-307-treated Mtb H37Rv. Moreover, INH-, EMB-, RIF- and STR-
treated Mtb clusters overlapped with untreated Mtb H37Rv as displayed by 2-D 
PLS-DA. Interestingly, 3-D PLS-DA (Figure 5.5, B) showed even better clustering 
of the data from which TPZ-, CK-2-63- and RKA-307-treated Mtb H37Rv were 
found to be in the same side but with different directions. In contrast, RIF-treated 
Mtb showed a defined cluster while INH- and STR-treated Mtb H37Rv 
demonstrated quite close distance clusters. EMB-treated Mtb H37Rv cluster was 
close to the untreated Mtb H37Rv cluster.  
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Figure 5.4: 2-D and 3-D PCA score plots for Mtb H37Rv upon exposure to different drugs and inhibitors 
The samples (the time course points) on both plots are colour coded as following: untreated Mtb H37Rv samples (light blue), Mtb H37Rv samples treated 
with isoniazid (INH, grey), ethambutol (EMB, orange), rifampicin (RIF, black), streptomycin (STR, pink), trifluoperazine (TPZ, green), CK-2-63 (red) and 
RKA-307 (dark blue). A) 2-D PCA score plot shows two distinct clusters with different directions. The first cluster includes untreated Mtb H37Rv samples 
and drug-treated samples with INH, EMB, RIF, STR, TPZ and CK-2-63 whereas the second cluster includes only RKA-307-treated Mtb. B) 3-D PCA score 
plot displays no clear cluster except for that of RKA-307- and TPZ-treated Mtb. Each time-point for each metabolite represents the normalized average of two 
independent replicates which were divided by the corresponding average values derived from Mtb harvested at time 0 day (arrow indicted) to generate the 
corresponding ratios. Ratios were log2 transformed and plotted using the metaboanalyst web server (388).  
A) B) 
 
 
 
Time = 0 day Time = 0 day 
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Figure 5.5: 2-D and 3-D PLS-DA scores for Mtb H37Rv upon exposure to different drugs and inhibitors. 
The samples (the time course points) on both plots are colour coded as following: untreated Mtb H37Rv samples (light blue), Mtb H37Rv samples treated 
with isoniazid (INH, grey), ethambutol (EMB, orange), rifampicin (RIF, black), streptomycin (STR, pink), trifluoperazine (TPZ, green), CK-2-63 (red) and 
RKA-307 (dark blue). A) 2-D PLS-DA score plot shows four distinct clusters with different directions which are TPZ-, RKA-307-, CK-2-63- and RIF-treated 
Mtb whereas untreated Mtb H37Rv, INH-, EMB- and STR-treated Mtb clusters are overlapped. B) 3-D PLS-DA score plot displays TPZ-, CK-2-63- and 
RKA-307- treated Mtb in the same side but different directions. INH- and STR-treated Mtb display approximately close distance clusters whereas RIF-treated 
Mtb cluster shows a separate cluster. EMB-treated Mtb cluster is close to untreated Mtb cluster. Each time-point for each metabolite represents the 
normalized average of two independent replicates which were divided by the corresponding average values derived from Mtb harvested at time 0 day (arrow 
indicted) to generate the corresponding ratios. Ratios were log2 transformed and plotted using the metaboanalyst web server (388).  
A) B) 
 
  
Time = 0 day 
Time = 0 day 
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5.3.2. Heat map profile of the Mtb metabolome 
The heat map is presented here as a visual aid for the similarity measures between 
the samples through expressing the relative difference of the dynamic changes in a 
scale of red and green colour (Figure 5.6). In comparison with untreated Mtb, RKA-
307-treated Mtb had the most visual differences of the dynamic changes, which 
included most of the CCM metabolites and some of amino acid metabolites. In 
contrast, Mtb treated with other drugs showed less visual differences of the dynamic 
changes in comparison with untreated Mtb. Individual analysis of each metabolite 
will be presented in the following section (Chapter 5.3.4).              
 
Figure 5. 6: Heat map profile of drug-treated and untreated Mtb H37Rv metabolome 
The heat map shows the dynamic changes of 25 metabolites in Mtb H37Rv treated with the 
following drugs/inhibitors: isoniazid (INH), ethambutol (EMB), rifampicin (RIF), 
streptomycin (STR), trifluoperazine (TPZ), CK-2-63 and RKA-307 and in untreated Mtb 
H37Rv (vehicle control). Each time-point for each metabolite represents the normalized 
average of two independent replicates which were divided by the corresponding average 
values derived from Mtb harvested at time 0 day to generate the corresponding ratios. Ratios 
were log2 transformed and plotted on a colour dynamic range scale using the metaboanalyst 
web server (388). Rows correspond to metabolites measured by LC-MS/MS. Columns 
correspond to the time course from day 0 to day 7 for each of treated and untreated Mtb 
H37Rv. Green and red colours represent decreases and increases of metabolites ratio, 
respectively. Black colour indicates the baseline. G-3-P, glycerol-3-phosphate.  
190 
 
5.3.3. Biochemical time–dependent of metabolite profiles in Mtb H37Rv. 
Following examination of the clusters and the dynamic change of the samples, time-
dependent graphs of untreated Mtb H37Rv and Mtb H37Rv treated with the 
following drugs/inhibitors: INH, EMB, RIF, STR, TPZ, CK-2-63 and RKA-307 for 
25 metabolites were plotted (GraphPad prism 5 Software Inc.).  
 
INH-treated Mtb showed a notable increase in the level of glycerol-3-phosphate (G-
3-P), α-ketoglutarate, valine, alanine and lysine. In addition, the levels of malate and 
hypoxanthine increased by day 7. Glutamate and ornithine utilization and threonine 
production were considerably low, compared to the drug-free control Mtb (Figures 
5.7-5.9). Regarding EMB-treated Mtb (Figures 5.10-5.12), the level of fumarate 
production was remarkably low whereas, the level of (iso)-citrate was notably 
reduced, compared to the drug-free control Mtb. Moreover, the level of alanine, 
proline and histidine was notably decreased in EMB-treated Mtb 
 
Compared to the untreated control Mtb, RIF-treated Mtb showed the following 
effects: the level of fumarate and (iso)-citrate was found to be notably decreased 
whereas the level of ornithine was shown to be considerably less utilized and 
threonine drastically less produced than that of untreated Mtb. Moreover, RIF-treated 
Mtb showed an important increase in (iso)-leucine and valine levels (Figures 5.13-
5.15). Concerning STR-treated Mtb, succinate, oxaloacetate and ornithine level 
displayed substantial accumulation whereas (iso)-citrate and proline levels were 
notably decreased. Furthermore, the histidine level was found to be lower compared 
to the drug-free control Mtb (Figures 5.16-5.18).  
 
TPZ-treated Mtb was found to have a remarkable reduction of (iso)-citrate, valine 
and malate levels and low production of hypoxanthine and threonine. Moreover, a 
considerable accumulation of ornithine and α-ketoglutarate levels and low utilization 
of glutamate were observed, compared to the drug-free control Mtb (Figures 5.19-
5.21).  
 
CK-2-63-treated Mtb (in comparison with untreated control Mtb) showed a notably 
low production level of alanine, valine, proline, (iso)-leucine, succinate and 
191 
 
hypoxanthine. Moreover, (iso)-citrate found to be considerably decreased while 
aspartate was remarkably increased in CK-2-63-treated Mtb. A complete inhibition 
of methionine consumption was also observed following CK-2-63-treatment 
(Figures 5.22-5.24).  
 
With regards to RKA-307-treated Mtb, most of the TCA cycle metabolites (Figure 
1.13, Chapter 1.6.2), which were succinate, malate and oxaloacetate were shown to 
have low production levels. Moreover, fumarate, (iso)-citrate and α-ketoglutarate 
revealed remarkable levels of reduction compared to the drug-free control Mtb. The 
following amino acids: citrulline, glutamine, valine, threonine, proline and histidine 
were found to be drastically decreased, in comparison with the untreated control Mtb 
(Figures 5.25-5.27).                   
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Figure 5.7: Time-dependent changes of Mtb H37Rv metabolites in INH-treated and untreated control cells 
The following metabolites levels in untreated (closed circle) and INH-treated (open circle) cells were determined by LC-MS/MS, A) Glucose, B) Glycerol-3-
phosphate (G-3-P), C) Succinate, D) Fumarate, E) Malate, F) Oxaloacetate, G) (iso)-citrate and H) α-Ketoglutarate. The final concentration of Isoniazid 
(INH) was at IC90 (2.38 µM). The points represent the mean ± SEM of duplicate independent experiments. In INH-treated Mtb H37Rv, G-3-P, malate and α-
Ketoglutarate show a substantial increase (GraphPad prism 5 Software Inc.).         
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Figure 5.8: Time-dependent change of Mtb H37Rv metabolites in INH-treated and untreated control cells  
The following metabolites levels in untreated (closed circle) and INH-treated (open circle) cells were determined by LC-MS/MS, A) Alanine, B) Aspartate, 
C) Glutamate, D) Citrulline E) Ornithine, F) Glutamine, G) Proline, H) Hypoxanthine and I) Histidine. The final concentration of Isoniazid (INH) was at IC90 
(2.38 µM). The points represent the mean ± SEM of duplicate independent experiments. In INH-treated Mtb H37Rv, glutamate and ornithine show notably 
low levels whereas alanine and hypoxanthine show obvious increase (GraphPad prism 5 Software Inc.).         
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Figure 5.9: Time-dependent changes of Mtb H37Rv metabolites in INH-treated and untreated control cells  
The following metabolites levels in untreated (closed circle) and INH-treated (open circle) cells were determined by LC-MS/MS, A) Valine, B) (iso)-leucine, 
C) Phenylalanine, D) Tryptophan E) Tyrosine, F) Lysine, G) Threonine and H) Methionine. The final concentration of Isoniazid (INH) was at IC90 (2.38 µM). 
The points represent the mean ± SEM of duplicate independent experiments. In INH-treated Mtb H37Rv, valine and lysine show notable increase; threonine 
shows a clearly low level (GraphPad prism 5 Software Inc.)  
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Figure 5.10: Time-dependent changes of Mtb H37Rv metabolites in EMB-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and EMB-treated (open circle) cells were determined by LC-MS/MS, A) Glucose, B) Glycerol-3-
phosphate (G-3-P), C) Succinate, D) Fumarate, E) Malate, F) Oxaloacetate, G) (iso)-citrate and H) α-Ketoglutarate. The final concentration of Ethambutol 
(EMB) was at IC90 (4.61 µM). The points represent the mean ± SEM of duplicate independent experiments. In EMB-treated Mtb H37Rv, fumarate and (iso)-
citrate show noticeable decreases (GraphPad prism 5 Software Inc.).     
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Figure 5.11: Time-dependent changes of Mtb H37Rv metabolites in EMB-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and EMB-treated (open circle) cells were determined by LC-MS/MS, A) Alanine, B) Aspartate, 
C) Glutamate, D) Citrulline E) Ornithine, F) Glutamine, G) Proline, H) Hypoxanthine and I) Histidine. The final concentration of Ethambutol (EMB) was at 
IC90 (4.61 µM). The points represent the mean ± SEM of duplicate independent experiments. In EMB-treated Mtb H37Rv, alanine, proline and histidine show 
notable decrease (GraphPad prism 5 Software Inc.). 
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
100
200
300
400
500
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
5
10
15
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0.5
0.6
0.7
0.8
0.9
1.0
1.1
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
20
40
60
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0.0
0.5
1.0
1.5
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
2
4
6
8
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
200
400
600
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
20
40
60
80
100
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
5
10
15
20
A 
 
 
 
 D 
 
 
 
 
B 
 
 
 
 
E 
 
 
 
 
G 
 
 
 
 
H 
 
 
 
 
F 
 
 
 
 
C 
 
 
 
 
I 
 
 
 
 
197 
 
Figure 5.12: Time-dependent changes of Mtb H37Rv metabolites in EMB-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and EMB-treated (open circle) cells were determined by LC-MS/MS, A) Valine, B) (iso)-leucine, 
C) Phenylalanine, D) Tryptophan E) Tyrosine, F) Lysine, G) Threonine and H) Methionine. The final concentration of Ethambutol (EMB) was at IC90 (4.61 
µM). The points represent the mean ± SEM of duplicate independent experiments. There are no noticeable changes among metabolites (GraphPad prism 5 
Software Inc.).    
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Figure 5.13: Time-dependent changes of Mtb H37Rv metabolites in RIF-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and RIF-treated (open circle) cells were determined by LC-MS/MS, A) Glucose, B) Glycerol-3-
phosphate (G-3-P), C) Succinate, D) Fumarate, E) Malate, F) Oxaloacetate, G) (iso)-citrate and H) α-Ketoglutarate. The final concentration of Rifampicin 
(RIF) was at IC90 (2.21x10
-3
 µM). The points represent the mean ± SEM of duplicate independent experiments. In RIF-treated Mtb H37Rv, fumarate and 
(iso)-citrate show remarkable decreases (GraphPad prism 5 Software Inc.).  
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Figure 5.14: Time-dependent changes of Mtb H37Rv metabolites in RIF-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and RIF-treated (open circle) cells were determined by LC-MS/MS, A) Alanine, B) Aspartate, C) 
Glutamate, D) Citrulline E) Ornithine, F) Glutamine, G) Proline, H) Hypoxanthine and I) Histidine. The final concentration of Rifampicin (RIF) was at IC90 
(2.21x10
-3
 µM). The points represent the mean ± SEM of duplicate independent experiments. In RIF-treated Mtb H37Rv, ornithine shows low levels 
(GraphPad prism 5 Software Inc.).         
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Figure 5.15: Time-dependent changes of Mtb H37Rv metabolites in RIF-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and RIF-treated (open circle) cells were determined by LC-MS/MS, A) Valine, B) (iso)-leucine, 
C) Phenylalanine, D) Tryptophan E) Tyrosine, F) Lysine, G) Threonine and H) Methionine. The final concentration of Rifampicin (RIF) was at IC90 (2.21x10
-
3
 µM). The points represent the mean ± SEM of duplicate independent experiments. In RIF-treated Mtb H37Rv, (iso)-leucine and valine show considerable 
increase whereas threonine shows very low production (GraphPad prism 5 Software Inc.).         
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
100
200
300
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
20
40
60
80
100
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
20
40
60
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
10
20
30
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
20
40
60
80
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
1
2
3
4
5
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
20
40
60
80
100
Time (Days)
Fo
ld
 c
ha
ng
e 
ra
tio
0 1 2 3 6 7
0
1
2
3
4
* P < 0.05
* P < 0.05
A 
 
 
 
 
D 
 
 
 
 
B 
 
 
 
 E 
 
 
 
 
G 
 
 
 
 
H 
 
 
 
 
F 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
201 
 
Figure 5.16: Time-dependent changes of Mtb H37Rv metabolites in STR-treated and untreated control cells 
The following metabolites levels in untreated (closed circle) and STR-treated (open circle) cells were determined by LC-MS/MS, A) Glucose, B) Glycerol-3-
phosphate (G-3-P), C) Succinate, D) Fumarate, E) Malate, F) Oxaloacetate, G) (iso)-citrate and H) α-Ketoglutarate. The final concentration of Streptomycin 
(STR) was at IC90 (0.23 µM). The points represent the mean ± SEM of duplicate independent experiments. In STR-treated Mtb H37Rv, succinate and 
oxaloacetate show a clear increase whereas (iso)-citrate shows a remarkable decrease (GraphPad prism 5 Software Inc.).                            
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Figure 5.17: Time-dependent changes of Mtb H37Rv metabolites in STR-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and STR-treated (open circle) cells were determined by LC-MS/MS, A) Alanine, B) Aspartate, C) 
Glutamate, D) Citrulline E) Ornithine, F) Glutamine, G) Proline, H) Hypoxanthine and I) Histidine. The final concentration of Streptomycin (STR) was at 
IC90 (0.23 µM). The points represent the mean ± SEM of duplicate independent experiments. In STR-treated Mtb H37Rv, ornithine shows considerable 
increase whereas histidine and proline are present at low level (GraphPad prism 5 Software Inc.).         
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Figure 5.18: Time-dependent changes of Mtb H37Rv metabolites in STR-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and STR-treated (open circle) cells were determined by LC-MS/MS, A) Valine, B) (iso)-leucine, 
C) Phenylalanine, D) Tryptophan E) Tyrosine, F) Lysine, G) Threonine and H) Methionine. The final concentration of Streptomycin (STR) was at IC90 (0.23 
µM). The points represent the mean ± SEM of duplicate independent experiments. There are no noticeable changes among metabolites (GraphPad prism 5 
Software Inc.). 
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Figure 5.19: Time-dependent changes of Mtb H37Rv metabolites in TPZ-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and TPZ-treated (open circle) cells were determined by LC-MS/MS, A) Glucose, B) Glycerol-3-
phosphate (G-3-P), C) Succinate, D) Fumarate, E) Malate, F) Oxaloacetate, G) (iso)-citrate and H) α-Ketoglutarate. The final concentration of Trifluoperazine 
(TPZ) was at IC90 (36.02 µM). The points represent the mean ± SEM of duplicate independent experiments. In TPZ-treated Mtb H37Rv, malate and (iso)-
citrate show a notable decrease while α-Ketoglutarate shows a clear increase (GraphPad prism 5 Software Inc.).      
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Figure 5.20: Time-dependent changes of Mtb H37Rv metabolites in TPZ-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and TPZ-treated (open circle) cells were determined by LC-MS/MS, A) Alanine, B) Aspartate, C) 
Glutamate, D) Citrulline E) Ornithine, F) Glutamine, G) Proline, H) Hypoxanthine and I) Histidine. The final concentration of Trifluoperazine (TPZ) was at 
IC90 (36.02 µM). The points represent the mean ± SEM of duplicate independent experiments. In TPZ-treated Mtb H37Rv, glutamate shows low utilization; 
ornithine is notably increased and hypoxanthine is present at low levels (GraphPad prism 5 Software Inc.).        
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Figure 5.21: Time-dependent changes of Mtb H37Rv metabolites in TPZ-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and TPZ-treated (open circle) cells were determined by LC-MS/MS, A) Valine, B) (iso)-leucine, 
C) Phenylalanine, D) Tryptophan E) Tyrosine, F) Lysine, G) Threonine and H) Methionine. The final concentration of Trifluoperazine (TPZ) was at IC90 
(36.02 µM). The points represent the mean ± SEM of duplicate independent experiments. In TPZ-treated Mtb H37Rv, threonine and valine are present at very 
low levels (GraphPad prism 5 Software Inc.). 
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Figure 5.22: Time-dependent changes of Mtb H37Rv metabolites in CK-2-63-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and CK-2-63-treated (open circle) cells were determined by LC-MS/MS, A) Glucose, B) 
Glycerol-3-phosphate (G-3-P), C) Succinate, D) Fumarate, E) Malate, F) Oxaloacetate, G) (iso)-citrate and H) α-Ketoglutarate. The final concentration of 
CK-2-63 was at IC90 (6.73 µM). The points represent the mean ± SEM of duplicate independent experiments. In CK-2-63-treated Mtb H37Rv, succinate is at 
low levels and (iso)-citrate is also considerably decreased (GraphPad prism 5 Software Inc.).     
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Figure 5.23: Time-dependent changes of Mtb H37Rv metabolites in CK-2-63-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and CK-2-63-treated (open circle) cells were determined by LC-MS/MS, A) Alanine, B) 
Aspartate, C) Glutamate, D) Citrulline E) Ornithine, F) Glutamine, G) Proline, H) Hypoxanthine and I) Histidine. The final concentration of CK-2-63 was at 
IC90 (6.73 µM). The points represent the mean ± SEM of duplicate independent experiments. In CK-2-63-treated Mtb H37Rv, aspartate is noticeably 
increased while alanine, proline and hypoxanthine are at very low levels produced (GraphPad prism 5 Software Inc.).     
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Figure 5.24: Time-dependent of changes Mtb H37Rv metabolites in CK-2-63-treated and untreated control cells  
The following metabolite levels in untreated (closed circle) and CK-2-63-treated (open circle) cells were determined by LC-MS/MS, A) Valine, B) (iso)-
leucine, C) Phenylalanine, D) Tryptophan E) Tyrosine, F) Lysine, G) Threonine and H) Methionine. The final concentration of CK-2-63 was at IC90 (6.73 
µM). The points represent the mean ± SEM of duplicate independent experiments. In CK-2-63-treated Mtb H37Rv, (iso)-leucine, valine and methionine are 
produced at low levels (GraphPad prism 5 Software Inc.).     
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Figure 5.25: Time-dependent changes of Mtb H37Rv metabolites in RKA-307-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and RKA-307-treated (open circle) cells were determined by LC-MS/MS, A) Glucose, B) 
Glycerol-3-phosphate (G-3-P), C) Succinate, D) Fumarate, E) Malate, F) Oxaloacetate, G) (iso)-Citrate and H) α-Ketoglutarate. The final concentration of 
RKA-307 was at IC90 (3.11 µM). The points represent the mean ± SEM of duplicate independent experiments. In RKA-307-treated Mtb H37Rv, succinate, 
malate, oxaloacetate are produced at low levels; fumarate, (iso)-citrate and α-Ketoglutarate levels are remarkably reduced (GraphPad prism 5 Software Inc.).  
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Figure 5.26: Time-dependent changes of Mtb H37Rv metabolites in RKA-307-treated and untreated control cells 
The following metabolite levels in untreated (closed circle) and RKA-307-treated (open circle) cells were determined by LC-MS/MS, A) Alanine, B) 
Aspartate, C) Glutamate, D) Citrulline E) Ornithine, F) Glutamine, G) Proline, H) Hypoxanthine and I) Histidine. The final concentration of RKA-307 was at 
IC90 (3.11 µM). The points represent the mean ± SEM of duplicate independent experiments. In RKA-307-treated Mtb H37Rv, citrulline, histidine, proline 
and glutamine are produced at low levels (GraphPad prism 5 Software Inc.). 
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Figure 5.27: Time-dependent changes of Mtb H37Rv metabolites in RKA-307-treated and untreated control cells  
The following metabolite levels in untreated (closed circle) and RKA-307-treated (open circle) cells were determined by LC-MS/MS, A) Valine, B) (iso)-
Leucine, C) Phenylalanine, D) Tryptophan E) Tyrosine, F) Lysine, G) Threonine and H) Methionine. The final concentration of RKA-307 was at IC90 (3.11 
µM). The points represent the mean ± SEM of duplicate independent experiments. In RKA-307-treated Mtb H37Rv, valine and threonine are at very low 
levels (GraphPad prism 5 Software Inc.). 
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5.4. Discussion 
The greatest obstacles towards significant advances in TB drug development that 
target both replicating and non-replicating Mtb arise from the lack of the knowledge 
of mycobacterial physiology and the mechanisms associated with drug sensitivity. 
Pharmaco-genomics, -transcriptomics and -proteomics have been applied in 
Mycobacterium tuberculosis studies (241, 386, 390, 391). However, so far 
pharmaco-metabolomic studies of Mtb were limited to the Chakraborty et al (2013) 
study which explored the MoA of the antifolate para-aminosalicylic acid (PAS) 
(392).  
 
Studies of the MoA of quinolone-type compounds used against Mtb bd-I and of 
current TB drugs were carried out to assess the potential of pharmaco-metabolomics 
to explore and/or validate the MoA of existing and new TB drugs. In this regard, the 
first-line TB drugs, INH-, EMB-, RIF- and STR-treated Mtb along with electron 
transport chain inhibitors, TPZ- and CK-2-63-treated Mtb were initially clustered in 
a 2-D PCA plot along with untreated Mtb H37Rv. Interestingly, however, RKA-307-
treated Mtb had a distinct cluster. When PLS-DA analysis was applied. 2-D PLS-DA 
confirmed the discrete clustering of RKA-307-treated Mtb and furthermore, TPZ and 
CK-2-63-treated Mtb were observed to be closely associated with this cluster, 
consistent with overlapping MoA of respiratory chain inhibitors. In contrast, the 
first-line TB drugs-treated Mtb were clustered in close distance to the untreated Mtb 
H37Rv cluster. These observations could be credited to the general effect of the first-
line TB drugs on the amino acids and common metabolic intermediates from which 
these amino acids are synthesized (Figure 1.14, Chapter I) or break down to (Figure 
5.29). In contrast, ETC inhibitors, RKA-307-, TPZ- and CK-2-63-treated Mtb 
showed quite different effects of which RKA-307-treated Mtb revealed noticeable 
down-regulation effect on the most of TCA cycle intermediates and some of their 
related amino acids. Table 5.2 summarizes the metabolites that showed noticeable 
effects among treated Mtb H37Rv in comparison with that of untreated Mtb H37Rv. 
TPZ- and CK-2-63-treated Mtb displayed an additional effect which is a clear down-
regulation of hypoxanthine, a purine synthesis intermediate (393). It is worth 
mentioning that although CK-2-63 and RKA-307 are Mtb bd-I inhibitors of the same 
class (quinolone-type compounds) and were found to cluster on the same side of 
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PLS-DA plots, they did exhibit different clustering directions. This might be 
explained by the structure variation between these compounds that, interestingly, 
also confirms the differences in the pharmacodynamics profiles that were found 
earlier (Chapter III). 
 
Table 5.2: Metabolites showing notable fold change following drug exposure 
(Summarised from Figs. 5.7 – 5.27) 
 
Drugs/inhibitors Metabolites showed notable effect upon drug exposure  
INH-treated Mtb G-3-P, α-Ketoglutarate, malate, glutamate, ornithine, valine, alanine, 
hypoxanthine, lysine and threonine 
EMB-treated Mtb Fumarate, (iso)-citrate, alanine, proline and histidine 
RIF-treated Mtb Fumarate, (iso)-citrate, ornithine, (iso)-leucine, valine and threonine 
STR-treated Mtb Oxaloacetate, succinate, (iso)-citrate, ornithine, proline and histidine 
TPZ-treated Mtb (iso)-citrate, α-Ketoglutarate, malate, glutamate, ornithine, threonine, valine 
and hypoxanthine 
CK-2-63-treated Mtb Succinate, (iso)-citrate, alanine, aspartate, hypoxanthine, (iso)-leucine, 
proline, valine and methionine 
RKA-307-treated Mtb Succinate, fumarate, malate, oxaloacetate, (iso)-citrate, α-Ketoglutarate, 
Citrulline, glutamine, histidine, valine, proline and threonine 
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Figure 5.28: Degradation of amino acids to one of seven common metabolic 
intermediates (194) 
Central carbon metabolic (CCM) pathways of Mtb, including the anabolic monomers (amino 
acids; green boxes) and the major catabolic intermediates that they breakdown to (dashed 
grey arrows) are shown. Arg, Arginine; Asn, Asparagine; Asp, Aspartic acid; Ala, Alanine; 
Cys, Cysteine; Gln, Glutamine; Glu, Glutamic acid; Gly, Glycine; Ile, Isoleucine; Leu, 
Leucine; Lys, Lysine; Pro, Proline; Ser, Serine; Thr, Threonine; Trp, Tryptophan; Tyr, 
Tyrosine; Val, Valine; Phe, Phenaylalanine; Met, Methionine. 
 
The discrimination between the first-line TB drugs was further improved in the 3-D 
PLS-DA plot where INH- and STR-treated Mtb displayed closely related distance 
clusters, whereas the EMB-treated Mtb cluster was close to that of the untreated Mtb 
cluster. Moreover, RIF-treated Mtb was shown to have a distinctive cluster. This 
discrimination implied that each of the first-line TB drugs had different MoA 
although sharing a general effect on amino acids and common metabolic 
intermediates. Therefore, observations from other omics studies on the MoA of the 
first-line TB drugs will be highlighted in the following section in order to point out 
the expected effect of these drugs on Mtb metabolism and thus indirectly explain the 
clustering pattern of the first-line TB drugs. 
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INH-treated cells revealed substantial increases in G-3-P, α-Ketoglutarate, valine, 
alanine and lysine levels. Moreover, the level of malate and hypoxanthine notably 
increased by day 7. Glutamate and ornithine of INH-treated Mtb were found to be at 
very low levels. Threonine was also present in low amounts. Importantly, INH is 
known as a cell wall synthesis inhibitor. Pharmaco-proteomic studies on 
Mycobacterium bovis BCG (394) and on Mycobacterium smegmatis (395) along 
with a pharmaco-genomic study (396) and pharmaco-transcriptomic studies on Mtb 
(241, 386, 390) showed that INH-treated Mtb had a significant up-regulation in the 
FAS-II system. FAS-II is involved in the synthesis of mycolic acids, the primary 
target of INH. Upon exposure of Mtb to INH, Takayama et al (1972) found 
inhibition of mycolic acid synthesis components using thin-layer chromatography 
(85). Moreover, Argyrou et al (2006) detected nucleic acid biosynthesis suppression 
in proteomic profiling of INH-treated Mtb (397) and earlier biochemical analysis of 
INH-treated Mtb found depletion of NADH and NADPH pools (398). A 
pharmacoproteomic study of INH-treated Mtb showed up-regulation of proteins 
involved in cell wall processes such as the ESAT-6 family proteins, and down-
regulation of 13 proteins including ATP-dependent DNA/RNA helicase (391). 
Unfortunately, FAS-II precursors such as acetyl-CoA, methylmalonyl-CoA and 
redox couples were below limits of detection in this study. Interestingly, an 
important perturbation of amino acid metabolism was observed in INH-treated Mtb.  
However, a previous study found that the total protein synthesis of Mtb treated with 
INH for 12 h remained unaffected using the Lowry et al (1951) conventional method 
for protein determination. These discrepancies might be because of the short drug 
incubation time in the study by Gangadharam et al (1963) (399, 400).  
 
Regarding EMB that primarily targets arabinogalactan in the Mtb cell wall, EMB-
treated Mtb showed a notable decrease in (iso)-citrate levels and low production of 
fumarate. Furthermore, the level of alanine, proline and histidine was notably 
decreased in EMB-treated Mtb. A pharmaco-proteomic study of EMB-treated 
Mycobacterium smegmatis found an up-regulation of FAS-II proteins (395). 
Similarly, Boshoff et al (2004) observed that the genes of FAS-II pathways were 
significantly affected, similarly to what has been seen with INH-treated Mtb, upon 
treating Mtb with EMB (241). Unfortunately in this study, for the EMB-treated Mtb 
group, the FAS-II precursors such as acetyl-CoA and methylmalonyl-CoA were not 
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determined (below LOD) as observed with INH-treated Mtb. Moreover, Jia et al 
(2005) found that Mtb treated with EMB had a similar effect to that of INH-treated 
Mtb in terms of up-regulating ESAT-6 family proteins. However, unlike INH-treated 
Mtb, up-regulation of ATP-dependent DNA/RNA helicase was also observed (391). 
It is worth mentioning that these differences between INH- and EMB-treated Mtb 
further explained the dissimilarities of those drugs in terms of 3D PLS-DA 
clustering, although both are cell wall synthesis inhibitiors.         
 
RIF is a RNA synthesis inhibitor that acts by binding to RNA polymerase. Mtb 
treated with RIF revealed reduced levels of (iso)-citrate and fumarate and low 
production of and low utilization of threonine and ornithine, respectively. Moreover, 
RIF-treated Mtb showed a considerably increased level of (iso)-leucine and valine 
compared with drug-free control Mtb. A transcriptional study on Haemophilus 
influenzae protein synthesis patterns conducted by Evers et al (2001) found that RIF-
treated H. influenza displayed up-regulation of RNA polymerase subunits and 
ribosomal protein along with the complete shutdown of RNA synthesis (401). 
Unfortunately, pyrimidine metabolism precursors such as carbamoyl-l-aspartate, 
orotate and dihydroorotate were below LOD. However, the obtained results of 
disruptions of some amino acids metabolism and TCA cycle metabolites could be 
regarded as a secondary effect of RIF on Mtb metabolome. 
 
STR is a protein synthesis inhibitor that binds to a ribosomal subunit. STR-treated 
Mtb showed reduced levels of (iso)-citrate and low production of histidine, but 
substantial increases in ornithine, suucinate and oxaloacetate levels. Unlike RIF-
treated H. influenzae, STR-treated H. influenzae exhibited no significant changes in 
RNA polymerase subunits, ribosomal protein and RNA synthesis (401). This 
observation supports 3-D PLS-DA data that showed a different pattern between RIF- 
and STR-treated Mtb. Moreover, Qiu et al (2005) wrote that the transcriptional study 
of STR-treated Yersinia pestis revealed a general repression of energy metabolism 
genes and retardation of metabolic process and RNA synthesis, but up-regulation of 
genes that relate to membrane proteins, lipoproteins and porins (402). Boshoff et al 
(2004) stated that RIF- and STR-treated Mtb resulted in global down-regulation of 
Mtb genes (241). Notably, these findings may explain this thesis finding of STR-
treated Mtb. 
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TPZ-treated Mtb showed drastically decreased levels of (iso)-citrate, valine and 
malate but a noticeable increase in the levels of α-Ketoglutarate and ornithine. In 
addition, there was little or no utilization of glutamate and a low production of 
threonine and hypoxanthine. Boshoff et al (2004) found that the main effects of 
chlorpromazine (CPZ) and thioridazine (TRZ), phenothiazine-based compounds, 
were a reduction in ATP levels and a decreased intracellular NADH/NAD
+
 ratio 
(241). Unfortunately, bioenergetic couples such as ATP and redox couples NADH 
and NAD were below LOD. However, the perturbations of amino acids metabolism 
and hypoxanthine could be related to the remote effect of TPZ on Mtb metabolome.       
 
Concerning Mtb treated with RKA-307, a quinolone-type inhibitor, drastic 
reductions in levels of most TCA cycle intermediates were observed including 
succinate, malate, (iso)-citrate, fumarate, α-Ketoglutarate and oxaloacetate 
(compared with drug-free Mtb). RKA-307-treated Mtb also showed remarkable 
decreases in valine, threonine, citrulline, glutamine, proline and histidine levels. In 
contrast, CK-2-63, a compound of similar class to RKA-307, exhibited notable 
reduction in the level of succinate, (iso)-citrate, (iso)-leucine, hypoxanthine, alanine, 
valine, proline and methionine and a visible increase in aspartate level. RKA-307 
and CK-2-63, as discussed earlier (Chapter 3.4), showed an inhibition effect against 
Mtb cytochrome bd-I oxidase. However, the difference between RKA-307 and CK-
2-63 pharmaco-metabolomic profiling could be attributed to the differences in the 
compounds’ structures, as discussed earlier (Chapter 3.4). The TCA cycle fluxes of a 
Bacillus subtilis mutant strain that lacked cytochrome aa3 oxidase were 
quantitatively assessed using gas chromatography-mass spectrometry (GC-MS) and 
revealed a severe reduction of TCA cycle fluxes (403). Importantly, the reduction of 
some TCA cycle metabolites in RKA-307-treated Mtb might imply the concept of 
multiple targets (i.e it could show an inhibition effect on different respiratory 
components besides cytochrome bd-I oxidase).  
 
Inside the cell, the level of metabolites is determined by complex regulatory 
processes, transcription and translation regulation, protein-protein interactions and 
enzymes-metabolites interactions (374, 377). The compensation of some metabolites 
by other pathways of a complex high connectivity metabolism network could explain 
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the absence of significant changes of drug/inhibitor-treated Mtb metabolites. Bhat et 
al (2010), who studied the metabolic adjustments in Mtb upon exposure to INH, 
wrote that, with regard to the disturbed metabolic pathways, the metabolic 
adjustment could be described as a distant effect within the metabolic network. This 
metabolic adjusment involves some important metabolites that are produced through 
alternate pathways to keep the biological reactions operational (404). For instance, 
although INH- and EMB-treated Mtb showed important changes that are involved in 
CCM metabolites but not in fatty acid or cell wall synthesis, they may still offer 
valuable information about the secondary effect of these drugs MoA.  
 
This is the first study to investigate the metabolomic profiling of Mtb in response to 
first-line TB drugs as well as ETC inhibitors. Although no conclusive results 
regarding the MoA were generated, this study opens the door for future promising 
research towards the understanding not only of the specific responses of anti-TB 
drugs (primary MoA) but also the important secondary effects on Mtb metabolic 
network. In turn, new directions of anti-TB therapy development would consider 
developing co-drugs that target secondary responses on the Mtb metabolic network 
(376). The sensitivity of the LC-MS/MS used in this method showed some 
limitations, since metabolites of bioenergetic and redox couples such as ATP and 
NADH were below the limit of detection. Thus, using more sensitive analysis 
instrumentation (e.g. Orbitrap MS) and improved sample preparation methods would 
be advised for future studies. Moreover, for future work it is worth using different 
concentrations of drugs/inhibitors since drugs were found to induce gene expression 
only within a certain window of concentration (376, 405). This might be applied at 
the metabolic level as well, where low concentrations of drugs/inhibitors might not 
be adequate for affecting metabolite levels, whereas a high concentration might show 
death-related effects.  
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Chapter VI 
General discussion 
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Mycobacterium tuberculosis, an organism discovered 130 years ago, remains a major 
health threat, claiming nearly 2 million individuals annually. After almost a century 
without the introduction of new vaccines, 11 candidates are currently in clinical trials 
(8). Likewise, after decades (nearly 50 years) with the current yet inadequate TB 
treatment and without novel classes of drugs to tackle today's TB pandemic, several 
candidates are currently in late development clinical phases (www.tballiance.org) 
(Chapter 1.7). On-going searches for new drug targets against Mtb are required in 
order to find the best multi-drug regimen that would overcome the current first- and 
second-line treatment drawbacks (Chapter 1.4). However, it is inevitable that the 
organism will develop resistance, even to new drugs. Therefore, a detailed 
understanding of the pathogenesis of Mtb (cross-talk with a human host) and the 
pathogen’s response to drugs is vital. Mainly, there are three strategies that 
contribute in the enormous success of Mtb pathogenesis: first, macrophage 
reprogramming to impair organism degradation; second, formation of well-
structured granulomas, creating a confined environment for the host-pathogen 
interfacing; and third, transition into a dormancy stage, rendering Mtb extremely 
resistant to host defence and drug action, which is characterised by slowing down of 
the metabolic machinery of Mtb, the carbon metabolic pathways and the membrane-
embedded respiratory components (3, 16, 406).  
 
Mtb has a heterogeneous, dynamic nature, and inter-conversion of diverse Mtb 
subpopulations does occur. This phenomenon, demonstrated through the Yin-Yang 
model (24) (Chapter 1.3.2.5), forms the basis of the current difficulties to eradicate 
Mtb, regardless of using the INH/RIF combination in the 4-month continuance phase 
of treatment to eliminate the possibility of dormant and/or persistent tubercle bacilli 
reverting. Therefore, the urgent medical need for new TB drugs will continuously 
present until efficient first-line and second-line regimens that have a bactericidal 
effect on active, latent and resistant forms of Mtb are established. Energy 
metabolism, including metabolic pathways and the ETC, have emerged as new 
target-pathways for the development of new anti-tubercular drugs, owing to the fact 
that active or dormant tubercle bacilli will need energy to keep them alive regardless 
of the level of this energy (i.e. high or low). Here, a review of this thesis is presented, 
conclusions are drawn and gaps in the work are highlighted so that they can be 
addressed in future research.  
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A key objective of the thesis (Chapter II) was the generation of a heterologous 
expression system for Mtb cytochrome bd-I oxidase in E. coli respiratory knockout 
mutant strains. A double-knockout ML16 strain, lacking two types of quinol:oxygen 
oxidoreductase (cytochrome bo3 and cytochrome bd-I), and a triple-knockout MB44 
strain, lacking all types of quinol:oxygen oxidoreductase (cytochrome bo3, 
cytochrome bd-I and cytochrome bd-II), were used. Successfully, a heterologous 
expression system for Mtb cytochrome bd-I oxidase was established in both strains. 
However, some limitations of the triple-knockout strain were found, which will be 
discussed shortly. First of all, the generation and validation of a heterologous 
expression system for Mtb cytochrome bd-I oxidase in the ML16 strain (named as 
TML16) was successful in terms of biochemical characterisation by spectral analyses 
of TML16 strain and of microbiological characterisation by assessment of growth 
phenotypes and oxygen depletion in cultures during both aerobic and O2-limited 
growth conditions. The spectral analyses of the TML16 stain confirmed the 
expression of recombinant Mtb cytochrome bd-I oxidase (Mtb bd-I) by restoration of 
its spectral signature, a peak at 631 nm. Importantly, an additional critical validation 
is that although the ML16 strain still harboured endogenous cytochrome bd-II genes, 
the haem-d absorbance peak that was expected to be present at about 628-632 nm 
(217, 218, 290, 292) was not recorded. Moreover, it was possible to correlate the 
spectrum profile with growth conditions. The ratios of the cytochrome d peak to the 
reference peak in TML16 and wild-type strains were higher in O2-limited than in 
aerobic conditions. The microbiological assessment of TML16 growth phenotypes 
revealed the ability of Mtb bd-I to restore some of the important wild-type growth 
phenotypes, maintaining cell viability during the stationary phase, unlike the ML16 
strain (4, 295) (Chapter 2.4).  
 
Multidisciplinary approaches towards the characterisation of Mtb bd-I were 
implemented in Chapter III, revealing original and conclusive data of Mtb bd-I 
kinetics. Optimum conditions for enzyme activity were examined, revealing a pH of 
7.5 to be for the highest Mtb bd-I activity. Moreover, for future biophysical 
characterisation, the effect of detergents on Mtb bd-I activity was assessed. Mtb 
cytochrome bd-I oxidase showed a substrate preference for dQH2 over Q1H2 and 
Q2H2 (Km = 19.25 μM, 51.5 μM and 65.2 μM). However, the physiological substrate 
of Mtb bd-I, MQH2, could not be examined in this study due to solubility issues. 
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Importantly, Mtb bd-I was confirmed to conclusively catalyse the oxidation of 
quinol simultaneously with O2 reduction resulting in a monophasic kinetic plot with 
dQH2 and Q1H2 substrates. However, this reaction showed a biphasic kinetic plot 
with the substrate Q2H2, which acted as a non-competitive inhibitor at high substrate 
concentrations. The steady-state kinetics of Mtb bd-I were within the range of bd-I 
kinetics of previously studied organisms (211-213, 290, 321, 336, 345, 349, 354-
357).       
 
Targeting ETC components, as demonstrated by the discovery of TMC207, is one of 
the most promising areas toward the discovery of new anti-tubercular drugs (267). 
Therefore, characterising Mtb bd-I oxidase facilitated the study of its competency as 
a novel target for new TB chemotherapeutics. The goal was identifying a novel 
inhibitor that acts on the quinol oxidation site. Therefore, quinolone-type compounds 
(from in house libraries) were screened against Mtb bd-I and Mtb H37Rv, and the 
quinolone core of these compounds was found to be the key target for SAR 
development. A total of 23 quinolone-type inhibitors were examined, of which 9 
inhibitors showed an acceptable inhibition profile with IC50 <4 μM against Mtb bd-I 
and with 50% or more inhibition against Mtb H37Rv (single-point screening at 5 μM 
inhibitor concentration). Interestingly, 5 compounds, RKA-307, RKA-310, MTD-
403, SCR-8-12 and CK-3-23, showed significant correlation (P value < 0.01) 
between Mtb bd-I and Mtb H37Rv growth inhibition assays, suggesting that Mtb bd-
I is a potential target for the quinolone-type inhibitors tested. This suggestion has 
been further confirmed by HepG2 assay, which showed that these compounds target 
the ETC. However, SCR-8-12 was shown to have a different mode of action, as it 
did not exhibit any differences between glucose and galactose HepG2 assays. This 
observation has been supported by time-kill kinetics, where SCR-8-12 was shown to 
have bactericidal activity, unlike the remaining quinolone-type compounds. Closer 
examination of the structure of SCR-8-12 (Dr G Nixon, Medicinal Chemists) 
indicates that this compound has a similar pharmacophore to fluoro-quinolones 
which may account for its distinct pharmacodynamic profile compared to other 
members of the series. The bacteriostatic activity of LT-9, RKA-307, RKA-310, CK-
2-63 and MTD-403 showed a visible reduction by day 7. Importantly, TMC207 
showed quite similar time-kill kinetics (365); thus, this observation strongly 
promotes increasing the drug incubation time for the quinolone-type compounds up 
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to at least 14 days in order to evaluate the full time-kill kinetics. Up to this point, 
MTD-403 was found to be the optimum compound against Mtb bd-I, although 
further improvements of the inhibitor DMPK are needed.    
    
Although the generation and validation of a heterologous expression system for Mtb 
cytochrome bd-I oxidase in the ML16 strain (named as TML16) was successful and 
robust in all aspects, Chapter IV demonstrated the generation and validation of 
another heterologous expression system for Mtb cytochrome bd-I oxidase, but in a 
triple-knockout MB44 strain (named as TMB44). The reason for generating this 
system at the beginning was due to the absence of endogenous cytochrome bd-II, 
since the role of cytochrome bd-II in the ML16 strain was unknown. Therefore, we 
needed a backup plan for the study, due to the challenges faced during Mtb bd-I 
expression trials, which were countless in terms of obtaining a successful 
transformation, finding the ideal growth condition and preparing crude membranes. 
As demonstrated in chapter IV, this system represented an additional support system 
for TML16 data, which confirmed the basic Mtb bd-I kinetics that were obtained 
using the TML16 strain. However, TMB44 cannot replace TML16 because of the 
weakness of the MB44 strain and difficulties in preparing crude membranes. 
 
Chapter V provided an introduction for future promising pharmaco-metabolomics 
works in Mtb. With the objective of contributing towards developing new 
therapeutics and obtaining a better picture of their MoA, two quinolone-type 
inhibitors that showed activity against Mtb bd-I were examined. Remarkably, RKA-
307-treated Mtb revealed significant effects of the inhibitor on TCA cycle 
intermediates and some amino acid metabolites. Moreover, this study initially 
highlights the differences between two inhibitors of similar classes (i.e. RKA-307 
and CK-2-63). The first-line TB drugs showed different significant fingerprints on 
Mtb metabolome; nevertheless, they were not conclusive. However, it confirmed the 
variation of MoA between these drugs and highlighted areas that require further 
detailed studies, such as the perturbation of amino acid metabolism. 
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With regards to the limitations of this study, qualitatively measuring O2 saturation in 
the culture was one of the study limitations. Thus, growing cells in a chemostat 
model (253) was advised. Moreover, measuring the oxygen affinity of Mtb bd-I (a 
limitation of this study) which could be carried out following the protocol of D'mello 
et al. (1994) is needed for further enzyme characterisation (372). 
 
Although MTD-403 was found to be the optimum inhibitor of Mtb bd-I and Mtb 
H37Rv, improving DMPK properties was necessary. Furthermore, extending the 
quinolone-type inhibitors incubation time in the time-kill assay was recommended in 
order to provide a conclusive view of the bactericidal/bacteriostatic nature of these 
inhibitors. This was owing to the TMC207 time-kill kinetic that showed a slow static 
effect in the first 7 days and a bactericidal action by 14 days (365).  
 
For advanced studies of Mtb bd-I, enzyme purification would be the next step; 
however, unfortunately, Mtb bd-I was not His-tagged and thus different purification 
methods were required. Blue-Native polyacrylamide gel electrophoresis (BN-PAGE) 
was successfully used for isolating various respiratory components from mammalian 
and yeast mitochondria (407, 408). BN-PAGE is known to reduce the tendency of 
protein aggregation during analysis and to eliminate the need for using detergents, 
which in turn reduces the risk of detergent-sensitive protein denaturation (409). 
Applying this technique for Mtb bd-I purification is recommended since Mtb bd-I 
was found to be over-expressed.       
      
The large diversity and complexity of the metabolites that exist in a living cell means 
that using only one method is unlikely to provide enough sensitivity to detect all 
metabolites. However, this is a predicted outcome, since many central metabolites 
are biosynthetic intermediates that are usually found at levels more than 10,000-fold 
lower than other metabolites (378, 410). Thus, due to the fact that such trace 
metabolites remain a challenge to measure, an instrument with increased sensitivity, 
such as the exactive Orbitrap MS is recommended (411). Moreover, this method is 
generic, as the column used in this method, Luna aminopropyl, detects most of the 
polar and few of the non-polar compounds. Therefore, fatty acid synthesis 
metabolites could not be included in this study. A variety of measurement tools exist 
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to obtain these diverse metabolites and using a single method makes it impossible to 
acquire them all (412). For instance, Kamphorst et al. (2011) successfully analysed 
fatty acid metabolism using a Luna C8 reversed-phase column (a column that is 
suitable for fatty acids metabolites) along with the exactive Orbitrap MS (413).  
 
It is worth mentioning that the metabolome processing steps (cell growth, 
metabolism quenching, metabolite extraction, concentration and detection by LC-MS 
and data analysis) would be expected to have a major impact on the obtained results 
(378). Therefore, the experiment was applied following the metabolomics standard 
initiative (MSI) (http://msi-workgroups.sourceforge.net/). Some extraction methods 
could convey more or equivalent drawbacks when compared to others. For example, 
using centrifugation for harvesting cells carries the possibility of metabolites loss. 
Thus, using the filter culture method entails minimal risk of metabolome loss. This 
method is based on transferring a filter (cells grown on filter) from an agarose plate 
into a cold quenching solvent (380, 414). However, using the filter culture method 
for Mtb experiments bears high category 3 hazards and requires special advanced 
category 3 laboratory facilities that would not be found in standard category 3 Mtb 
laboratories.  
 
 
Future work 
Expressing Mtb bd-I allows the initial characterisation of the enzyme and would 
expedite future advanced characterisation, such as X-ray crystallographic studies and 
docking studies. The cutting-edge method used in this thesis and the findings 
necessitate the further application of metabolomics and exploration of the secrets of 
Mtb pathogenesis. The metabolic capability of an organism to adapt to diverse 
environments is considered a hallmark of microbial pathogenesis (378). Therefore, 
using the powerful technique of metabolomics to study Mtb opens doors for a wide 
range of applications and for global readouts of all ‘omic’ data. Revealing the mode 
of action of either current or future potential drugs and their relevance to the 
proposed primary target and on the secondary subsequent actions of these drugs 
would create a better strategy to improve and/or develop TB therapy (376). 
Furthermore, metabolomics would facilitate the study of the diverse dynamic nature 
of the Mtb subpopulations by using different latency models, from the simple in 
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vitro model (Wayne model) to the advanced in vivo model (Cornell model) in mice 
(20, 32, 33, 36). Watanabe et al. (2011) studied the metabolism of Mtb in response 
to hypoxia using a chemostat model. This study found a significant difference 
between Mtb aerobic and hypoxic cultures, in which succinate was found to be 
accumulated in the extracellular part of hypoxic cultures. Watanabe et al. (2011) 
concluded that Mtb sustained an energised membrane by coupling the secretion of 
succinate to the reductive branch of the TCA cycle (415). Moreover, targeted 
knockout techniques could be applied in order to reveal the function of Mtb bd-I and 
to assess its role during various stressful conditions, as well as during macrophage 
infection. Imaging techniques could be applied to examine the effect of Mtb bd-I 
absence on Mtb pathogenesis. This hypothesis is based on the high NO dissociation 
rate of cytochrome bd-I in E. coli, providing a strategy to evade the NO-mediated 
host immune attack (231, 416, 417). Remarkably, Jones et al. (2007) found that the 
E. coli mutant strain lacking bd-I failed to colonise the mouse intestine, which was in 
contrast to the E. coli mutant strain lacking cytochrome bo3 (222). This finding 
emphasises the importance of cytochrome bd-I in organism pathogenicity. Such 
multidisciplinary approaches applied to expand our knowledge of Mtb would 
pinpoint the potential targets that could contribute to developing better interventions 
to tackle the problem of TB. 
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Appendix I: Growth curve of Mtb H37Rv 
 
 
 
 
        Figure A: Growth curve of aerobic culture of Mtb 
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Appendix I: (Continued) 
 
 
  
  
  
Figure B: Fluorescence microscopy images of Mtb H37Rv bacilli  
Mtb H37Rv bacilli grown in aerobic culture was stained using Auramine Phenol.  At the 
following OD values, 0.02, 0.22, 0.54, 0.75, 1.14, 1.47 and 1.5 which correspond to days of 
Mtb H37Rv culture that was shown in Figure A, Mtb H37Rv bacilli were stained and 
visualised under fluorescence microscopy. The images were viewed using 100 x 
amplification and the scale was at 2 µm.  
 
 
231 
 
Appendix I: (Continued) 
 
 
 
Figure C: Growth curve of anaerobic culture of Mtb (Wayne model) 
There was a gradual depletion of oxygen from the Mtb culture, grown anaerobically. Mtb 
presents a distinct four-stage of growth, an initial exponential growth phase followed by 
non-replicating persistence (NRP) phase 1 (NRP-1) where a small increase in the optical 
densities presents. Subsequently, a phase of OD decreasing is shown which may represent 
the death of some cells that did not stand the stress of oxygen limitation. NRP-2 
demonstrates the stabilisation of the numbers of the bacteria.  
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Appendix I: (Continued) 
 
  
  
  
  
Figure D: Fluorescence microscopy images of Mtb H37Rv bacilli 
Mtb H37Rv bacilli grown in anaerobic culture was stained using an Auramine Phenol staining.  At the 
following OD values, 0.09, 0.29, 0.4, 0.45, 0.46, 0.41, 0.38, 0.3 and 0.24 which correspond days of Mtb 
H37Rv culture that was showed in Figure C, Mtb H37Rv bacilli were stained and visualised under 
fluorescence microscopy. Mtb H37Rv bacilli show visible increasing in length by OD = 0.45 (starts of 
NRP-1). The images were viewed using 100 x amplification and the scale was at 5 µm.  
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Appendix I: (Continued) 
Auramine phenol staining method of Mtb 
Auramine phenol and potassium permanganate (Pro-Lab Diagnostics, USA) were 
diluted 1 in 10 in dH2O and stored at room temperature in the dark. Differentiator 
solution consisted of 1% (v/v) hydrochloric acid and 75% (v/v) absolute ethanol in 
dH2O. 
A Mtb H37Rv culture was transferred to a 15 ml Falcon tube before being 
centrifuged at 3000 g for 10 min. Pelleted materials were resuspended in sterile 
phosphate buffer saline (PBS). A thin, uniform smear in a glass slide was prepared 
using 10 µl of suspension before being heat fixed on a heat block placed inside the 
safety cabinet for 5-10 min. Slides were flooded with the Auramine phenol stain, left 
to stand for 10 min and then rinsed with dH2O.  Slides were then flooded with 
differentiator solution (1% hydrochloric acid: ethanol: dH2O) for 10 min, rinsed a 
second time with ddH2O, flooded with 0.1% (w/v) potassium permanganate for 45-
60 s and finally rinsed again with ddH2O before being air dried. Subsequently, slides 
were mounted in 100μl of sterile PBS, a coverslip was placed on top of the smears 
and the slides sealed using nail polish.  Slides were kept in darkness and examined 
immediately by fluorescence oil immersion microscopy using a wide blue (> 525 
nm) long-pass filter at a magnification of 100x.  Images were captured using a 
camera fitted to the fluorescence microscope. 
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Appendix II: Metabolomic technique tables 
Table 1: LC-MS/MS parameters for metabolites detected in positive ESI mode 
(protonation, Molecule + H
+
) Abbreviations: MW, Molecular Weight; CID, Collision 
Induced Dissociation; RT, retention time. 
Metabolite MW (g.mol
-1
) Precursor mass CID Product mass RT (min) 
Alanine 89.09 90.1 14 44.1 12.8 
B-alanine 89.09 90.3 5 71.8 12.5 
Serine 105.09 106 10 60 13.1 
Proline 115.13 116 11 70 12.4 
Valine 117.15 118 11 55 12.1 
Threonine 119.12 120 11 74 13.3 
Cysteine 121.16 122 21 59 26.1 
(iso)-leucine 131.17 132 11 86 11.4 
Asparagine 132.12 133 17 74 13.4 
Ornithine 132.19 133 15 70 14.4 
Aspartate 133.1 134 15 74 16.4 
Glutamine 146.14 147 15 84 13.1 
Lysine 146.19 147 16 84 14.4 
Glutamate 147.13 148 15 84 16.5 
Methionine 149.21 150 10 133 12 
Histidine 155.15 156 12 110 13.6 
Phenylalanine 165.19 166 28 103 11.6 
Arginine 174.2 175 14 60 13.7 
Citrulline 175.19 176 12 159 12.9 
Carbamoyl-l-aspartate 176.12 177 17 74 21.5 
Tyrosine 181.19 182 26 77 13 
Tryptophan 204.23 205 16 146 11.9 
GSH 307.32 308 19 162 19.7 
UMP 324.18 325 12 97 22.3 
AMP 347.22 348 21 136 22.8 
UDP 404.16 405 19 97 23.1 
ADP 427.20 428 31 136 23.5 
TTP 482.16 483 25 81 27.3 
CTP 483.15 484 21 112 25.1 
UTP 484.14 485 30 97 27.7 
ATP 507.18 508 37 136 25.5 
GTP 523.18 524 37 152 27.8 
GSSG 612.63 613 33 231 22 
NAD 663.43 664 30 428 16.5 
NADH 664.43 666 26 514 27.1 
NADP 744.41 744 48 136 22.9 
NADPH 745.41 746 16 729 31.9 
FAD 785.55 786 24 348 22.9 
Acetyl-CoA 809.57 810 28 303 24 
Propionyl-CoA 823.60 824 33 317 24.2 
Succinyl-CoA 867.60 868 38 361 25 
 
 
235 
 
Appendix II: (Continued) 
Table 2: LC-MS/MS parameter for metabolites detected in negative ESI mode 
(deprotonation, Molecule – H+) Abbreviations: MW, Molecular Weight; CID, Collision 
Induced Dissociation; RT, retention time. 
Metabolite MW (g.mol
-1
) Precursor mass CID Product mass RT (min) 
Lactate 90.08 89 11 43 14 
Fumarate 116.07 115 11 71 25.5 
Succinate 118.09 117 16 73 21.5 
Oxaloacetate 132.07 131 12 87 24.2 
Malate 134.09 133 12 115 21.6 
Hypoxanthine 136.12 135 16 92 13.4 
Methylmalonyl-CoA 867.61 866 20 821 25.0 
Carbamyl phosphate 141.02 140 38 79 25.7 
2-Oxoglutarate 146.11 145 11 101 26.6 
DL-arabinose 150.13 149.1 7 130.6 10.8 
Orotate 156.10 155 13 111 15.3 
Dihydroorotate 158.11 157 14 113 14.1 
PEP 168.04 167 20 79 23.3 
DHAP 170.06 169 43 79 29 
G-3-P 172.07 171 13 79 21.8 
Glucose 180.16 179 18 59 11.7 
(iso)-citrate 192.12 191 18 111 23.3 
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Appendix II: (Continued) 
Table 3: Regression coefficients R
2
, linearity range and limit of detection (LOD) for 
metabolites targeted in LC-MS/MS method 
Metabolite R² 
Linear Range 
(uM) 
LOD 
(nM) 
Metabolite R² 
Linear Range 
(uM) 
LOD 
(nM) 
Propionyl-CoA 0.99 0.003 – 108.41 3 AMP 0.99 0.025 – 102.86 25 
Tryptophan 0.98 0.005 – 174.87 5 NAD 0.99 0.026 – 53.83 26 
Phenylalanine 0.99 0.006 – 216.2 6 UMP 0.98 0.026 – 110.17 26 
Glucose 0.99 0.006 – 198.25 6 GSH 0.98 0.028 – 116.21 28 
Citrulline 0.99 0.006 – 203.86 6 GSSG 0.98 0.028 – 58.3 28 
Tyrosine 0.99 0.006 – 197.11 6 2-Oxoglutarate 0.99 0.029 – 244.45 29 
G-3-P 0.99 0.006 – 207.55 6 Valine 0.99 0.037 – 304.86 37 
(iso)-citrate 0.99 0.006 – 93 6 UDP 0.99 0.042 – 88.37 42 
Methionine 0.99 0.007 – 239.36 7 NADP 0.99 0.047 – 48.04 47 
Histidine 0.98 0.007 – 230.19 7 Succinyl-CoA 0.98 0.049 – 102.91 49 
Dihydroorotate 0.99 0.007 – 56.47 7 Hypoxanthine 0.99 0.063 – 262.61 63 
Lysine 0.99 0.007 – 244.3 7 GTP 0.99 0.066 – 68.26 66 
Orotate 0.98 0.007 – 57.2 7 CTP 0.99 0.072 – 73.92 72 
Glutamate 0.99 0.007 – 242.74 7 UTP 0.98 0.072 – 73.77 72 
Acetyl-CoA 0.99 0.007 – 220.58 7 Proline 0.99 0.074 – 310.21 74 
Ornithine 0.99 0.008 – 270.24 8 Alanine 0.99 0.096 – 400.87 96 
Aspartate 0.99 0.008 – 268.32 8 NADPH 0.99 0.096 – 47.9 96 
Malate 0.99 0.008 – 266.35 8 
Carbamoyl-l-
aspartate 
0.99 0.097 – 202.78 97 
Succinate 0.99 0.009 – 302.44 9 NADH 0.99 0.107 – 53.67 107 
FAD 0.99 0.011 – 45.46 11 PEP 0.99 0.206 – 212.53 206 
Glutamine 0.99 0.015 – 244.38 15 TTP 0.99 0.578 – 74.07 578 
(iso)-leucine 0.98 0.016 – 272.27 16 Fumarate 0.98 0.615 – 307.69 615 
Asparagine 0.98 0.016 – 270.32 16 Serine 0.99 0.68 – 339.84 680 
ATP 0.98 0.017 – 70.42 17 DHAP 0.99 0.84 – 420.17 840 
Threonine 0.99 0.018 – 299.82 18 Cysteine 0.98 1.179 – 589.73 1179 
ADP 0.99 0.020 – 83.6 20 Oxaloacetate 0.98 5.4 – 2704.14 5400 
Lactate 0.99 0.024 – 793.03 24 
Carbamoyl 
phosphate 
0.98 7.59 – 3799.39 7590 
Arginine 0.99 0.025 – 205.02 25 
Methylmalonyl-
CoA 
0.98 4.38 – 68.96 4380 
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Appendix III: Metabolites calibration curves 
 
 
 
 
 
Figure 1. Standard calibration curves for alanine, arginine and asparagine show R
2 ≥0.99. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 2. Standard calibration curves for aspartate, cysteine and glutamate show R
2 ≥0.98. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 3. Standard calibration curves for (iso)-leucine, lysine and methionine show R
2 ≥0.99. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 4. Standard calibration curves for proline, tryptophan and phenyalanine show R
2 ≥0.99. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 5. Standard calibration curves for tyrosine, valine and threonine show R
2 ≥0.99. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 6. Standard calibration curves for serine, ornithine and citrulline show R
2 ≥0.98. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 7. Standard calibration curves for hypoxanthine, methylmalonyl CoA and DHAP show 
R
2 ≥0.98. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 8. Standard calibration curves for glycerol-3-phosphate, 2-oxoglutarate and malate show 
R
2 ≥0.99. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
.    
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Figure 9. Standard calibration curves for succinate, fumarate and oxaloacetate show R
2 ≥0.99. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 10. Standard calibration curves for (iso)-citrate, acetyl-CoA and succinyl-CoA show R
2 
≥0.99. 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 11. Standard calibration curves for AMP, ADP and ATP show R
2 ≥0.99 . 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
.    
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Figure 12. Standard calibration curves for CTP, UMP and UDP show R
2 ≥0.99 . 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 13. Standard calibration curves for UTP, TTP and GTP show R
2 ≥0.98 . 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 14. Standard calibration curves for FAD, GSH and GSSG show R
2 ≥0.98 . 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 15. Standard calibration curves for NAD, NADH and NADP show R
2 ≥0.99 . 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 16. Standard calibration curves for NADPH, glucose and lactate show R
2 ≥0.99 . 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 17. Standard calibration curves for dihydroorotate, orotate and carbamoyl-phosphate 
show R
2 ≥0.98 . 
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 18. Standard calibration curves for carbamoyl-l-aspartate, propionyl-CoA and PEP 
show R
2 ≥0.99.  
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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Figure 77. Standard calibration curves for histidine and glutamine show R
2 ≥0.99.  
The line of best fit for each calibration curve was generated using equal weighted linear regression as 
the mathematical model of best fit. Metabolites concentrations in samples were calculated from the 
resulting area ratio and the regression equation of the calibration curve.    
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